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9through the activities of COX and LOX (Russo, 2009). The eicosanoids derived from AA
are synthesised in larger quantities than ever before due to increases in n-6 PUFA
dietary intake (Olivier et al., 2010).
Eicosanoids are biologically active lipids, and include prostaglandins (PGs),
thromboxanes (TXs), leukotrienes (LTs), and hydroxyeicosatetraenoic acids (HETEs)
which have all been implicated in various pathological processes such as inflammation
and cancer (Table 1.1.2) (Wang and DuBois, 2010). When they are present in high
quantities, they influence various metabolic activities besides inflammation such as
platelet aggregation, haemorrhage, vasoconstriction and vasodilation (Benatti et al.,
2004). In general, AA-derived eicosanoids are proinflammatory but they have
important homeostatic functions in regulating both the promotion and resolution of
inflammation in the immune response (Ricciotti and FitzGerald, 2011). In contrast, it is
known that n-3 PUFA and their LC-derivatives mostly promote anti-inflammatory
activities (Tai and Ding, 2010). In a recent study involving 250 clinically stable chronic
obstructive pulmonary disease (COPD) patients, higher intakes of n-3 PUFA were
associated with lower proinflammatory cytokine concentrations (e.g., tumour necrosis
factor alpha (TNFα)), while higher n-6 PUFA intake was associated with higher pro-
inflammatory interleukin-6 (IL-6) and C-reactive protein (CRP) concentrations in the
disease state (de Batlle et al., 2011). While COPD is a complex chronic inflammatory
condition, it is interesting to see the association between dietary intake of n-6 versus
n-3 PUFA on serum inflammatory markers associated with the disease (de Batlle et al.,
2011). Despite ample evidence that increased dietary consumption of n-6 PUFA
induces a proinflammatory response in the host, it must also be reported that recent
studies have also shown the opposite (Poudel-Tandukar et al., 2009; Yoneyama et al.,
1Chapter 1
Literature reviews
2In Journal of Nutrition and Metabolism, 2012, doi:
10.1155/2012/539426
Chapter 1.1
Health implications of high dietary omega-6
polyunsaturated fatty acids
31.1.1 ABSTRACT
Omega-6 (n-6) polyunsaturated fatty acids (PUFA) (e.g., arachidonic acid (AA)) and
omega-3 (n-3) PUFA (e.g., eicosapentaenoic acid (EPA)) are precursors to potent lipid
mediator signalling molecules, termed “eicosanoids”, which have important roles in
the regulation of inflammation. In general, eicosanoids derived from n-6 PUFA are
proinflammatory while eicosanoids derived from n-3 PUFA are anti-inflammatory.
Dietary changes over the past few decades in the intake of n-6 and n-3 PUFA, show
striking increases in the n-6: n-3 ratio (~15:1), which are associated with greater
metabolism of the n-6 PUFA, compared with n-3 PUFA. Coinciding with this increase in
the ratio of n-6: n-3 PUFA, are increases in chronic inflammatory diseases such as
nonalcoholic fatty liver disease (NAFLD), cardiovascular disease (CVD), obesity,
inflammatory bowel disease (IBD), rheumatoid arthritis and Alzheimer’s disease (AD).
By increasing the ratio of n-3: n-6 PUFA in the Western diet, reductions may be
achieved in the incidence of these chronic inflammatory diseases.
1.1.2 INTRODUCTION
Fatty acids are hydrocarbon chains with a carboxyl group at one end and a methyl
group at the other. The biological reactivity of fatty acids is defined by the length of
the carbon chain and by both the number and position of any double bonds present.
While saturated fatty acids do not contain double bonds within the acyl chain,
unsaturated fatty acids contain at least one double bond. When two or more double
bonds are present, unsaturated fatty acids are referred to as PUFA (Calder, 2008a).
There are two families of PUFA and they are classified as omega-3 (n-3) and omega-6
4(n-6) based on the location of the last double bond relative to the terminal methyl end
of the molecule (Wall et al., 2010). The human body can produce all but two of the
fatty acids it requires. Linoleic acid (LA, 18:2n-6) (precursor to the n-6 series of fatty
acids) and α-linolenic acid (ALA, 18:3n-3) (precursor to the n-3 series of fatty acids) are
the simplest members of each family of PUFA and are termed essential fatty acids as
the body cannot synthesise them. PUFA regulate a wide variety of biological functions,
depending on the location of the last double bond, which range from blood pressure
and blood clotting, to the correct development and functioning of the brain and
nervous system (Wall et al., 2010). In addition, lipid mediators generated from long-
chain (LC-) PUFA (AA in the n-6 series and EPA and docosahexaenoic acid (DHA) in the
n-3 series) have important roles in immune regulation and inflammation (Calder,
2009). The main dietary sources of LA include plant oils such as sunflower, safflower
and corn oils (Table 1.1.1), but they are also present in cereals, animal fat and
wholegrain bread. Rich dietary sources of ALA include green leafy vegetables, flaxseed,
and rapeseed oils (Wall et al., 2010) (Table 1.1.1).
Over the last few decades, extreme qualitative nutritional changes have taken
place with the increased levels of fatty acid consumption (Olivier et al., 2010). Today,
industrialised societies are characterised by an increase in saturated fat, n-6 PUFA, and
trans fatty acid intake, as well as an overall decrease in n-3 PUFA intake (Simopoulos,
2011). Fatty acids now represent 28-42% of total energy consumed by European
populations (Linseisen et al., 2009; Olivier et al., 2010), whereas in ancestral nutrition,
fatty acid consumption was only approximately 20-30% of total energy (Eaton et al.,
2010; Olivier et al., 2010; Simopoulos, 2001). As a result of the increased consumption
of LA-rich vegetable oils associated with the Western diet, n-6 PUFA consumption has
5become progressively much higher than that of n-3 PUFA (Anderson and Ma, 2009).
Optimal dietary intakes of the n-6: n-3 ratio should be around 1-4:1, whereby in
ancestral nutrition, this ratio was balanced. However, according to the nutritional
changes described above in the Western diet, this ratio has now increased to be within
the range of 10:1 to 20:1 (Olivier et al., 2010). In parallel, there are coinciding increases
in the incidence of diseases involving inflammatory processes such as CVD, obesity,
IBD, rheumatoid arthritis and cancer. Neurodegenerative and psychiatric illnesses such
as AD and depression are other examples (Corsinovi et al., 2011). A study carried out
by Hassan and Hanachi, involving 984 Iranian women, suggested that a good dietary
pattern rich in fruits, legumes, vegetables, cereals and fish, rich in n-3 PUFA, can
decrease the likelihood of developing the Metabolic Syndrome (Hassan and Hanachi,
2009). Another study carried out in France, involving 912 men, concluded that a low
consumption of fish rich in n-3 PUFA is associated with a higher probability of
developing the Metabolic Syndrome (Ruidavets et al., 2007). Thus, high intake of n-6
PUFA, along with low intakes of n-3 PUFA, shifts the physiological state to one that is
proinflammatory and prothrombotic with increases in vasospasm, vasoconstriction
and blood viscosity and the development of diseases associated with these conditions.
PUFA play an important role in the composition of all cell membranes where they
maintain homeostasis for correct membrane protein function and influence membrane
fluidity, thus regulating cell signalling processes, cellular function and gene expression
(Das, 2006b). Other functions of PUFA require their metabolism to more highly
unsaturated members of their family. For example, LA is converted to AA (20:4n-6) via
γ-linolenic acid (GLA, 18:3n-6) and dihomo-γ-linolenic acid (DGLA, 20:3n-6). By the
same set of enzymes, ALA can be converted to EPA (20:5n-3) and DHA (22:6n-3). The
6primary site for PUFA metabolism is the liver, however, it can also take place in various
other tissues (Hughes CL, 2002). It is these longer chain metabolites of LA and ALA that
are of major clinical importance within different organs such as the brain, kidney and
liver (El-Badry et al., 2007; Lauretani et al., 2008; Uauy and Dangour, 2006).
Cyclooxygenases (COX) and lipoxygenases (LOX) can convert AA to the 2-series of
prostaglandins, the 2-series of thromboxanes and the 4-series of leukotrienes. These
are very important, active and short-lived hormones termed “eicosanoids” which are
involved in various pathological processes involving inflammatory conditions such as
atherosclerosis, obesity and IBD (Das, 2006b).
Since PUFA give rise to a variety of biologically active compounds which all have
important roles in pathological and physiological processes, a proper understanding is
needed regarding the contribution these active compounds have on the coinciding
increases in inflammatory diseases seen with the disruption of the balance in the ratio
of n-6: n-3 associated with the Western diet.
1.1.3 METABOLISM OF n-6 FATTY ACIDS AND BIOSYNTHESIS OF EICOSANOIDS
LA can be metabolised to other more unsaturated, long chain members of the n-6
family by the insertion of additional double bonds during consecutive elongation and
desaturation reactions (Figure 1.1.1). The initial rate limiting desaturation of LA to GLA
is catalysed by the enzyme Δ-6-desaturase (FADS2) (Stoffel et al., 2008). Elongation
then takes place to convert GLA to DGLA, by elongation of very long chain fatty acids
(ELOVL)-5, and finally a cycle of elongation and desaturation by Δ-5-desaturase
(FADS1) generates AA (Moon et al., 2009).
7The importance of the FADS2 gene in LC-PUFA synthesis has recently been
demonstrated in mice (Stoffel et al., 2008; Stroud et al., 2009). The first study
demonstrated that loss of the FADS2 gene abolishes synthesis of LC-PUFA, with further
downstream effects on the COX and LOX pathways, eventually leading to
hypogonadism and sterility of male and female mice (Stoffel et al., 2008). Further
demonstrated by this FADS2 null model was the pivotal role PUFA-substituted
phospholipids play in establishing cell polarity, shown here for tight junctions of Sertoli
cells of the testis and the gap junction network between ovarian follicle cells (Stoffel et
al., 2008). Impairment of male reproduction and both dermal and intestinal ulceration
have been shown in FADS2 null mice (Stroud et al., 2009).
ELOVL5 is one of seven mammalian fatty acid condensing enzymes involved in
microsomal fatty acid elongation (Moon et al., 2009), required for the elongation of
GLA to DGLA. Studies using liver microsomal protein from ELOVL5 null mice found
greater tissue accumulation of GLA and a decrease in the levels of downstream
metabolism products such as AA for n-6 metabolism and DHA for n-3 metabolism. The
metabolic consequence of this reduction of AA and DHA, was the activation (or de-
repression) of sterol regulatory element-binding protein (SREBP)-1c. Activation of this
transcription factor (as will be discussed in further detail later) in ELOVL5 null mice
resulted in the activation of further genes involved in fatty acid and triglyceride
synthesis, which culminated in the development of hepatic steatosis (Moon et al.,
2009).
There are many other factors involved in the regulation of FADS1 and FADS2
enzyme activity. For example, decreased activity in both FADS1 and FADS2 have been
demonstrated in the liver of obese NAFLD patients (Araya et al., 2010). Glucagon,
8adrenaline, glucocorticoids and thryroxin depress FADS1 and FADS2 activity (Brenner,
2003). Low FADS2 enzyme activity was reported in diabetic rats whereby insulin acts as
a FADS2 stimulator (Brenner, 1981). Since LA and ALA are metabolised by the same set
of enzymes, a natural competition exists between these two fatty acids, whereby
FADS1 and FADS2 will exhibit affinity to metabolise n-3 over n-6 PUFA, provided that
they exist in a ratio of 1:1-4. However, the higher consumption of LA, as now seen in
the Western diet, shows an increase in the preference of these enzymes to metabolise
n-6 PUFA, leading to AA synthesis, despite the fact that these enzymes show higher
affinity for n-3 PUFA (Das, 2006a). Supplementation of the diet with EPA and DHA has
been shown to correct this imbalance by partially replacing AA from the cell
membranes of platelets, erythrocytes, neutrophils, monocytes and hepatocytes where
AA is usually found in high proportions (Simopoulos, 2002).
The intermediates of PUFA metabolism can either be incorporated into
phospholipids or undergo further elongation/desaturation. In the n-6 pathway, AA,
synthesised from the desaturation of DGLA by FADS1 can be further elongated by
ELOVL2 to docosatetraenoic acid (22:4n-6) or to its respective set of eicosanoids via
COX and LOX enzymes. The importance of ELOVL2 derived PUFA in mammals have
recently been demonstrated in ELOVL2-ablated mice, thus demonstrating the
importance of this elongase enzyme (Zadravec et al., 2011). This study showed the role
ELOVL2 plays in the elongation of 20:0 and 22:0 PUFA in order to produce 24:4n-6 up
to 30:5n-6 PUFA in testis, where they are required for normal spermatogenesis and
fertility (Zadravec et al., 2011). Binding of growth factors and hormones to membrane
receptors leads to activation of phospholipase A2 which releases AA from the cell
membrane where the free acid can become a substrate for eicosanoid biosynthesis
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2007). A recent review has suggested that n-6 PUFA have some anti-inflammatory
actions such as those of n-3 PUFA (Fritsche, 2008). For example, mean serum CRP
concentrations tended to decrease with increased n-6 PUFA consumption in both
Japanese men (Poudel-Tandukar et al., 2009) and women (Yoneyama et al., 2007).
Nevertheless, evidence of these associations is limited.
Metabolism of AA by the COX enzymes (COX-1 a constitutive enzyme, or COX-2 an
inducible enzyme) leads to the synthesis of the 2-series of prostaglandins: PGE2, PGI2,
PGD2 and PGF2α, (largely produced by monocytes and macrophages) and
thromboxanes A2 and B2. Collectively, the prostaglandins and thromboxanes are
referred to as prostanoids. The synthesis of AA-derived eicosanoids is however
dependent on the concentration of DGLA, as DGLA competes with AA for COX and LOX.
When DGLA is in excess, it inhibits the synthesis of AA-derived eicosanoids due to its
higher affinity for the COX and LOX enzymes (Levin et al., 2002). The activity of 5-LOX
metabolises AA to hydroxyl and hydroperoxy derivatives: 5-HETE and 5-hydro-
peroxyeicosatetraenoic acid (5-HPETE). These derivatives in turn produce the 4- series
of leukotrienes: LTA4, LTB4, LTC4, LTD4 and LTE4. Monocytes, macrophages and
neutrophils produce LTB4, while mast cells, eosinophils and basophils produce LTC4,
LTD4 and LTE4 (Bagga et al., 2003).
Prostaglandin overproduction has various proinflammatory effects. For example,
PGI2 and PGE2 exert their acute inflammatory response in arthritis (Kojima et al., 2005;
Pulichino et al., 2006). PGE2 can also increase its own synthesis through induction of
COX-2 leading to the production of the pro-inflammatory cytokine IL-6 in macrophages
(Bagga et al., 2003; Tilley et al., 2001). TXB2 is a potent vasoconstrictor and platelet
activator. LTB4 has many proinflammatory functions, acting as an important activator
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of neutrophils, a chemotactic agent for leukocytes, induces release of lysosomal
enzymes, accelerates reactive oxygen species (ROS) production and increases vascular
permeability (Schmitz and Ecker, 2008). LTB4 also leads to the production of
inflammatory cytokines like TNFα, IL-1β and IL-6 by macrophages (Peters-Golden and
Henderson Jr, 2007). However, the overall pathophysiological outcome will depend on
the cells present, the nature of the stimulus, the timing of eicosanoid generation, the
concentrations of different eicosanoids generated and the sensitivity of target cells
and tissues to the eicosanoids generated (Calder, 2008a).
In contrast, EPA can also act as a substrate for COX and LOX enzymes and gives rise
to an entirely different set of eicosanoids (Table 1.1.2). These are the 3-series
prostaglandins and thromboxanes and the 5-series leukotrienes, which are considered
to be less inflammatory or even anti-inflammatory in comparison to the eicosanoid
family derived from AA (Robinson and Stone, 2006).
1.1.4 HOW n-6 PUFA-DERIVED EICOSANOIDS INFLUENCE INFLAMMATORY
RESPONSES
The mode by which prostaglandins and leukotrienes exert their biological
homeostatic and inflammatory actions depends on binding to their respective G-
protein coupled receptors (GPCRs). Specific GPCRs have been identified for all the
prostanoids, where there are at least nine known prostanoid receptor forms in mouse
and man (Hata and Breyer, 2004; Narumiya and FitzGerald, 2001). Although most of
the prostaglandin GPCRs are localised at the plasma membrane of platelets, vascular
smooth muscle cells and mast cells, some are situated at the nuclear envelope (Ide et
al., 2003). Four of these receptor subtypes bind PGE2 (EP1-EP4), two bind PGD2 (DP1
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and DP2) and more specific receptors bind PGF2α, PGI2 and TXA2 (FP, IP and TP,
respectively) (Harizi et al., 2008). PGE2 and PGI2 are the predominant proinflammatory
prostanoids and through their activation of EP2 and IP, respectively, they can increase
vascular permeability and leukocyte infiltration. In individuals with asthma, a bronchial
allergen leads to enhanced PGD2 production. Thus, during asthmatic attacks in
humans, PGD2 is released in large amounts by mast cells (Arima and Fukuda, 2011).
PGD2 can also promote inflammation via DP2 through activation of eosinophils (Hata
and Breyer, 2004; Pettipher et al., 2007).
Four distinct GPCRs for leukotrienes have been characterised. LTB4 interacts with
BTL1 and BTL2 through which important roles in host defence of cells and inflammation
are mediated (Lundeen et al., 2006). LTB4 induces leukocyte infiltration and as already
mentioned above, leads to the release of proinflammatory cytokines. In patients with
IBD, the colonic mucosa contains 3- to 7- fold higher counts of cells expressing the 5-
LOX pathway, thus increasing the tissue synthesis of LTB4 (Jupp et al., 2007). LTC4 and
LTD4 can contract smooth muscle by interacting with two subtypes of cysteinyl
leukotriene receptors, CysLT1 and CysLT2 (Funk, 2001).
The proinflammatory effects of the AA-derived prostanoids and leukotrienes have
been described (Harizi et al., 2008). A mechanism has been proposed whereby a co-
ordinated program for resolution initiates in the first few hours after the inflammatory
response. A switch occurs whereby the AA-derived prostanoids and leukotrienes,
which have set the inflammatory response to begin, undergo further metabolism to
become another generation of eicosanoids derived from AA, termed lipoxins, and
hence terminate inflammation at the local contained sites (Serhan and Savill, 2005).
Since these lipoxins are involved in the resolution of the acute inflammation that
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occurs as a result of the overproduction of the proinflammatory eicosanoids derived
from AA, they are said to have ‘pro-resloving’ and anti-inflammatory functions. These
events coincide with the biosynthesis of resolvins and protectins from n-3 fatty acids,
which act to shorten the period of neutrophil infiltration (Serhan and Savill, 2005).
However, while the initial response of the AA-derived eicosanoids to promote
inflammation is beneficial in one respect, for example, in the control of blood flow and
vessel dilation, with the increase in the ratio of n-6: n-3 PUFA, there is an overall
increase in the production of proinflammatory cytokines and an unnecessary over
reactive inflammatory response leading to the pathogenesis of inflammatory diseases.
In addition, the decrease in consumption of n-3 PUFA which leads to an overall
decrease in resolvin and protectin production is detrimental to the inflammatory
response as these products, which have the ability to dominate the resolution phase of
inflammation, can no longer exert this potential, thus the inflammatory response
cannot be terminated effectively.
1.1.5 n-6 PUFA REGULATION OF INFLAMMATORY GENE EXPRESSION
Nuclear receptors are a family of ligand-activated transcription factors that either
directly or indirectly control various genes of lipid metabolism and inflammatory
signalling (Schmitz and Ecker, 2008). Upon ligand binding, nuclear receptors can
undergo conformational changes which dissociate corepressors and facilitate
recruitment of coactivator proteins to enable transcription activation (Chawla et al.,
2001; Schmitz and Ecker, 2008). LC-PUFA and their eicosanoid derivatives can act as
ligands for these transcription factors and hence, elicit changes in gene expression by
governing the activity of nuclear transcription factors. The regulation of gene
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expression by dietary fats is believed to be one of the greatest factors impacting on the
development of certain diseases related to the Metabolic Syndrome, such as hepatic
steatosis and NAFLD.
The peroxisome proliferator-activated receptor (PPAR) family is composed of three
proteins; PPARα, PPARβ/δ and PPARγ and although they each have different tissue 
distributions, their biological functions overlap (Bensinger and Tontonoz, 2008). The
PPARs have emerged as important regulators of metabolic and inflammatory
signalling, in both metabolic disease and immunity (Bensinger and Tontonoz, 2008).
The role PPARα plays in the regulation of genes involved in lipid metabolism was first
identified in the early 1990s, on the basis of being a target of the hypolipidaemic
fibrate drugs and other compounds that induce peroxisome proliferation in rodents
(Bensinger and Tontonoz, 2008; Issemann and Green, 1990). PUFA, especially those of
the n-3 family and their eicosanoid derivatives are ligands for the PPARs. The n-3 PUFA
EPA and DHA have been shown as more potent as in vivo activators of PPARα than n-6
PUFA (Couet et al., 1997; Hu et al., 1999; Mori et al., 1999; Power and Newsholme,
1997). Once PPARs become activated, they form heterodimers with the retinoid X
receptor (RXR) and these dimers then bind to PPAR responsive elements (PPREs) in
target genes to alter coactivator/corepressor dynamics and induce transcription
(Chakravarthy et al., 2009). PPARα has recently been shown to exert hypolipidaemic
effects through activation of skeletal muscle, cardiac and hepatic genes encoding
proteins which are involved in lipid oxidation (Chakravarthy et al., 2009; Fujita et al.,
2008; Yoon et al., 2006). Thus, the PPARs, particularly PPARα, play an important role in
insulin sensitisation, atherosclerosis and metabolic diseases. In the regulation of
inflammatory signalling, PPARs inhibit nuclear factor-κB (NF-ĸB) expression.
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NF-ĸB, another transcription factor regulated by PUFA, is found in almost all animal
cell types, has a crucial role in inflammatory signalling pathways and plays a key role in
regulating the immune response to infection. It controls several cytokines (e.g., IL-1, IL-
2, IL-6, IL-12 and TNFα), chemokines (e.g., IL-8, monocyte chemoattractant protein-1),
adhesion molecules and inducible effector enzymes (e.g., inducible nitric oxide
synthase and COX-2) (Wall et al., 2010). NF-ĸB becomes activated as a result of a 
signalling cascade triggered by extracellular inflammatory stimuli (such as free radicals,
bacterial or viral antigens), which involves phosphorylation of an inhibitory subunit of
NF-ĸB (IĸB), which in turn allows the translocation of the remaining NF-ĸB dimer to the 
nucleus, with the result of an increase in expression of inflammatory genes (Perkins,
2007). Since n-3 LC-PUFA exhibit anti-inflammatory action, they inhibit NF-ĸB activity.
As an example, both EPA and DHA have been shown to block the activity of NF-ĸB 
through decreased degradation of IĸB, in human monocytes and human THP-1
monocyte derived macrophages (Weldon et al., 2007; Zhao et al., 2004) . However, this
effect is not observed to the same extent with n-6 LC-PUFA, due to potency in the
inhibition of NF-ĸB (De Caterina et al., 1999). Interestingly, 5-LOX, the enzyme which
converts AA to the 4-series leukotrienes and 5-HETE translocates into the nucleus in
association with NF-ĸB (Lepley and Fitzpatrick, 1998; Soberman and Christmas, 2003).
SREBP-1c is a transcription factor required for the insulin-mediated induction of
hepatic fatty acid and triglyceride synthesis. Responsive targets in mammalian cells
include genes of fatty acid metabolism, such as fatty acid synthase (FAS) and its
expression is most commonly found in high levels in macrophages, liver, white adipose
tissue, adrenal glands, and the brain of both mice and humans (Ecker et al., 2007).
PUFA have the ability to modulate SREBP-1c activity and expression. For example, n-3
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LC-PUFA have been shown to suppress SREBP-1c gene expression and so inhibit
transcription of lipogenic and hepatic genes involved in lipid biosynthesis (Teran-Garcia
et al., 2007; Xu et al., 2002). Studies have shown that a decrease in hepatic SREBP-1c
leads to a decrease in hepatic FAS, thus reducing lipid accumulation within the liver
(Howell III et al., 2009; Xu et al., 1999; Xu et al., 2001). However, n-3 PUFA are more
potent inhibitors of SREBP-1c, than n-6 PUFA (Schmitz and Ecker, 2008). More recently,
the liver X receptors (LXR-α and –β) have been shown to play a major role in
lipogenesis through regulation of transcription of the gene encoding SREBP-1c (Howell
III et al., 2009). This study concluded that the downregulation of SREBP-1c
transcription by n-3 PUFA results from attenuated transactivation of the ligand-
activated nuclear receptor LXR-α (Howell III et al., 2009). A more recent study in mice
fed an n-3 PUFA depleted diet showed increased activation of SREBP-1c and related
pathways which was consistent with increased LXR activity, thus highlighting the
importance of n-3 PUFA depletion related to lipid accumulation in the liver (Pachikian
et al., 2011). However, another study demonstrated that fish oil feeding in rats
suppressed hepatic SREBP-1c target genes with change in expression of genes directly
regulated by LXR (Pawar et al., 2003). Inhibition of LXR may also be an indirect effect of
PUFA stimulation of PPAR transcription factors (Schmitz and Ecker, 2008). Cross talk
between PPARα and LXR via SREBP-1c has been reported, whereby overexpression of
PPARα inhibited LXR induced SREBP-1c promoter activity, through a reduction of LXR
binding to its activator, RXR (Yoshikawa et al., 2003). Both n-6 and n-3 PUFA are often
interchangeable in regulating gene expression. However, it is well known that n-3
PUFA are more potent ligands to these nuclear receptors than n-6 PUFA (Schmitz and
Ecker, 2008). Through n-3 PUFA mediated activation of PPARα and inhibition of SREBP-
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1c, lipid biosynthesis can be reduced and lipid degradation can be increased (Russo,
2009; Schmitz and Ecker, 2008).
By targeting the transcription of various nuclear receptors involved in regulating
lipogenic gene expression through dietary fatty acids, prevention of certain diseases
related to the Metabolic Syndrome, such as hepatic steatosis and NAFLD can be
reduced. The contribution n-6 PUFA make to the development of liver disease due to
the increased consumption of LA-rich foods and the decreased consumption of ALA
rich foods will be discussed in further detail. Already discussed are the positive
contributions of n-3 PUFA in the prevention of lipid biosynthesis in various organs,
such as the liver, for example, through the activation of PPARα and inhibition of NF-ĸB 
and SREBP-1c. However, since these n-3 PUFA are more potent ligands for these
nuclear receptors and Western diets overall consumption of n-6: n-3 has increased
dramatically over the last 50 years in particular, what now becomes the fate of the
these nuclear receptors and how have our dietary changes impacted upon our health
status through regulation of inflammatory gene expression? Determination of the
molecular and cellular mechanisms regulated by PUFA, may identify novel sites for
pharmacological intervention.
1.1.6 n-6 PUFA CONTRIBUTION TO CHRONIC INFLAMMATORY CONDITIONS
Clinical studies indicate that inflammation is at the base of many diseases including
NAFLD, CVD, atherosclerosis, IBD, and neurodegenerative diseases such as AD (Figure
1.1.2). The contributions of n-6 PUFA to inflammatory conditions are reviewed, with a
particular focus on NAFLD.
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1.1.6.1 NAFLD
NAFLD is often described as the hepatic component of the Metabolic Syndrome and
is rapidly becoming a serious public health problem (Byrne et al., 2009). The range of
liver damage associated with NAFLD begins with steatosis and can often persist to
further steatohepatitis (NASH), advanced fibrosis and cirrhosis (Byrne, 2010). NAFLD
itself is an independent risk factor for CVD. Occurrences of NAFLD are much higher in
subgroups of the population with obesity, Metabolic Syndrome and type 2 diabetes,
whereby prevalence in developing the disease for those with type 2 diabetes may be
as high as 70% (Byrne, 2010; Erickson, 2009). Both nutritional factors and alterations in
lipid metabolism of the liver are the primary metabolic abnormalities which lead to
hepatic steatosis (Videla et al., 2006).
The role of n-3 LC-PUFA as a potential therapeutic target in the pathogenesis of
NAFLD has recently been demonstrated (Larter et al., 2008). Within the liver, n-3 LC-
PUFA presence is associated with an increased ability to direct fatty acids away from
triacylglycerol storage and to enhance their oxidation. However, n-3 LC-PUFA levels are
decreased in the hepatic tissue of patients with NAFLD (Araya et al., 2004; Spadaro et
al., 2008). Depletion of n-3 LC-PUFA within the liver of NAFLD patients is a major
problem as liver fatty acids now become directed away from oxidation and secretion
and instead towards triacylglycerol storage. In addition, a higher n-6: n-3 LC-PUFA ratio
within the liver of NAFLD patients may contribute to the development of fatty liver due
to a derangement in the capacity to regulate liver lipid metabolism (Araya et al., 2004).
A recent comparative review also demonstrated various mechanisms through which
consumption of fish oil has been beneficial in the alleviation of NAFLD such as (i)
decreased plasma nonesterified fatty acids (NEFA) concentrations; (ii) decreased de
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novo lipogenesis, very low-density lipoprotein (VLDL) export and plasma triglyceride
concentrations; (iii) decreased adipocyte size and visceral fat content (Zivkovic et al.,
2007). The mechanisms which lead to the development of fatty liver, such as impaired
fatty acid oxidation and increased de novo fatty acid synthesis are regulated by hepatic
gene transcription.
n-3 LC-PUFA regulate lipid metabolism in the liver by acting as ligand activators of
the transcription factor PPARα. Activation of PPARα results in the upregulation of
genes which are involved in fatty acid and lipid metabolism and which stimulate fatty
acid oxidation (El-Badry et al., 2007; Jump, 2008). In two separate studies employing
murine models of NASH, administration of a PPARα agonist prevented steatohepatitis
and reversed the establishment of the disease (Ip et al., 2004; Ip et al., 2003).
VLDL is a type of lipoprotein synthesised by the liver from triglycerides, cholesterol
and apolipoproteins. Within the bloodstream, VLDL transports cholesterol from the
liver, thus enabling fats to move within the bloodstream and it is here that VLDL itself
can also act as a precursor to low-density lipoprotein (LDL), often referred to as “bad
cholesterol”. PPARα activation increases the secretion of apoliopoprotein B-100 (apo
B-100), which is the main structural protein of VLDL and upregulates the expression of
liver fatty acid binding protein (LFABP) which is essential for the secretion of apo B-100
(Carlsson et al., 2001; Linden et al., 2002). Since n-3 LC-PUFA upregulate PPARα,
hepatic fatty acid oxidation has the potential to occur within the liver and since more
apo B-100 is secreted out of the liver, less VLDL is synthesised, with the result of less of
this harmful cholesterol entering the bloodstream, where the downstream further
effects on the development of atherosclerosis are attenuated (Savage and Semple,
2010). However, with the reduced availability of n-3 LC-PUFA from dietary intake, and
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the increases in n-6 PUFA consumption, PPARα does not become activated to its full
potential. This results in PUFA favouring fatty acid and triglyceride synthesis over fatty
acid oxidation. As demonstrated by PPARα -/- mice, rates in their ability to oxidise fatty
acids are decreased during periods of food deprivation, thus, they develop
characteristics of adult-onset diabetes including fatty livers, elevated blood triglyceride
concentrations and hyperglycemia (Kersten et al., 1999).
n-3 LC-PUFA are also involved in the negative regulation of the transcription factor
SREBP-1c within the liver, thus acting as inhibitors in the expression of lipogenic genes
such as FAS (Xu et al., 2002). The effect n-3 LC-PUFA have on SREBP-1c is to reduce
endogenous lipid production and accumulation of triglycerides in the liver (Masterton
et al., 2010) and this is achieved by reducing the amount of mature SREBP-1c available
for de novo lipogenesis within the nucleus (Yahagi et al., 1999). Therefore, depletion of
n-3 LC-PUFA and an increase in the ratio of n-6: n-3 LC-PUFA in the liver of NAFLD
patients results in fatty acid and triacylglycerol synthesis over oxidation, again leading
to fatty liver. A recent study by Pachikian et al., using mice fed a depleted n-3 PUFA
diet showed increases in hepatic activation of SREBP-1c leading to increased
lipogenesis, contributing to hepatic steatosis (Pachikian et al., 2011). This is consistent
with a previous study in rats fed an n-3 PUFA depleted diet whereby hepatic
accumulation of triglycerides and esterified cholesterol led to both macro- and
microvesicular steatosis caused by changes in the fatty acid pattern that resulted from
n-3 PUFA depletion (Malaisse et al., 2009).
Another mechanism involved in the depletion of n-3 LC-PUFA from the liver of
obese NAFLD patients and which further exacerbates the disease progression is the
decreased hepatic FADS1 and FADS2 activity in these patients (Araya et al., 2010).
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Impairment of these enzymes affects the desaturation and elongation pathways of LA
and ALA, which are required for the synthesis of their LC-PUFA derivatives within the
liver (Videla et al., 2004). Decreased activity of both FADS1 and FADS2 have been
demonstrated in the liver of obese NAFLD patients (Araya et al., 2010). This may be
attributed to the lower intake of ALA, the imbalance in the n-6: n-3 LC-PUFA ratio and
higher consumption of trans isomers (18:1, n-9 trans) inhibiting FADS2 (Araya et al.,
2004). The depletion of n-3 LC-PUFA within the liver of these patients resulting from
the decrease in FADS1 and FADS2 activity may lead to further development of
steatosis by altering the activity of PPARα and SREBP-1c (Araya et al., 2010). This will
determine a metabolic imbalance favouring lipogenesis over fatty acid oxidation since
n-3 LC-PUFA depletion induces SREBP-1c expression and upregulation of lipogenic
genes (Videla et al., 2006). In general, it is also understood that the adipose tissue acts
as a suitable biomarker for dietary fatty acid intake. Considering that in NAFLD, there is
an enhancement in n-6 PUFA adipose tissue content and a significant decrease in n-3
adipose tissue content suggests that while there is an adequate amount of n-6 PUFA
for metabolism within the liver, n-3 PUFA cannot be metabolised to the same extent
due to inadequate dietary intake. Also, decreased dietary intake of n-3 PUFA
constitutes a limiting factor for the production of n-3 LC-PUFA in liver lipids of NAFLD
patients, resulting from the competition between the two metabolic pathways (Figure
1.1.1), particularly at the desaturation steps (Araya et al., 2004). Thus, a dietary
imbalance comprising inadequate intake of n-3 PUFA and an excess intake of n-6 PUFA
leads to defective desaturation of PUFA (Araya et al., 2004).
Oxidative stress, caused by the accumulation of liver triglycerides and insulin
resistance are major contributors in the pathogenesis of NAFLD (Narasimhan et al.,
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2010). Both oxidative stress and mitochondrial dysfunction are often associated with
the increased production of ROS and proinflammatory cytokines related to NAFLD
(Byrne, 2010). Recent human studies have described a strong association between the
severity of NASH and the degree of oxidative stress (Chalasani et al., 2004; Narasimhan
et al., 2010; Yesilova et al., 2005). The increased pro-oxidant activity associated with
oxidative stress, leads to elevation in hepatic lipid peroxidation status. Lipid
peroxidation can also cause immunological dysfunction, which could lead to the
development of hepatic fibrogenesis (Byrne, 2010). This could potentially lead to an
increase in the release of 4-hydroxy-20-nonenal (HNE), which can bind hepatocyte
proteins forming new antigens and therefore provoking a harmful immunological
response (Byrne, 2010). For example, a correlation between hepatic expression of HNE
and the degree of severity of necroinflammation and fibrosis has been reported (Seki
et al., 2002). Oxidative stress associated with NAFLD has also been shown to increase
production of proinflammatory cytokines. This hepatotoxicity associated with the
production of inflammatory cytokines, induced through oxidative stress may indirectly
activate transcription factors such as NF-ĸB. The accumulation of NEFA within
hepatocytes of NAFLD patients is another source of NF-ĸB activation (Feldstein et al.,
2004).
Oxidative stress and changes in dietary intake trends may contribute to low hepatic
LC-PUFA (Allard et al., 2008). The increase in lipid peroxidation associated with NAFLD,
as discussed, may contribute to the decrease in LC-PUFA, as they are particularly
susceptible to lipid peroxidation (Allard et al., 2008; Sevanian and Hochstein, 1985).
Thus, oxidative stress-dependent lipid peroxidation may represent an alternative
mechanism to liver n-3 LC-PUFA depletion in NAFLD (Videla et al., 2004), since lipids
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containing PUFA are more susceptible to peroxidation and the availability of n-6 LC-
PUFA in the liver of NAFLD patients results in enhanced peroxidation of these LA
derived LC-PUFA into their eicosanoid derivatives (Videla et al., 2004). For example,
LTB4, an AA-derived eicosanoid, is involved in acceleration of ROS production. The
increased production of proinflammatory cytokines and eicosanoids, produced from n-
6 PUFA metabolism, cause enhanced liver Kupffer cell production of inflammatory
cytokines causing activation of NF-ĸB, further exacerbating systemic and hepatic
insulin resistance with worsening inflammation and fibrosis (Byrne, 2010). Insulin
resistance as seen in NAFLD may be related to the depletion in n-3 LC-PUFA because
they are expected to modify membrane-mediated processes such as insulin signalling
(Lombardo and Chicco, 2006).
In summary, the depletion in n-3 LC-PUFA, the decrease in the ratio of
product/precursors of LC-PUFA, the increase in n-6 PUFA and the increase in n-6 LC-
PUFA derived eicosanoid production within the liver, all contribute to the development
of NAFLD and related pathophysiologies such as insulin resistance. The relationship
between the n-6: n-3 PUFA ratio within the liver and severity of steatosis has also been
demonstrated (Vuppalanchi et al., 2007). In this study, patients with NAFLD showed
significant correlation between the n-6: n-3 PUFA ratio and the quantity of hepatic
triglycerides, as a marker of the severity of hepatic steatosis (Vuppalanchi et al., 2007).
Defective desaturation of PUFA due to dietary imbalance comprises inadequate intake
of n-3 PUFA and a higher intake of n-6 PUFA further enhances the contribution of
desaturase inhibition in NAFLD.
1.1.6.2 CVD AND ATHEROSCLEROSIS
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Atherosclerosis is now considered a “systemic disease” characterised by low grade
arterial inflammatory lesions that can mature along with disease progression
(Montecucco and Mach, 2009). It is the underlying cause of coronary heart disease
(CHD), and abnormalities in the metabolism of essential fatty acids are characteristic of
the associated risk factors (Das, 2007). Under normal physiological conditions, healthy
endothelial cells synthesise and release adequate amounts of NO, PGI2 and PGE1,
maintaining a downstream balance between pro- and anti-inflammatory molecules.
However, in atherosclerosis, this balance becomes disrupted, leaning towards an
increase in the production of proinflammatory cytokines such as IL-1, IL-2, IL-6 and
TNFα, resulting in the further progression of the disease (Das, 2007). These
proinflammatory cytokines can induce oxidative stress by enhancing the production of
ROS by monocytes, macrophages and leukocytes. Since PUFA and their eicosanoid
derivatives modulate inflammation, they play a significant role in this disease (Das,
2006a). Decreases in ALA-derived LC-PUFA such as EPA and DHA seen in recent
endothelial cell PUFA deficiency, increases the production of proinflammatory
cytokines and free radicals which results in the development of insulin resistance (Das,
2006a). As an example, early studies in Greenland Eskimos, a population consuming a
high fat diet, but rich in n-3 PUFA, showed that ingestion of EPA and DHA led to
decreases in the mortality rate from CVD (Bang HO, 1976). Similarly, Japanese
populations eat more fish than North Americans and present a lower rate of acute
myocardial infarction and atherosclerosis (Holub, 2002; Menotti et al., 1999). Later
studies have further demonstrated strong associations between n-3 PUFA and
decreased risks of CVD (He et al., 2004; Lemaitre et al., 2003; Mozaffarian et al., 2005).
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The role of n-6 PUFA in CVD is much more complex than the role of n-3 PUFA. PGE2,
PGF2α, TXA2 and LTs produced from AA metabolism are proinflammatory (Das, 2007).
TXA2 acts as a potent vasoconstrictor and powerful activator of platelet aggregation
(Sellers and Stallone, 2008). Studies have shown that TXA2 promotes the initiation and
progression of atherosclerosis by regulating platelet activation and leukocyte-
endothelial cell interactions (Kobayashi et al., 2004). LTB4 acts as a potent chemotactic
agent, by inducing the generation of ROS, activating neutrophils and inducing the
aggregation and adhesion of leukocytes to the vascular endothelium (Das, 2007). The
leukotrienes LTC4, LTD4 and LTE4 induce vasoconstriction and bronchospasm (Das,
2007). Since AA is derived from LA, it is a substrate for the synthesis of a variety of
proinflammatory molecules and therefore, a reduction of LA intake will reduce tissue
AA content, which in turn will reduce any inflammatory potential and therefore lower
the risk for CVD (Harris et al., 2009). There are many other lines of evidence that link
LA with atherosclerosis. Endothelial dysfunction (ED), is a characteristic of early-state
atherosclerosis common in patients with insulin resistance and diabetes (Maingrette
and Renier, 2005). One recent review reported that diets enriched with LA increase the
LA content of LDL and its susceptibility to oxidation, whereby oxidative modification
increases the atherogenicity of LDL cholesterol (Simopoulos, 2008). Studies have also
shown that in patients with type 2 diabetes susceptible to developing ED, there are
substantial increases in LA concentrations in all LDL subfractions (Prescott et al., 1999).
Cellular oxidative stress associated with LA oxidation of LDL and LA mediated ED, is a
critical signal transduction pathway involved in NF-κB activation, whereby NF-κB is
critical for the expression of inflammatory genes associated with ED (Maingrette and
Renier, 2005). The susceptibility of LDL to oxidation by LA and its associated
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metabolites is linked to the severity of coronary atherosclerosis development
(Regnstrom et al., 1992; Simopoulos, 2008). Despite the evidence to suggest that n-6
PUFA consumption increases the risk of developing CVD, recent evidence has
suggested that both LA and ALA have the ability to prevent CVD (Poudel-Tandukar et
al., 2009). In this study, LA significantly reduced levels of CRP, an inflammatory marker,
upregulated in CVD in Japanese men (Poudel-Tandukar et al., 2009). However, other
evidence to suggest that n-6 PUFA have an anti-inflammatory effect when consumed
in such high quantities, such as that seen in the Western diet, is limited.
Since it has been proposed that diets high in LA reduce ALA metabolism (Liou et al.,
2007) and since ALA metabolites such as EPA and DHA have been shown to reduce
mortality rates from CVD (Bang HO, 1976; Holub, 2002; Menotti et al., 1999), the
balance of n-6 and n-3 PUFA is important in the prevention of atherosclerosis and CVD.
1.1.6.3 IBD
IBD is classified as a group of chronic systemically natured diseases of unclear
pathology which cause inflammation of the digestive tract, including Crohn’s disease
(CD) and ulcerative colitis (UC) (Lucendo and De Rezende, 2009). While environmental
factors indeed play a significant role in the etiology of the disease, more recent
attention has been placed on various dietary and nutritional factors, specifically the
lipid components of the diet as triggers of IBD (Cashman and Shanahan, 2003; Lucendo
and De Rezende, 2009). It is difficult to suggest that dietary influences or
supplementation can reduce the incidence of IBD or impact beneficially (through anti-
inflammatory effects) upon disease progression since, like many chronic diseases, IBD
is multifactorial. Despite this, lower prevalence of IBD has been observed with
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consumption of diets rich in n-3 LC-PUFA derived from fish oils, such as that seen of
the Greenland Eskimos (Bang et al., 1980; Kromann and Green, 1980). It has also been
reported that patients of IBD who supplement their diets with n-3 PUFA, show anti-
inflammatory actions, with decreased production of LTB4 by neutrophils and colonic
mucosa, resulting from incorporation of the n-3 PUFA into the gut mucosal tissue
(Hawthorne et al., 1992; Shimizu et al., 2003). A recent study using IL-10 knockout
mice (mice that spontaneously develop colitis) demonstrated significantly reduced
colonic inflammation when fed n-3 PUFA-rich fish oil compared with mice that were
fed n-6 PUFA-rich corn oil (Chapkin et al., 2007). In Japan, increased reports in the
incidence of IBD correlate with the increased dietary intake of n-6 PUFA (Sakamoto et
al., 2005; Shoda et al., 1996). Importantly, while n-3 PUFA decrease production of LTB4
by neutrophils and colonic mucosa (Hawthorne et al., 1992; Shimizu et al., 2003),
metabolism of AA increases the production of LTB4 within the inflamed intestinal
mucosa of IBD (Sharon and Stenson, 1984). A more recent report demonstrated
abnormal prevalence of the enzymes that co-ordinate to generate LTB4 from
membrane-derived AA in active IBD biopsies (Jupp et al., 2007). The recruitment of
neutrophils and other leukocytes to the IBD gut mucosa seen with colonic injury may
be a direct result of the increased ability to generate LTB4 from AA (Jupp et al., 2007). It
is clear from the literature that n-3 PUFA have a positive effect on reducing the risk of
IBD (Belluzzi et al., 1996; Ferrucci et al., 2006; Sijben and Calder, 2007). The situation is
less clear for n-6 PUFA, although the proinflammatory eicosanoids derived from AA
have been shown to play a crucial role in the pathogenesis of all these related
inflammatory disorders. Since n-3 PUFA have been shown to alleviate the progression
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of IBD, while n-6 PUFA have been implicated in the origin of IBD, the importance of a
balance in the ratio of n-6: n-3 in today’s dietary regime is highlighted.
1.1.6.4 RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a long-term disease that leads to inflammation of the joints
and surrounding tissues, causing pain, swelling and impaired function. It is
characterised by infiltration of T-lymphocytes, macrophages, and plasma cells into the
synovium, with the initiation of a chronic inflammatory state that involves the
overproduction of proinflammatory cytokines (Calder, 2008b). Studies have shown
that AA-derived eicosanoids, PGE2 and PGI2, play a role in the pathogenesis of
rheumatoid arthritis (Honda et al., 2006; Pulichino et al., 2006). PGI receptor-deficient
(IP-/-) mice subjected to collagen induced arthritis (CIA), showed a significant reduction
in arthritic scores and reduction in IL-1β and IL-6 levels in arthritic paws (Honda et al.,
2006). Inhibition of both PGE receptors (EP2 and EP4), suppressed inflammatory
events and arthritis in CIA. These results suggest that both PGE2 and PGI2 participate in
rheumatoid arthritis. Supplementation with n-3 PUFA has been demonstrated to
modulate the activity of inflammatory factors that cause cartilage destruction during
arthritis (Calder, 2008b; Curtis et al., 2000). Moreover, by decreasing n-6 PUFA intake
(particularly AA) down to less than 90 mg/day through an anti-inflammatory
lactovegetarian (vs. normal Western) diet was shown to improve the clinical symptoms
associated with rheumatoid arthritis (Adam et al., 2003).
1.1.6.5 ALZHEIMER’S DISEASE (AD)
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AD is the most common form of dementia in the elderly, clinically characterised by
memory dysfunction, loss of lexical access, spatial and temporal disorientation and
impaired judgement (Corsinovi et al., 2011). The pathogenesis of AD is extremely
complex, with genetic factors, education and lifestyle all playing crucial roles in disease
onset. However, a poor understanding of the pathogenesis of AD means that there are
no curative treatments yet available. Recently, the role of diet has gained much
interest in both the pathogenesis and prevention of this disease. The role of n-6 PUFA
and oxidised eicosanoid derivatives of n-6 PUFA have recently been reviewed as
contributing to β-amyloid deposition, a hallmark of AD onset and progression
(Björkhem et al., 2009; Whelan, 2008). AA is distributed in several different cell types
in both the grey and white matter in the brain (Corsinovi et al., 2011). The role AA
plays in oxidative stress and lipid peroxidation has already been discussed in relation to
NAFLD, however, oxidative stress and production of ROS has also been suggested to
play a role in AD, thus suggesting a role of AA and lipid oxidation products
(eicosanoids) in the onset and progression of the disease (Lee et al., 2010; Rothman
and Mattson, 2010). Furthermore, the enhanced consumption of n-6 PUFA leads to an
excessive production of the proinflammatory cytokines derived from AA through COX
and LOX enzymatic activity which lead to brain damage (Farooqui et al., 2007; Tassoni
et al., 2008). As an example, a study using transgenic mice with memory impairment
and β-amyloid deposition, fed a diet poor in n-3 PUFA but rich in n-6 PUFA was found
to have a significant decrease in the postsynaptic receptor complex in the brain which
regulates memory and learning and a net potentiation of programmed cell death
(Calon et al., 2005). In contrast, n-3 PUFA may play a role in the prevention of AD.
Studies have shown that DHA provides support to learning and memory events in
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animal models of AD and protection against the disease (Hashimoto et al., 2002; Lim et
al., 2005; Schaefer et al., 2006). Another recent epidemiological study indicated a
relationship between higher fish consumption and improved cognitive function in later
life (Dangour et al., 2009). Both DHA and EPA have been shown to competitively
counteract the production of proinflammatory eicosanoids derived from n-6 PUFA in
the brain of AD patients (Freeman et al., 2006). The neuroprotective role of EPA has
been demonstrated since EPA competes with AA for incorporation into cell membrane
phospholipids and for oxidation by the COX enzyme, thus exerting anti-inflammatory
actions. The resulting production of anti-inflammatory PGE3 might result in decreased
levels of proinflammatory PGE2 (Freemantle et al., 2006). The balance between the n-
6: n-3 PUFA ratio may therefore play a crucial role in the onset of AD. A recent study
showed that a lower n-6: n-3 PUFA ratio was associated with a lower incidence of
dementia, especially in depressed patients (Samieri et al., 2008). Furthermore, we
have previously demonstrated in patients with depression, increases in plasma AA and
IL-6 associated with inflammation (Dinan et al., 2009). Therefore, a dietary pattern
consisting of lower n-6 PUFA and higher n-3 PUFA or a more balanced n-6: n-3 PUFA
ratio may be therapeutic in the pathogenesis of AD.
1.1.7 CONCLUSION
Increases in the ratio of n-6: n-3 PUFA, characteristic of the Western diet, could
potentiate inflammatory processes and consequently predispose to or exacerbate
many inflammatory diseases. The change in ratio and increase in n-6 PUFA
consumption changes the production of important mediators and regulators of
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inflammation and immune responses towards a proinflammatory profile. Chronic
conditions such as CVD, diabetes, obesity, rheumatoid arthritis, and IBD are all
associated with increased production of LTB4, TXA2, IL-1β, IL-6 and TNFα, whereby the
production of these factors increases with increased dietary intake of n-6 PUFA and
decreased dietary intake of n-3 PUFA. In conclusion, the unbalanced dietary
consumption of n-6: n-3 PUFA is detrimental to human health, and so, the impact of
dietary supplementation with n-3 PUFA upon the alleviation of inflammatory diseases,
more specifically, NAFLD, needs to be more thoroughly investigated.
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TABLE 1.1.1 PUFA content of dietary oils
Data are expressed as mg/100g edible portion. Data are elaborated from (Benatti et
al., 2004; Das, 2006b; Hughes CL, 2002). Content of fatty acids may vary slightly
according to species, sources and analytical factors.
Fat type LA ALA AA EPA + DHA
Saturated
Lard
Butter fat
Coconut oil
Beef tallow
Unsaturated
1)Monounsaturated
8600
2300
1400
80
1000
1400
1070
Peanut oil 23900
Pecans 20600 1000
Almonds 9860 260
Olive oil 8000 950
Avocado 1970
2)Polyunsaturated
-Omega-6
Safflower oil 74000 470
Sunflower oil 60200 500
Soybean oil 53400 7600
Corn oil 50000 900
Cotton seed oil 47800 1000
Walnut 34100 6800 590
Brazil nut 24900
-Omega-3
Linseed oil 13400 5530
Canola oil 19100 8600
Salmon 440 550 300 1200
Tuna 260 270 280 400
Herring 150 62 37 1700
Trout 74 30 500
Cod 4 2 3 300
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TABLE 1.1.2 Proinflammatory effects of n-6 PUFA-derived eicosanoids and anti-
inflammatory effects of n-3 PUFA-derived eicosanoids
Proinflammatory effects of n-6 PUFA-derived eicosanoids
AA (n-6) derived
eicosanoids Physiological effects Organs or cells
Bronchoconstriction Bronchi
PGD2 Proinflammatory Activation of eosinophils
Proarrhythmic Vessels
Induces fever
Prostaglandins PGE2 Causes pain Nociceptor sensory neurons
Increases production of IL-6
PGF2 Bronchoconstriction Bronchi
Proarrhythmic Vessels
PGI2 Causes pain Nociceptor sensory neurons
Proaggregation Platelets
TXA2 Vasoconstriction Vessels
Thromboxanes Bronchoconstriction Bronchi
Proaggregation Platelets
TXB2 Vasoconstriction Vessels
Bronchoconstriction Bronchi
Proinflammatory Leukocytes
Leukotrienes LTB4 Chemotaxis Leukocytes
Release of reactive oxygen species Granulocytes
LTA4, LTC4, LTD4, LTE4
Anti-inflammatory effects of n-3 PUFA derived eicosanoids
EPA and DHA
(n-3) derived
eicosanoids
Physiological effects Organs or cells
PGI3 Antiarrhythmic Vessels
Prostaglandins PGE3 Antiarrhythmic Vessels
PGF3, PGD3
Thromboxanes TXA3 Antiaggregation Platelets
TXB3 Antiaggregation Platelets
LTA5, LTC5, LTD5, LTE5
LTB5 Anti-inflammatory Leukocytes
RVE1 Antiaggregation Platelets
Resolvins Anti-inflammatory Dendritic cells
RVD Anti-inflammatory
Anti-inflammatory
Retina (photoreceptor cells)
and brainNeuroprotectin NPD1 Antiapoptotic
Decreases oxidative stress
Data elaborated from (Bazan, 2009; Fredman and Serhan, 2011; Harizi et al., 2008;
Schmitz and Ecker, 2008).
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FIGURE 1.1.1 Metabolism of n-6 and n-3 PUFA
The metabolism of PUFA is a complex process involving several enzymes of
desaturation, elongation, and β-oxidation. Shown here is the pathway of both n-6 and
n-3 PUFA metabolism to more unsaturated, long-chain members of each family. Also
shown are their respective eicosanoid derivatives. Data elaborated from (Schmitz and
Ecker, 2008).
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FIGURE 1.1.2 Effects of unbalanced n-6: n-3 PUFA intake on various diseases of
inflammation
Dietary imbalance in the consumption of n-6 and n-3 PUFA, representative of the
Western diet. Greater consumption of n-6 PUFA leads to an increase in their
metabolism to their LC-PUFA derivatives (AA). Decreases in n-3 PUFA consumption
leads to a decrease in their metabolism to their LC-PUFA derivatives (EPA/DHA). The
increase in AA in cell membrane phospholipids leads to an increase in COX and LOX
enzyme production of AA derived eicosanoids and a decrease in EPA/DHA derived
eicosanoids, leading to an increase in inflammation and proinflammatory cytokine
production. This in turn leads to a decrease in PPARα gene expression, while there is
n-6
n-3
AA derived TXA2, PGE2, LTB4, LTC4-LTE4
EPA/DHA derived TXA3, PGE3, LTB5, LTC5-LTE5
Proinflammatory cytokine production
Anti-inflammatory cytokine production
NF-ĸBSREBP-1c PPARα
NAFLD, CVD, IBD, Rheumatoid
Arthritis, AD
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an increase in both SREBP-1c and NF-ĸB gene expression. This change in gene 
expression can also cause an increase in lipogenesis, as well as increasing
inflammation. The result is an increase in various diseases of inflammation, some of
which are highlighted in the figure.
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Chapter 1.2
Microbiota, metabolite production and host health
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1.2.1 ABSTRACT
A healthy gut microbiota contributes towards the health and welfare of the host in
a number of ways including participation in the correct development and functioning
of the immune system, performance of a broad range of vital metabolic and
biochemical functions and production of health-beneficial bioactive metabolites.
Perturbations in the composition of the gut microbiota are highlighted in many disease
states and are thought in some instances to render the host susceptible to infection.
Metabolites produced by the gut microbiota include antimicrobials, conjugated
polyunsaturated fatty acids (PUFA) and exopolysaccharides (EPS) which benefit host
health. Evidence is also emerging of microbially-produced molecules with neuroactive
functions that can have influences across the brain-gut axis. For example, gamma-
aminobutyric acid (GABA), serotonin, catecholamines and acetylcholine, may modulate
neural signalling within the enteric nervous system, when released in the intestinal
lumen and consequently signal brain function and behaviour. Dietary supplementation
with probiotics and prebiotics are fast becoming the most widely used dietary adjuncts
to modulate the gut microbiota. Furthermore, evidence is emerging of the interactions
between administered microbes and dietary substrates, i.e. fatty acids, which may
promote neurological development in infants, as well as improved mental health
status among adults.
1.2.2 INTRODUCTION
The microbial ecosystem residing in the human gut harbours over 100-fold more
genes than the human genome (Backhed et al., 2004; Ley et al., 2006; Qin et al., 2010)
and is tantamount to a virtual organ. To a large extent, intestinal ecological conditions
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are set by the host and resident commensals must adapt to this environment. Host-
microbe, environment-microbe and microbe-microbe interactions may also dictate the
composition of this microbial community. A symbiotic relationship between the gut
microbiota and host is the most favourable where both partners benefit; the host
provides protection and nutrients for the microorganisms to flourish within (Maynard
et al., 2012), while the microbiota contribute to food digestion, inhibit the growth of
potential invading pathogens, convert harmful compounds to less toxic substances and
produce bioactive molecules which play a role in host physiology (Marques et al.,
2010). However, disruptions to this symbiotic relationship can occur, during which
certain commensal gut microbes can adopt pathogenic potential such as small
intestinal bacterial overgrowth (Bouhnik et al., 1999; Riordan et al., 2001) and/or
translocation to other tissues and organs (Maes et al., 2013; Teltschik et al., 2012). The
relationship between the gut microbiota and host is however important for health, and
although it remains unclear whether disease development is causal or consequential of
an altered microbiota, an increasing body of evidence describes a link between the
two.
Microbial colonisation of the infant intestine begins at birth (Koenig et al., 2011).
Extrinsic factors contribute to the initial colonisation of the infant gut (Butel et al.,
2007; Scholtens et al., 2012), whereby feeding regime (Bezirtzoglou et al., 2011; Fallani
et al., 2010), gestational age (Hallab et al., 2013) and antibiotic therapy to which the
infant is exposed to (Fouhy et al., 2012; Hussey et al., 2011) can all significantly impact
early colonisation. Intestinal establishment of a healthy microbiota in early life is
believed to have a profound impact on the development and maturation of the
immune system (Palmer et al., 2007). Vaginally born infants are initially colonised by
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faecal and vaginal bacteria from the mother, whereas infants delivered by Caesarean-
section render the gut susceptible to colonisation by maternal skin microbiota and
bacteria from the hospital environment (Dominguez-Bello et al., 2010; Huurre et al.,
2008; Penders et al., 2006). It has been shown that vaginally born babies have higher
numbers of Lactobacillus and Bifidobacterium, compared with infants delivered by
Caesarean-section (Dominguez-Bello et al., 2010). The weaning process determines the
transition of an unstable infant microbiota to a more complex adult-like microbial
ecosystem (Fallani et al., 2011; Koenig et al., 2011). The development and
diversification of the gut microbiota continues into adulthood and is further influenced
by several factors, including diet and environment (Yatsunenko et al., 2012). To a large
extent, the gut microbiota remains relatively stable throughout adulthood, unless
perturbed by extrinsic or host factors, for example, antibiotic treatment and
inflammation, respectively.
The tools used to study the link between gut microbial diversity and health status
have improved our knowledge of the host-microbe relationship significantly. Culture-
independent analysis of the composition and functional capacity of the gut
microbiome targets the 16S rRNA gene, due to its presence in all prokaryotes with the
existence of variable domains that allow different taxa to be identified. Although
compositional studies generate a large volume of data, they fail to provide direct
information regarding the microbial viability or the functional potential of the
populations present and so the knowledge generated is somewhat limited in these
aspects. Metagenomic studies go beyond the 16S rRNA gene to sequence small
fragments of metagenomic DNA at random to characterise the full genetic content and
functional potential of the microbial community (Kurokawa et al., 2007; Qin et al.,
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2010; Turnbaugh et al., 2009). The development of methods used to analyse gene
expression (metatranscriptomics), protein products (metaproteomics) and metabolic
profiles (metabolomics) of the gut microbiota have further enabled such studies to
identify the microbial activity and to link this with compositional analysis, to determine
host-microbe interactions (Guinane and Cotter, 2013).
Dietary interventions with probiotics and prebiotics, due to the dynamic nature of
the gut microbial ecosystem, have fast become an attractive means of self-
manipulating the microbiota to improve health status, and have been extensively
reviewed (Sanders et al., 2013; Vyas and Ranganathan, 2012). Probiotics are defined as
“live microorganisms which when administered in adequate amounts confer a health
benefit on the host” and have been shown to improve intestinal barrier function,
modulate the immune system and enhance the host defence system by competing
against pathogens for nutrients and binding sites. In addition, numerous probiotic
intervention studies have revealed their functional capacity to improve certain
gastrointestinal disorders, for example, irritable bowel syndrome (IBS), inflammatory
bowel disease (IBD) (Cappello et al., 2013; Whelan and Quigley, 2013) and antibiotic-
associated diarrhoea (AAD) (Hempel et al., 2012; Hickson, 2011). Bifidobacterium and
Lactobacillus are the main genera of microorganisms used as probiotics as many of
them can survive gastrointestinal transit, have the capability to adhere to intestinal
epithelial cells and are regarded as safe (Marques et al., 2013). Prebiotics on the other
hand, are ‘non-digestible food ingredients that selectively stimulate the growth of
beneficial indigenous microbes already established within the gut such as
bifidobacteria and lactobacilli (Saulnier et al., 2009). Typically, prebiotics must reach
the large intestine unaltered, resisting host digestion, absorption and adsorption to be
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fermented by the gut microbiota. Commonly used prebiotics include inulin,
fructooligosaccharides (FOS) and galactooligosaccharides (GOS) (Preidis and Versalovic,
2009). The fermentation of prebiotics by the gut microbiota generates short chain fatty
acids (SCFA), such as butyric and acetic acids, which have demonstrated numerous
health benefits in vivo (Preidis and Versalovic, 2009; Saulnier et al., 2009). This review
will focus on the importance of the microbiota to host health and in establishing a
healthy immune system and describes some of the known beneficial bioactive
metabolites produced by the microbiota that impact on health.
1.2.3 ROLE OF THE MICROBIOTA IN ESTABLISHING A HEALTHY IMMUNE SYSTEM
During the first year of life, the immature developing gut microbial ecosystem
rapidly shapes the maturation of the infant immune system, while the immune system
also influences the gut microbiota (Hansen et al., 2012). From birth, breast milk
provides passive transfer of maternal antibodies to the infant which shapes both the
immature immune system and gut microbiota (Maynard et al., 2012). Much of the
information regarding the influence of gut microbes on the host immune system are
generated from studies using germ-free animals. Germ-free animals are those born
and reared without exposure to microorganisms and so the immune responses of such
animals have not been influenced by interactions with molecules of commensal and
pathogenic microorganisms. Unsurprisingly, germ-free mice show defects in both the
development of the immune system and in immune responses. One of the first
immunological defects observed in these animals was a marked reduction in
antibodies produced within the intestine (Moreau et al., 1978). Furthermore, germ-
free animals show extensive defects in the development of gut-associated lymphoid
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tissue (GALT) and have fewer and smaller Peyer’s patches and mesenteric lymph nodes
(MLNs), compared with animals housed under specific pathogen-free conditions (Falk
et al., 1998; Hoshi et al., 1992; Macpherson and Harris, 2004; Pollard and Sharon,
1970). Intestinal epithelial cells have many immunological functions; they secrete and
respond to various cytokines and express molecules that directly interact with
lymphocytes and line the gut to form a physical barrier between the luminal contents
(including the microbiota) and the underlying cells of the immune system (Round and
Mazmanian, 2009). Germ-free mice demonstrate a reduced number of these cells,
whereby the toxicity of intestinal epithelial cells from germ-free mice is compromised
(Imaoka et al., 1996; Umesaki et al., 1993) and demonstrate a decreased cell turnover
rates of these cells (Abrams et al., 1963). Furthermore, animals lacking a gut
microbiota are more susceptible to infection due to a poorly developed immune
system; e.g. germ-free guinea pigs challenged with the enteric pathogen Shigella
flexneri demonstrated a decrease in the immune resistance to infection coupled with
an increase in mortality (Sprinz et al., 1961), while infection with the intracellular
pathogen Listeria monocytogenes in germ-free mice resulted in decreased pathogen
clearance, compared with conventionalised animals (Zachar and Savage, 1979).
Deliberate colonisation of the sterile gut of these animals either with a single microbial
species or a defined species mixture, termed “gnotobiotics” is a powerful technological
tool for determining which host immune functions are genetically encoded and which
require interactions with microbes (Hooper and Macpherson, 2010). For example,
colonisation of germ-free animals with a single bacterium, Bacteroides fragilis, has
been shown to protect against inflammation in an animal model of experimental colitis
(Mazmanian et al., 2005; Mazmanian et al., 2008). Collectively, these observations
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suggest that developmental defects through the absence of a gut microbial ecosystem
compromise immune function of the host at the tissue, cellular and molecular levels
and highlight a role of the microbiota in the establishment of a functional immune
system.
1.2.4 INTERRUPTION OF THE SYMBIOTIC HOST-MICROBE RELATIONSHIP WITH
IMPLICATIONS FOR IMMUNE FUNCTION AND HEALTH
Disruptions in the development of the gut microbiota from infancy are common.
Early antibiotic therapy of up to eight weeks after treatment has been shown to impact
the gut microbiota composition of infants, which could have a negative impact on the
development of the immune system, predisposing the infant to asthma, obesity and
allergies (Fouhy et al., 2012; Hussey et al., 2011). Thus, disruptions in the host-microbe
relationship can undoubtedly predispose to disease, from infancy to adulthood. Within
this respect, there has been a rapid increase in the development of disorders such as
IBS, asthma, rheumatoid arthritis, diabetes and obesity, particularly within developed,
Western populations. Indeed, the role of a perturbed gut microbial ecosystem in such
diseases is becoming more evident, although much future work is needed to decipher
the mechanisms which link this relationship with disease.
1.2.4.1 IBD
IBD comprises a group of disorders characterised by severe inflammation in the
intestine. The symptoms and inflammation pattern in the host characterise IBD as
either Crohn’s disease (CD) or ulcerative colitis (UC). While the exact causes of IBD
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remain unclear, the onset of both conditions is generally thought to be due to an
overall disruption in the host-microbe relationship, and not by a single causal organism
(Lepage et al., 2011; Martinez et al., 2008). Recently reviewed, numerous studies
which indicate a role of the gut microbiota in the manifestation of IBD generally
conclude that the gut microbiota are involved in the development of mucosal lesions
causing intestinal inflammation in the host (Manichanh et al., 2012). Inflammatory
damage in IBD has been linked to alterations in the relative abundances of
Enterobacteriaceae, Ruminococcaceae and Leuconostocaceae (Morgan et al., 2012)
and an overall decrease in bacterial diversity (Manichanh et al., 2006; Sokol et al.,
2006). The incidence of Clostridium difficile carriage, an opportunistic pathogen
frequently linked with AAD, has been reported to be over 8- fold higher in patients
suffering from IBD, compared with healthy controls (Clayton et al., 2009).
1.2.4.2 TYPE-1 AND TYPE-2 DIABETES
The incidence of both type-1- (T1D) and type-2- (T2D) diabetes have become
increasingly prevalent in recent decades. While genetic factors play a major role in
disease onset, particularly in predisposing individuals to T1D, T2D is principally linked
to obesity associated insulin resistance. Recent studies demonstrate disruptions to the
host-microbe relationship and gut microbial composition and diversity associated with
both T1D and T2D. Compositional sequencing studies have revealed a reduction in the
relative proportions of Firmicutes, while Bacteroidetes were enriched in T2D subjects,
compared with healthy controls (Larsen et al., 2010). Identification of gut microbial
markers associated with the moderate degree of microbial disruption in patients with
T2D could be useful in the future management of this disease (Qin et al., 2012).
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Furthermore, increases in opportunistic pathogens such as Clostridium were also
identified as contributing to disruption in the host-microbe interactions associated
with T2D (Qin et al., 2012). Creating a link between the gut microbiota and T1D is
much more difficult, since genetic factors play a more significant role in this disease.
However, evidence indicates that alterations in the intestinal microbiota are associated
with T1D and subsequent insulin dependence in various models of the disease. While
one study demonstrated that the stool of bio-breeding diabetes-resistant (BBDR) rats
contained higher relative abundances of Lactobacillus and Bifidobacterium, compared
with bio-breeding diabetes-prone (BBDP) rats (Roesch et al., 2009), others have
reported that lactate producing species such as Lactobacillus, Lactococcus and
Bifidobacterium were increased in the stool of children who tested positive for T1D
associated autoimmunity (Brown et al., 2011; Giongo et al., 2011). Furthermore, low
relative abundances of two of the most common Bifidobacterium species, B.
adolescentis and B. pseudocatenulatum have been associated with autoimmunity in
children who tested positive for at least two T1D-associated autoantibodies (de Goffau
et al., 2013).
1.2.4.3 OBESITY
Obesity develops from a prolonged imbalance of energy intake and expenditure.
Undoubtedly, while lifestyle, genetic factors, diet and exercise contribute largely to
this modern epidemic, an increasing body of evidence suggests that disruptions to the
host-microbe relationship contributes towards disease (Ley, 2010; Ley et al., 2005; Tilg
and Kaser, 2011; Turnbaugh et al., 2006). Identifying specific populations which may be
associated with weight gain has been the subject of much debate, often differing
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between the various models of obesity in both rodent and humans. Genetically
(ob/ob) and diet-induced obese (DIO) mice have demonstrated an increase in the
Firmicutes: Bacteroidetes ratio, compared with their lean counterparts (Ley et al.,
2005). Furthermore, weight loss in human subjects has been linked with decreasing
the Firmicutes: Bacteroidetes ratio (Ley et al., 2006). However, the relevance of the
Firmicutes: Bacteroidetes ratio in obesity is still unclear (Schwiertz et al., 2010). The
gut microbiota also increase the dietary energy harvesting capacity of the host
(Murphy et al., 2010) and conventionally raised mice have 40% more body fat than
their germ-free counterparts, whereby colonisation with what is considered a
conventional gut microbiota induced hepatic lipogenesis and increased lipid storage in
adipocytes (Backhed et al., 2004).
Obesity is also associated with low grade inflammation in the host which may be
linked to host-microbe interactions. Data from several studies have revealed that the
lipopolysaccharide (LPS) endotoxin derived from certain components of the gut
microbiota contributes towards obesity associated inflammation. Endogenous LPS is
continuously produced in the gut as a consequence of the death of Gram-negative
bacteria, since LPS is a component of the Gram-negative bacterial cell wall and acts
through the Toll-like receptor 4 (TLR4)/ MyD88/ NF-κB signalling pathway. LPS induced
inflammation could also be an early factor which triggers high-fat diet-induced
metabolic diseases, otherwise known as metabolic endotoxemia (Cani et al., 2007). It
has been shown that high-fat feeding increased plasma LPS levels throughout the day,
compared with controls, resulting in significant increases in fasting blood glucose,
insulin, liver triglyceride content, body weight and proinflammatory cytokine mRNA
expression, similar to mice that were infused with LPS (Cani et al., 2007). Further
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studies examined the effect of changes in the gut microbiota leading to LPS induced
metabolic endotoxemia in the host (Cani et al., 2008). It was revealed that while
plasma LPS levels were increased following high-fat feeding relative to controls, this
result was overturned in high-fat diet-fed mice following antibiotic treatment (Cani et
al., 2008). Such studies reveal that disruptions to host-microbe interactions within the
gut following obesity and high-fat dietary feeding may generate increased
gastrointestinal levels of microbial-derived LPS endotoxin, associated with metabolic
endotoxemia.
1.2.5 HOST-MICROBE INTERACTIONS, GENERATION OF LC-PUFA AND MICROBIAL
METABOLITE PRODUCTION WITH HEALTH EFFECTS
The products of human enteric microbial metabolism often act as signalling
molecules, developing ‘intelligent communication systems’ in the body. These
microbial metabolites termed ‘pharmabiotics’, can exert beneficial health effects
which directly impact host intestinal function but may also affect the liver and brain
(Shanahan, 2009). Host-microbe interactions can together co-metabolise dietary
components to produce a large array of molecules with beneficial impacts on health.
Commensal bacteria have been shown to synthesise essential vitamins such as vitamin
K2 and vitamin B12 (Said, 2011), can alter n-3 PUFA metabolism to generate increased
levels of LC-PUFA metabolites such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) (Wall et al., 2012; Wall et al., 2009), can produce
conjugated fatty acid derivatives of PUFA such as conjugated linoleic acid (CLA) and
conjugated α-linolenic acid (CALA) (Barrett et al., 2012a; Hennessy et al., 2012) and can
increase production of SCFA (Wall et al., 2012). The beneficial impacts of some of these
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bioactive compounds on host health are reviewed below and summarised in Table
1.2.1.
1.2.5.1 VITAMIN SYNTHESIS
Some commensals of the human gut microbiota possess the ability to synthesise
menaquinone (vitamin K2), as well as many of the water-soluble B vitamins, such as
biotin, cobalamin, folate, nicotinic acid, panthotenic acid, pyridoxine, riboflavin and
thiamine (LeBlanc et al., 2013). In particular, many Bifidobacterium strains have been
shown to exhibit vitamin production capabilities (Deguchi et al., 1985; Noda et al.,
1994; Pompei et al., 2007). Vitamin K is a lipophilic vitamin which acts as a co-factor for
the enzyme γ-carboxylase which converts specific glutamyl residues in a limited
number of proteins to γ-carboxyglutamyl (Gla) residues, responsible for high-affinity
binding of calcium ions (LeBlanc et al., 2013). The daily requirement for vitamin K is
fulfilled by dietary phylloquinone, present in plants and to an undermined extent, by
bacterially produced vitamin K2 (LeBlanc et al., 2013). Vitamin K is important for blood
clotting, bone and vascular health and deficiencies have been associated with low
bone mineral density (Knapen et al., 1998; Szulc et al., 1994), increased risk of fracture
(Luukinen et al., 2000; Szulc et al., 1993) and cardiovascular disease (Geleijnse et al.,
2004).
Vitamin B12 is a type of cobalt corrinoid, particularly of the cobalamin group and is
solely synthesised by some bacteria and archea. Vitamin B12 biosynthesis was first
identified in Propionibacteria freudenreichii, now used in the commercial production of
the vitamin (Roessner et al., 2002). Furthermore, Lactobacillus reuteri CRL1098 was
shown to be the first lactic acid producing bacterial strain capable of producing a
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cobalamin-like compound with an absorption spectrum resembling that of standard
cobalamin (Taranto et al., 2003). The genetic pathway responsible for the de novo
synthesis of vitamin B12 by L. reuteri have previously been described for two L. reuteri
strains (Saulnier et al., 2011). More recently, the presence of bifidobacterial genes,
predicted to be involved in the biosynthesis of several B-vitamins have been identified
in bifidobacteria residing in faecal samples of adult subjects (Gosalbes et al., 2011;
Klaassens et al., 2011; Klaassens et al., 2009).
1.2.5.2 POLYUNSATURATED AND CONJUGATED FATTY ACID SYNTHESIS
PUFA contain two or more double bonds and are classified as either n-3, n-6 or n-9,
based on the location of the last double bond relative to the terminal methyl end of
the molecule. Linoleic acid (LA, 18:2n-6) (precursor to the n-6 series of fatty acids) and
α-linolenic acid (ALA, 18:3n-3) (precursor to the n-3 series of fatty acids) are the
simplest members of each family of PUFA and are essential fatty acids. PUFA regulate a
wide variety of biological functions, ranging from blood pressure and blood clotting, to
the development and functioning of the brain and nervous system. It has been shown
that the gut microbiota not only affects fat quantity (Backhed et al., 2004) but also fat
quality (Wall et al., 2010; Wall et al., 2009) in various models. CLA refers to a family of
positional and geometric isomers of LA which have been associated with several health
benefits. The CLA isomers cis-9, trans-11 and trans-10, cis-12 are most often studied
for their beneficial in vitro and in some cases in vivo health effects associated with
various types of cancer, atherosclerosis, obesity, diabetes, as well as an ability to
improve immune function, body composition and bone formation (Belury, 2002;
Benjamin and Spener, 2009; Bhattacharya et al., 2006; Brownbill et al., 2005; Chin et
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al., 1994; Churruca et al., 2009; Jaudszus et al., 2005; Kelley et al., 2007; Nagao and
Yanagita, 2005; Pariza et al., 2001; Silveira et al., 2007; Valeille et al., 2006; Watras et
al., 2007). It has recently been shown that plasma CLA metabolite concentrations in
humans following dietary CLA supplementation were comparable with those
previously observed in experimental animal models and sufficient enough to exert
health benefits (Mele et al., 2013). Considerable species variations amongst
bifidobacteria have been observed for PUFA and CLA production. While
Bifidobacterium breve has been reported as one of the most efficient CLA producers
among various strains tested (Coakley et al., 2003; Rosberg-Cody et al., 2004),
Bifidobacterium bifidum (Rosberg-Cody et al., 2004) and Bifidobacterium dentium
(Coakley et al., 2003) have also demonstrated good conversion rates in vitro. It has
been shown that administration of CLA producing strains of bifidobacteria are
metabolically active in the gastrointestinal tract of mice and pigs (Wall et al., 2009).
Furthermore, administration of B. breve NCIMB 702258 in combination with LA
resulted in modulation of tissue fatty acid composition, significantly increasing levels of
cis-9, trans-11 CLA in the liver of both mice and pigs (Wall et al., 2009). Increased
tissue concentrations of n-3 LC-PUFA, EPA and DHA were also found in the adipose
tissue of both mice and pigs (Wall et al., 2009). Furthermore, the ratio of arachidonic
acid to EPA in the liver and adipose tissue were reduced following B. breve
supplementation, coupled with an anti-inflammatory cytokine profile in the host (Wall
et al., 2009). Both EPA and DHA have previously been shown to exert anti-
inflammatory properties (Nobre et al., 2013). In a related study, it was found that
administration of B. breve NCIMB 702258 in combination with ALA was associated with
alterations in the fatty acid composition of the brain, with elevated levels of EPA and
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DHA (Wall et al., 2012). Although the mechanisms responsible for the bifidobacteria-
mediated changes in host n-3 PUFA composition are largely unclear, such studies have
demonstrated that manipulation of the gut microbiota with metabolically active strains
may represent a therapeutic strategy for various disorders related to inflammation in
the host, through the production of LC-PUFA and PUFA-derived conjugated fatty acids.
1.2.5.3 PRODUCTION OF SCFA
SCFA are the end products of anaerobic gut microbial fermentation of undigested
dietary fibers and have important functions in host energy metabolism. Indeed, SCFA
play a key role in the prevention and treatment of metabolic and bowel disorders and
certain types of cancer (Blouin et al., 2011; Gao et al., 2009; Hu et al., 2010; Scharlau et
al., 2009; Tang et al., 2011). The positive influence of SCFA treatment on UC and CD
have been demonstrated in various clinical studies (Breuer et al., 1991; Di Sabatino et
al., 2005; Harig et al., 1989; Scheppach, 1996; Vernia et al., 1995). Butyrate is the
primary energy source for cellular metabolism in the colonic epithelium (den Besten et
al., 2013). The colonic epithelial cells of germ-free mice are severely energy-deprived
and are characterised by increased activation of AMP-activated protein kinase (AMPK),
which senses cellular energy status (Donohoe et al., 2011). SCFA also regulate gene
expression in the host by binding to the G-protein coupled receptors (GPCR), GPR41
and GPR43 to impact on several different cellular functions in the host, depending on
the cell type (Tremaroli and Backhed, 2012). For example, SCFA suppress inflammation
through GPR43 signalling in immune cells (Maslowski et al., 2009; Sina et al., 2009) and
modulate secretion of the insulin secreting and antidiabetic hormone glucagon-like
peptide-1 (GLP-1) in the distal small intestine and colon (Tolhurst et al., 2012).
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1.2.5.4 MICROBIAL PRODUCTION OF EPS
Many organisms including some resident microbes of the gut microbial ecosystem
have the ability to synthesise EPS with a large variation in composition, charge and
molecular structure (Stack et al., 2010). EPS producing strains are responsible for a
“ropy” phenotype and are beneficial in the food and health industries. Health benefits
associated with EPS include immunostimulatory effects (Kitazawa et al., 1998;
Vinderola et al., 2006), blood cholesterol lowering effects (Maeda et al., 2004;
Nakajima et al., 1992) and prebiotic effects (Korakli et al., 2002; O’Connor et al., 2005).
Beta-glucan is a water soluble fiber found in cereals, as well as in yeast, bacteria, algae
and mushrooms (Theuwissen and Mensink, 2008). The EPS beta-glucan has been
reported to have many health promoting properties including immunomodulatory
effects (Akramiene et al., 2007; Hida et al., 2009; Tsoni and Brown, 2008; Volman et
al., 2008), lowering serum cholesterol levels (Theuwissen and Mensink, 2008; Wilson
et al., 2004), antiosteoporotic (Shin et al., 2007), antitumorigenic, anticytotoxic and
antimutagenic effects (Gu et al., 2008; Mantovani et al., 2008). Furthermore, oat beta-
glucan has also been associated with the ability to modulate satiety, thus controlling
appetite (Beck et al., 2009a; Beck et al., 2009b). Heterologous expression of the
pediococcal glycotransferase (gtf) gene responsible for the synthesis and secretion of
the 2 substituted (1,3) beta-D-glucan in Lactobacillus paracasei NFBC 338 increased the
stress tolerance of the probiotic, due to EPS production (Stack et al., 2010).
Furthermore, Bifidobacterium breve UCC2003 has been shown to produce two EPS
which have been associated with an increased resilience of this strain to tolerate acid
and bile while reducing the intestinal colonisation levels of pathogenic Citrobacter
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rodentium (Fanning et al., 2012). Thus, EPS production is thought to be important not
only in host interactions but also for protection against pathogenic infection.
1.2.6 THE GUT-BRAIN AXIS: MICROBIAL METABOLITE PRODUCTION WITH
IMPLICATIONS ON HOST PSYCHIATRIC HEALTH
The gut-brain axis is a bidirectional communication system between the brain and
the gut, including the metabolically complex gut microbiota which integrates neural,
hormonal and immunological signalling between the gut and the brain (Collins et al.,
2012). The gut microbiota and the metabolites they produce may also modulate the
peripheral (PNS) and central nervous system (CNS) to influence brain development and
function (Forsythe et al., 2010). To date, numerous studies have demonstrated the
importance of the gut microbiota in the stress response (Neufeld et al., 2011; Sudo et
al., 2004) and neurodevelopmental disorders (de Theije et al., 2011; Desbonnet et al.,
2013; Finegold et al., 2010). Commensal microbiota have demonstrated the ability to
interact with the serotonergic system in the host by regulating the development of the
hypothalamus-pituitary-adrenal (HPA) axis, a neuroendocrine system which controls
reactions to stress (Sudo et al., 2004). Recent studies have demonstrated that germ-
free mice display a reduction in anxiety like behaviour (Clarke et al., 2013; Heijtza et
al., 2011), compared with conventionally colonised mice, possibly through an
enhanced HPA response. Another study using germ-free mice described how in the
absence of a gut microbiota, mice exhibited deficits in social motivation and
preference for social novelty, behavioural characteristics indicative of disruptions in
distinct normal social behaviours (Desbonnet et al., 2013). Probiotic intervention has
proven successful for the treatment of psychiatric disorders such as anxiety (Bravo et
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al., 2011; Messaoudi et al., 2011), depression (Desbonnet et al., 2008) and autism
(Hsiao et al., 2013). Administration of Bifidobacterium infantis 35624 has displayed
antidepressant properties in a maternal separation model of depression (Desbonnet et
al., 2008), Lactobacillus rhamnosus JB-1 has also demonstrated antianxiety and
antidepressant properties through activation of the vagus nerve in mice, compared
with broth-fed controls (Bravo et al., 2011) and Bacteroides fragilis administration
alleviated autistic-like behavioural impairments in communication, social behaviour,
social abnormalities, and restricted/repetitive behaviour in mice symptomatic of this
disorder, compared with autistic, untreated controls (Hsiao et al., 2013). Furthermore,
administration of Bifidobacterium breve NCIMB 702258 to mice had a significant
impact on the fatty acid composition of the brain (Wall et al., 2012). Mice that received
the bacteria for 8 weeks exhibited higher concentrations of bioactive fatty acids,
arachidonic acid and DHA, compared with unsupplemented controls (Wall et al., 2012),
whereby these bioactive fatty acids have a role in neurotransmission and protection
against oxidative stress (Henriksen et al., 2008; Yurko-Mauro et al., 2010).
A broad range of microbes, either probiotics or commensals can manufacture and
secrete neurochemicals which can positively impact on mental health and thus, could
be used for the treatment of CNS disorders, such as anxiety and depression. Recently
defined, a psychobiotic is “a live microorganism that, when ingested in adequate
amounts, produces a health benefit in patients suffering from psychiatric illness”
(Dinan et al., 2013). Moreover, disruptions in the composition of the gut microbiota
may lead to a deterioration of gastrointestinal, neuroendocrine and immune
pathways, which could in turn lead to alterations in gut-brain interactions and
consequently result in disease (Cryan and O'Mahony, 2011). The gut microbiota
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produce a range of neurotransmitters and neuromodulators, bioactive metabolites
which impact on host psychiatric health, only some of which have been demonstrated
in vivo (Table 1.2.1).
1.2.6.1 GABA
GABA is a major inhibitory neurotransmitter of the vertebrate CNS and is the main
inhibitory neurotransmitter in the brain. Dysfunctions of GABA have been linked with
anxiety and depression (Cryan and Kaupmann, 2005; Schousboe and Waagepetersen,
2007). Certain strains of Lactobacillus and Bifidobacterium secrete GABA via the same
biosynthetic pathway as in neuronal tissue involving conversion of glutamate by the
action of the enzyme glutamate decarboxylase and vitamin co-factor pyridoxal
phosphate (Komatsuzaki et al., 2008). Furthermore, the GABA producing capability of
some bacterial strains is thought to protect the organism from the acidic environment
of the stomach (Higuchi et al., 1997). Several human-derived lactobacilli and
bifidobacteria were screened for their ability to produce GABA from monosodium
glutamate (MSG), and it was found that five strains had this ability (Barrett et al.,
2012b). Of these strains, Lactobacillus brevis and Bifidobacterium dentium were the
most efficient GABA producers (Barrett et al., 2012b). Ko et al., (2013) recently
demonstrated GABA production in black soybean milk by L. brevis FPA3709 and its
administration to rats resulted in an antidepressant effect similar to that of fluoxetine,
a common antidepressant drug, but without the side-effects such as appetite and
weight loss (Ko et al., 2013). At the level of gene expression, ingestion of L. rhamnosus
JB-1 altered the mRNA expression of both GABAA and GABAB, two GABA receptors
which have been implicated in anxiety and depression (Bravo et al., 2011).
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1.2.6.2 SEROTONIN
Serotonin (5-HT) is a metabolite of the amino acid tryptophan and plays an
important role in the regulation of a number of brain functions, including mood (Dinan
et al., 2013). The vast majority of antidepressant drugs work to increase serotonin
levels in the brain and some studies have shown that bacteria can synthesise serotonin
in vivo. For example, plasma serotonin levels were shown to be nearly 3-fold higher in
conventional mice than in their germ-free counterparts (Wikoff et al., 2009). Oral
ingestion of Bifidobacterium infantis 35624 increased the plasma levels of tryptophan,
precursor to serotonin, suggesting that commensal bacteria have the ability to
influence tryptophan metabolism and could potentially act as antidepressants
(Desbonnet et al., 2008). This effect on tryptophan metabolism may be mediated by
the impact of the microbiota on the expression of indoleamine-2,3-dioxygenase, a key
enzyme in the physiologically dominant kynurenine pathway of tryptophan
metabolism (Forsythe et al., 2010). Early life stress induces changes in the gut
microbiota and is a risk factor for major depression in adulthood (O'Mahony et al.,
2009). This phenomenon has been shown in rhesus monkeys, whereby prenatal
stressors have been shown to alter the microbiome by reducing the overall numbers of
bifidobacteria and lactobacilli (Bailey and Coe, 1999).
1.2.6.3 CATECHOLAMINES AND ACETYLCHOLINE
Catecholamines such as dopamine and norepinephrine are the major
neurotransmitters that mediate a variety of CNS functions such as motor control,
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cognition, memory processing, emotion and endocrine regulation. Tsavkelova et al.,
(2000) identified a wide range of bacteria which produce mmol quantities of dopamine
(Tsavkelova et al., 2000) and which could be used for the treatment of Parkinson’s
disease, Alzheimer’s disease and other major depressive disorders whereby
dysfunctions in catecholamine neurotransmission are implicated. In addition, bacteria
which constitute the normal gut microbiome in mice have been shown to be capable
of the production of norepinephrine in vivo (Asano et al., 2012). Acetylcholine is a
neurotransmitter found in the CNS and PNS which plays a critical role in cognitive
function, particularly in memory and learning. Previous studies have shown that
acetylcholine is both a component of bacterial strains and a microbial metabolite,
including Lactobacillus plantarum and Bacillus subtilis (Girvin and Stevenson, 1954;
Horiuchi et al., 2003; Rowatt, 1948).
1.2.7 CONCLUSION
Bioactive metabolites produced by the gut microbiota can induce local changes in
the gut epithelium and the enteric nervous system, as well as the immune system with
an impact on CNS signalling (Cryan and Dinan, 2012). Disturbances to the delicate host-
microbe relationship may disrupt development of the immune system, which in turn
may result in disease development. This inflammatory state has been implicated in a
wide variety of disorders. The gut microbiota have the ability to produce a variety of
metabolites which exert beneficial impacts on biological and neurological functions.
Probiotics, prebiotics and dietary PUFA offer the potential to modulate the gut
microbiota with knock-on health effects. Further future studies are needed to better
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understand the mechanisms by which probiotic and prebiotic administration improve
host health. Microbe manipulation to strengthen the host-microbe symbiotic
relationship may be crucial for the future prevention of immune and psychiatric
related disorders.
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TABLE 1.2.1 Effects of probiotic metabolite production on host metabolic and psychiatric health
Metabolite Probiotic Strain Model
Trial
Duration Health Effects Reference
Metabolic health
CLA Lactobacillus rhamnosus PL60 C57Bl/6J mice 8 weeks
Reduced bodyweight, reduced white adipose tissue and no
presence of liver steatosis. Anti-obesity effect.
(Lee et al.,
2006)
Lactobacillus plantarum PL62 C57Bl/6J mice 8 weeks
Reduced bodyweight, reduced serum and leptin levels. Anti-
obesity effect.
(Lee et al.,
2007)
Bifidobacterium breve NCIMB
702258
BALB/c mice,
SCID mice,
swine 8-10 weeks
Reduced inflammatory profile and higher concentrations of n-3
fatty acids in the adipose tissue
(Wall et al.,
2009)
n-3 LC-
PUFA
Bifidobacterium breve NCIMB
702258 BALB/c mice 8 weeks Increased liver EPA and brain DHA concentrations
(Wall et al.,
2010)
C57BL/6J mice 8 weeks Increased arachidonic acid and DHA concentrations in the brain
(Wall et al.,
2012)
SCFA
Bifidobacterium breve DPC
6330 C57BL/6J mice 8 weeks Both strains increased propionate concentrations in the caecum.
(Wall et al.,
2012)
Bifidobacterium breve NCIMB
70228
EPS
Lactococcus lactis subsp
cremoris SBT 0495 F-344 rats 7 days
Serum cholesterol level of rats fed the ropy fermented milk were
the lowest among the three treatments
(Nakajima et
al., 1992)
Lactobacillus kefiranofaciens BALB/c mice
2, 5 and 7
days
Positive influence of EPS on systemic immunity and maintenance
of intestinal homeostasis
(Vinderola et
al., 2006)
Psychiatric health
GABA Lactobacillus brevis FPA3709
Sprague Dawley
rats 28 days
Similar antidepressant effects to a commonly used
antidepressant drug in the forced swin test
(Ko et al.,
2013)
Lactobacillus rhamnosus JB-1 BALB/c mice 28 days
Reduced stress and corticosterone and reduced anxiety and
depression-related behaviour
(Bravo et al.,
2011)
Serotonin Bifidobacterium infantis 35624
Sprague-Dawley
rats 14 days
Elevated the plasma levels of the serotonergic precursor,
tryptophan
(Desbonnet
et al., 2008)
96

97
Published, British Journal of Nutrition (2014), 111, 1905-1917
Chapter 2
Impact of dietary fatty acids on metabolic activity and
host intestinal microbiota composition in C57BL/6J mice
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2.1 ABSTRACT
Different dietary fat and energy subtypes have an impact on both the metabolic
health and the intestinal microbiota population of the host. The present study
assessed the impact of dietary fat quality, with a focus on dietary fatty acid
compositions of varying saturation, on the metabolic health status and the intestinal
microbiota composition of the host. C57BL/6J mice (n 9-10 mice per group) were fed
high-fat (HF) diets containing either (1) palm oil, (2) olive oil, (3) safflower oil or (4)
flaxseed/fish oil for 16 weeks and compared with mice fed low-fat (LF) diets
supplemented with either high maize starch or high sucrose. Tissue fatty acid
compositions were assessed by gas-liquid chromatography (GLC) and the impact of the
diets on host intestinal microbiota populations was investigated using high-throughput
16S rRNA sequencing. Compositional sequencing analysis revealed that dietary palm
oil supplementation resulted in significantly lower populations of Bacteroidetes at the
phylum level, compared with dietary olive oil supplementation (P < 0.05). Dietary
supplementation with olive oil was associated with an increase in the population of the
family Bacteroidaceae, compared with dietary supplementation of palm oil,
flaxseed/fish oil and high sucrose (P < 0.05). Ingestion of the HF-flaxseed/fish oil diet
for 16 weeks led to significantly increased tissue concentrations of eicosapentaenoic
acid (EPA), docosapentaenoic acid and docosahexaenoic acid (DHA), compared with
ingestion of all the other diets (P < 0.05); furthermore, the diet significantly increased
the intestinal population of Bifidobacterium at the genus level, compared with the LF-
high-maize starch diet (P < 0.05). These data indicate that both quantity and quality of
fat have an impact on host physiology with further downstream alterations to the
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intestinal microbiota population, with a HF diet supplemented with flaxseed/fish oil
positively shaping the host microbial ecosystem.
2.2 INTRODUCTION
Excessive dietary intakes of refined carbohydrates and fat strongly correlate with
weight gain, obesity and associated metabolic diseases (Conterno et al., 2011), while
also influencing the intestinal microbiota composition of the host (Hildebrandt et al.,
2009; Turnbaugh et al., 2008; Turnbaugh et al., 2009b; Walker et al., 2011). The human
intestine harbours trillions of microorganisms, containing over 100-fold more genes
than the host genome, whereby the collective genome of these micoorganisms has co-
evolved with the host and contributes to biochemical and metabolic functions that the
host could not otherwise perform (Backhed et al., 2004; Ley et al., 2006; Qin et al.,
2010).
Recent advances in non-culture-based analysis, such as 16S rRNA sequencing
technology, have provided extensive data in relation to the microbial composition of
an ecosystem. Briefly, the 16S rRNA gene has been most frequently targeted as a
means of identifying the microbial compositions due to its presence in all prokaryotes
and the existence of variable domains that allow different taxa to be distinguished
(Guinane and Cotter, 2013). Such technology has revealed clear alterations in the
intestinal microbiota of obese mouse models (Murphy et al., 2010) and human
subjects (Ley et al., 2006), compared with their lean counterparts. The obese
phenotype harbours an intestinal microbial population capable of extracting energy
efficiently from ingested food and superior ability to produce short chain fatty acids
(SCFA) (Schwiertz et al., 2010; Turnbaugh et al., 2006). Recent studies have reported
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the effects of specific dietary fatty acid subtypes, such as saturated fatty acids (SFA),
monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) on
metabolic parameters and intestinal microbial populations. (Buettner et al., 2006; de
Wit et al., 2012; Devkota et al., 2012; Liao et al., 2010; Mujico et al., 2013). For
example, Buettner et al., (2006) showed a reduction in liver inflammation and
triglyceride (TAG) levels following high levels of fish oil feeding (Buettner et al., 2006),
while others have demonstrated that hamsters fed a low-MUFA diet with a low ratio of
PUFA: SFA exhibited increased weight gain and body fat accumulation (Liao et al.,
2010). Furthermore, while a diverse intestinal microbiota is preferable, ingestion of a
high-fat diet containing palm oil has been reported to decrease bacterial diversity (de
Wit et al., 2012; Mujico et al., 2013). While some studies have shown that subtle
alterations caused by the ingestion of different dietary fatty acid subtypes indeed have
an impact on the intestinal microbiota, the major difficulty arises in linking these
changes in the microbiota to the metabolic health status of the host. Potential
mechanisms that link how the diet alters the intestinal microbiota have been
suggested, such as through changes to lipid metabolism-related genes in the distal
small intestine or through changes in host bile composition caused by diet (de Wit et
al., 2012; Devkota et al., 2012; Huang et al., 2013); however, it is imperative to further
understand the influence that different fat qualities, as opposed to quantities and
energy types, have on the intestinal microbiota for the future prevention of obesity.
Therefore, the aims of the present study were to investigate how different qualities
of fat in the diet, achieved through altering dietary fatty acid compositions and
different sources of energy in the diet, have an impact on the metabolic health status
of the host, and furthermore, to investigate the influence of diets on the delicate
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nature of host intestinal microbiota composition by employing 16S rRNA sequencing
technology. For this purpose, mice were fed high-fat (HF, 45% energy from fat) diets
containing either (1) palm oil (mainly SFA), (2) olive oil (MUFA), (3) safflower oil (n-6
PUFA) or (4) flaxseed/fish oil (n-3 PUFA). In parallel, to investigate metabolic
parameters and the intestinal microbiota composition of the host, mice were fed low-
fat (LF) diets rich in either maize starch (12% energy from fat and 41% maize starch) or
sucrose (12% energy from fat and 65% sucrose) for 16 weeks.
2.3 MATERIALS AND METHODS
2.3.1 ANIMALS AND DIETS
Wild type C57BL/6J male mice (21 days old) were obtained from Harlan Limited
(Briester, Oxon, UK) and housed under barrier-maintained conditions within the
Biological Services Unit, Teagasc, Moorepark. All animal experiments were approved
by University College Cork Animal Ethics Committee, and experimental procedures
were conducted under appropriate license from the Irish Government in compliance
with the institutional and national guidelines for the care and use of animals. Mice
were allowed to acclimatise for 5 weeks before the commencement of the
experiments and were subsequently randomly divided into the following six dietary
groups (n 9-10 mice per group): (1) LF-high-maize starch diet (12% energy from fat and
41% maize starch; n 10); (2) LF-high-sucrose diet (12% energy from fat and 65%
sucrose; n 10); (3) HF-palm oil (mainly SFA) diet (45% energy from fat; n 10); (4) HF-
olive oil (extra virgin) (MUFA) diet (45% energy from fat; n 9); (5) HF-safflower oil (n-6
PUFA) diet (45% energy from fat; n 10); and (6) HF-flaxseed/fish oil (n-3 PUFA) diet
(45% energy from fat; n 9). Mice were housed in groups of four to five per cage with
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two cages per dietary treatment group, allowed free access to food and water at all
times and maintained under a 12 hr light-12 hr dark cycle. All diets were supplied by
Harlan Limited. Fatty acid compositions of the experimental diets are shown in Table
2.1. Body weight and food intake were recorded weekly. Following 16 weeks of dietary
treatment, fat and lean body masses were measured using a Minispec mq benchtop
NMR spectrometer (Bruker Instruments, Germany) and mice were killed by cervical
dislocation. Liver, brain, fat pads (epididymal, perirenal, mesenteric and subcutaneous)
and caecal contents were removed, blotted dry on filter paper, weighed, and flash
frozen immediately in liquid nitrogen. Blood samples were collected from fasted
animals into plasma collection tubes, containing ethylenediaminetetraacetic acid
(EDTA) (BD Diagnostics, Oxford, UK) and allowed to clot for at least 30 min at 4°C, then
centrifuged at 10,000g for 20 min to separate the plasma. All samples were stored at -
80 until processed.
2.3.2 BIOCHEMICAL MARKERS AND MEASUREMENTS OF PLASMA VARIABLES
Blood glucose was determined using a Contour glucose meter and blood glucose
strips. Plasma insulin and leptin concentrations were measured using the Ultra
Sensitive Mouse Insulin ELISA kit (Crystal Chem Inc., IL, USA) and the Mouse Leptin
ELISA kit (Crystal Chem Inc.), according to the manufacturer’s instructions. Plasma non-
esterified fatty acids (NEFA) were determined using the commercial NEFA-HR (2) kit
(Wako Diagnostics, Neuss, Germany), and plasma TAG levels were measured using
Infinity Triglyceride Liquid Stable Reagent (Thermo Scientific, Dublin, Ireland).
2.3.3 DETERMINATION OF LIVER TAG LEVELS
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Lipids from 50 mg of frozen liver were extracted and purified according to the
method of Folch (Folch, 1957). Liver lipids were extracted using chloroform-methanol
(2:1, vol:vol; Thermo Scientific) and an aliquot of the organic phase was collected,
dried and resuspended in Infinity Triglyceride Liquid Stable Reagent (Thermo
Scientific). All samples and standards were analysed in duplicate and TAG content was
determined as described previously (Murphy et al., 2010).
2.3.4 RNA EXTRACTION AND COMPLEMENTARY DNA SYNTHESIS
Total RNA was isolated from liver tissue using the commercial RNeasy Mini Kit
(Qiagen, West Sussex, UK), according to the manufacturer’s instructions, and
quantified using the Nanodrop (Thermo Scientific). Single-stranded complementary
DNA (cDNA) was synthesised from 1μg of total RNA using 2.5ng/μL of random primers
(Promega, WI, USA), 10mM PCR nucleotide mix (Promega), 40units/μL of RNasin Plus
RNase Inhibitor (Promega) and Im-Prom II reverse transcriptase (Promega), according
to the manufacturer’s instructions.
2.3.5 REAL-TIME PCR ANALYSIS
Amplification of generated cDNA was performed in the Lightcycler 480 system
(Roche Diagnostics Limited, West Sussex, UK) using 0.25μM primers (Eurofins MWG
Operon, Ebersberg, Germany), 1μL cDNA and the Lightcycler 480 SYBR Green I Master
kit (Roche Diagnostics Limited), according to the manufacturer’s instructions. Real-
time PCR conditions were set at: 95°C for 10 min followed by fifty cycles at 95°C for 10
s, 60°C for 5 s and 72°C for 15 s. Specific forward and reverse primers used to amplify
cDNA were newly designed and are listed as follows: fatty acid synthase (Fas) cDNA:
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forward, 5'-GGCCACCTCAGTCCTTGATATCATG-3' and reverse, 5'-
GCCCGCGAACCACTAACGAG-3' ; sterol regulatory element binding protein-1c (Srebp-
1c) cDNA: forward, 5'-CTCCAGCTCATCAACAACCAAGAC-3' and reverse, 5'-
AGAGGAGGCCAGAGAAGCAGAAGA-3' ; peroxisome proliferator activated receptor α
(Pparα) cDNA: forward, 5'-ATGGGGGTGATCGGAGGCTAATAG-3' and reverse, 5'-
GGGTGGCAGGAAGGGAACAGAC-3' ; peroxisome proliferator activated receptor γ 
(Pparγ) cDNA: forward, 5'-TCAGGTTTGGGCGGATGC-3' and reverse, 5'-
TCAGCGGGAAGGACTTTATGTATG-3'. All samples were analysed in duplicate and
normalised to β-actin as a constitutively expressed control gene: forward, 5'-
AGAGGGAAATCGTGCGTGAC-3' and reverse, 5'-CAATAGTGATGACCTGGCGT-3'. Melting
curve analysis allowed the validation of the authenticity of the real-time PCR products.
Basic relative quantification of expression was determined using the comparative 2-ΔΔCt
method.
2.3.6 LIPID EXTRACTION AND FATTY ACID ANALYSIS
Lipids were extracted and purified with chloroform-methanol (2:1, vol:vol; Thermo
Scientific) according to the method of Folch (Folch, 1957). Fatty acid methyl esters
(FAME) were prepared by using first 10mL 0.5 M NaOH (Sigma, Wicklow, Ireland) in
methanol for 10 min at 90°C followed by 10mL 14% BF3 in methanol (Sigma) for 10 min
at 90°C (Park and Goins, 1994). FAME were recovered with hexane (Fisher Scientific,
Dublin, Ireland). Before GLC analysis, samples were dried over 0.5g anhydrous sodium
sulphate (Sigma) for 1 hr and stored at -20°C. FAME were separated by GLC (Varian
3400; JVA Analytical) fitted with a flame-ionisation detector by using a Chrompack CP
Sil 88 column (Chrompack, JVA Analytical; 100 m x 0.25 mm internal diameter, 0.20-
105
μm film thickness) and helium as carrier gas. The column oven was programmed
initially at 80°C for 8 min and then increased by 8.5°C/min to a final column
temperature of 200°C. The injection volume used was 0.6 μL, with an automatic
sample injection on a SPI 1093 splitless on-column temperature-programmable
injector. Peaks were integrated by using the Varian Star Chromatography Workstation
version 6.0 software, and peaks were identified by comparison of retention times with
pure FAME standards (Nu-Chek Prep., MN, USA). The percentage of individual fatty
acids was calculated according to the peak areas relative to the total area (total fatty
acids were set at 100%). All fatty acid data are presented as means ± standard errors of
the mean (SEM) in g/100g FAME.
2.3.7 SCFA ANALYSIS
Approximately 100 mg caecal content was vortex-mixed with 1.0 mL Milli-Q water
and after standing for 10 min at room temperature, centrifuged at 10,000g for 5 min
to pellet bacteria and other solids. The supernatant fluid was collected, 3.0 mmol 2-
ethylbutyric acid/L (Sigma) was added as internal standard, and samples were filtered
before being transferred to clean vials. Standard solutions containing 10.0, 8.0, 6.0,
4.0, 2.0, 1.0 and 0.5 mmol/L of a mix of acetic acid, propionic acid, isobutyric acid and
butyric acid (Sigma) were used for calibration. The concentration of SCFA was
measured using a Varian 3800 GC flame-ionisation system, fitted with a ZB-FFAP
column (30 m x 0.32 mm x 0.25 μm; Phenomenex, Cheshire, UK). Helium was used as
the carrier gas at a flow rate of 1.3 mL/min. The initial oven temperature was 100°C for
0.5 min, raised to 180°C at 8°C/min and held for 1 min, then increased to 200°C at
20°C/min, and finally held at 200°C for 5 min. The temperature of the detector and
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injector were set at 250°C and 240°C, respectively. Peaks were integrated by using the
Varian Star Chromatography Workstation version 6.0 software. Standards were
included in each run to maintain the calibration.
2.3.8 DNA EXTRACTION AND PYROSEQUENCING
Total DNA was extracted from the caecal contents of all mice using the QIAamp
DNA Stool Mini Kit (Qiagen), coupled with an initial bead-beating step. Universal 16S
rRNA primers, designed to amplify from highly conserved regions corresponding to
those flanking the V4 region, as described previously (Murphy et al., 2010), were used
for Taq based PCR amplification. Sequencing was performed on a Roche 454 GS-FLX
using Titanium chemistry within the Teagasc 454 Sequencing Platform. Raw sequences
were quality trimmed using the Qiime Suite of programmes (Caporaso et al., 2010);
any reads not meeting the quality criteria of a minimum quality score of 25 and
sequence length shorter than 150 bp for 16S amplicon reads were discarded. Trimmed
FASTA sequences were then BLASTed (Altschul et al., 1997) against a previously
published 16S-specific database (Urich et al., 2008) using default parameters. The
resulting BLAST output was parsed using MEGAN (Huson et al., 2007). MEGAN assigns
reads to NCBI taxonomies by using the Lowest Common Ancestor algorithm. Bit scores
were used from within MEGAN for filtering the results before tree construction and
summarisation. A bit score of 86 was selected as previously used for 16S ribosomal
sequence data (Urich et al., 2008). Phylum, family and genus counts for each sample
were extracted from MEGAN. Sequences were clustered into operational taxonomical
units (OTU), chimera checked and aligned using the default pipeline within Qiime, and
subsequently α and β diversities were generated. A phylogenetic tree was calculated
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using the FastTree software (doi:10.1093/molbev/msp077). Resulting Principal
Coordinate analysis was visualised within KiNG.
2.3.9 STATISTICAL ANALYSIS
All results are presented as means ± SEM (per group). To assess whether differences
between the treatment groups were significant, data were analysed using one-way
ANOVA followed by post hoc Tukey’s multiple comparison test using GraphPad Prism
version 4.0 for Windows (GraphPad Software). Compositional data were statistically
analysed using Minitab release 15.1.1.0 (www.minitab.com). A non-parametric
Kruskal-Wallis test was used to estimate the relationships between different dietary
groups. Statistical significance was accepted at P < 0.05.
2.4 RESULTS
2.4.1 EFFECT OF VARYING DIETARY FATTY ACID COMPOSITIONS ON WEIGHT GAIN,
BODY COMPOSITION AND HOST FAT STORAGE
A higher percentage of weight gain was observed in the group fed the HF-palm oil
diet for 16 weeks, compared with the HF-olive oil (P < 0.05)- and LF-high sucrose (P <
0.05)-fed groups, despite no differences in cumulative energy intake between these
groups (Table 2.2). Furthermore, subcutaneous fat mass was higher following feeding
of the HF-palm oil diet than after feeding of the HF-olive oil diet (P < 0.05; Table 2.2).
The group supplemented with the HF-palm oil diet also had a higher percentage of fat
mass (P < 0.05; Figure 2.1(A)) and a lower percentage of lean mass (P < 0.05; Figure
2.1(B)) than the HF-olive oil-fed group and the LF-high sucrose-fed group. The
percentage lean mass was higher in the group fed the olive oil diet for 16 weeks than
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in the other HF diet-fed groups (P < 0.05; Figure 2.1(B)). The percentage of weight gain
was higher in the LF-high maize starch-fed group than in the LF-high sucrose-fed group
(P < 0.05; Table 2.2), which was most probably due to the greater food intake (P < 0.05;
Table 2.2), and therefore greater cumulative energy intake (P < 0.05; Table 2.2) in the
former group. Visceral fat mass was also higher in the LF-high maize starch-fed group
than in the LF-high sucrose-fed group after feeding for 16 weeks (P < 0.05; Table 2.2).
Since the energy content of the LF-high-carbohydrate diets (16 kJ/g) was only
approximately 3 kJ/g lower than that of the high-fat diets (19 kJ/g), differences in total
cumulative energy intake between the groups resulted from differences in food intake,
due to dietary preference. The LF-high maize-starch fed group consumed more food
over the study period than the groups supplemented with the HF-safflower oil and HF-
flaxseed/fish oil diets and the LF-high-sucrose diet (P < 0.05). However, no differences
in the overall percentage of weight gain were observed between the groups fed the LF-
high-maize starch, HF-safflower oil and HF-flaxseed/fish oil diets.
2.4.2 HIGHER PLASMA GLUCOSE AND LEPTIN CONCENTRATIONS ASSOCIATED WITH
SATURATED FAT
No differences in plasma TAG, insulin or NEFA concentrations were found between
the groups following 16 weeks of dietary feeding (Table 2.3). Fasting glucose levels
were higher in the HF-palm oil-fed group than in both the HF-safflower oil- and LF-high
sucrose-fed groups (P < 0.05; Table 2.3), while plasma glucose concentrations were
lower in the LF-high-sucrose-fed group than in the groups fed the LF-high-maize starch,
HF-palm oil and HF-olive oil diets (P < 0.05; Table 2.3). Circulating plasma leptin
109
concentrations were also higher in the HF-palm oil-fed group than in the HF-olive oil-
and both LF-high carbohydrate-fed groups (P < 0.05; Table 2.3).
2.4.3 SATURATION OF FAT INFLUENCES HOST LIVER MASS, TAG LEVELS AND HEPATIC
GENE EXPRESSION
Liver tissue weight (Figure 2.2(A)) and total liver TAG levels (Figure 2.2(B)) were
higher (P < 0.05) in the palm oil-fed group than in all the other dietary groups. Among
the high-fat diets, as the degree of saturation shifted from the more SFA source of
palm oil to the n-3 PUFA source of flaxseed/fish oil, the levels of liver TAG steadily
decreased in a coinciding manner (Figure 2.2(B)).
Briefly, the expression of certain genes related to fatty acid metabolism and
inflammation in the liver were assessed in an effort to correlate their expression with
liver mass and TAG levels. Hepatic expression of Fas was higher in the palm oil-fed
group than in the flaxseed/fish oil-fed group (P < 0.05; Supplementary Figure 2.1).
Furthermore, the olive oil-fed group had a higher hepatic expression of Fas than the
flaxseed/fish oil-fed group (P < 0.05; Supplementary Figure 2.1), while Fas expression
was higher in the LF-high-maize starch-fed group than in the HF-safflower oil-, HF-
flaxseed/fish oil- and LF-high sucrose-fed groups (P < 0.05; Supplementary Figure 2.1).
Hepatic expression of Srebp-1c was higher in the LF-high-maize starch-fed group than
in the high-fat diet-fed groups (except the olive oil-fed group) and the LF-high sucrose-
fed group (P < 0.05; Supplementary Figure 2.1). Hepatic expression of Pparα was
reduced in all the dietary groups, compared with the LF-high-maize starch-fed group (P
< 0.05; Supplementary Figure 2.1), while Pparγ expression was higher in all the high-fat
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diet-fed groups than in the LF-high sucrose-fed group (P < 0.05; Supplementary Figure
2.1).
2.4.4 IMPACT OF DIFFERENT SOURCES OF FAT AND ENERGY ON HOST TISSUE FATTY
ACID COMPOSITIONS
The palm oil-fed group had higher levels of palmitic acid (16:0) in the liver and
brain, compared with the other high-fat diet-fed groups and the LF-high sucrose-fed
group (P < 0.05; Tables 2.4 and 2.6) and in epididymal adipose tissue, compared with
all the other dietary groups (P < 0.05; Table 2.5). Additionally, the palm oil-fed group
had higher levels of oleic acid (18:1 cis-9) in liver (P < 0.05; Table 2.4) and epididymal
adipose tissue (P < 0.05; Table 2.5), compared with all the other dietary groups, except
the olive oil-fed group, which had higher levels of oleic acid in the epididymal adipose
tissue only, compared with all the other diet-fed groups (P < 0.05; Table 2.5). The
safflower oil-fed group had higher levels of linoleic acid (18:2n-6), γ-linolenic acid
(18:3n-6) and arachidonic acid (20:4n-6) in all tissues, compared with all the other diet-
fed groups (P < 0.05; Tables 2.4-2.6). Both the LF-high carbohydrate-fed groups had
higher levels of dihomo-γ-linolenic acid (20:3n-6) in the brain (P < 0.05; Table 2.6) and
higher levels of palmitoleic acid (16:1 cis-9) in the liver (P < 0.05; Table 2.4), compared
with all the other dietary groups. α-linolenic acid (18:3n-3) levels were higher in all
tissues (P < 0.05; Tables 2.4-2.6) of the flaxseed/fish oil-fed group than those of the
other diet-fed groups, except in the brain of the LF-high sucrose-fed group.
Furthermore, the flaxseed/fish oil-fed group had higher levels of EPA (20:5n-3),
docosapentaenoic acid (22:5n-3) and DHA (22:6n-3) in all tissues (P < 0.05; Tables 2.4-
2.6), lower levels of arachidonic acid in the brain (P < 0.05; Table 2.6) and higher levels
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of stearic (18:0) and myristic (14:0) acids in epididymal adipose tissue (P < 0.05; Table
2.5), compared with the other dietary groups.
2.4.5 SATURATED FAT IS ASSOCIATED WITH HIGHER CAECAL CONCENTRATIONS OF
SCFA
The mean total concentrations of SCFA (acetate, propionate, butyrate and
isobutyrate) in caecal contents were found to be highest in the palm oil-fed group,
compared with the other dietary groups (P < 0.05; Table 2.7). Of these SCFA, the
concentrations of propionate, butyrate and isobutyrate were found to be higher in the
palm oil-fed group than in the other diet-fed groups (P < 0.05; Table 2.7), while the
concentration of acetate was found to be higher in the palm oil-fed group, compared
with the other diet-fed groups (P < 0.05; Table 2.7), except the LF-high maize starch-
fed group.
2.4.6 FAT AND ENERGY SOURCES INFLUENCE DIFFERENTLY ON THE COMPOSITION OF
THE INTESTINAL MICROBIOTA
The microbial composition in the caecal contents of individual mice was elucidated
through high-throughput DNA sequencing (Roche 454-Titanium) of 16S rRNA (V4)
amplicons after 16 weeks of dietary intervention. A total of 355,743 reads were
sequenced, corresponding to an average of 6,134 reads per mouse. Of these reads,
318,586 (89%) were assigned at the phylum level, 285,224 (80%) at the family level
and 180,584 (51%) at the genus level. At the 97% similarity level, a total of five
measures were used to indicate sufficient sampling for all the groups. Estimations for
species richness, coverage and diversity were calculated for each data set
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(Supplementary Figures 2.2-2.6). All measures showed a high level of overall diversity
within all samples and rarefraction curves for each group indicated a sufficient depth
of sequencing. For the Chao1-α diversity metric (Supplementary Figure 2.2), olive oil
and flaxseed/fish oil feeding resulted in the least and most diverse intestinal
microbiota, respectively. This trend is somewhat reflected in all the other diversity
metrics (Supplementary Figures 2.3-2.6). Furthermore, all diets were significantly
different from each other. Principal coordinate analysis plots generated using an
unweighted Unifrac distance matrix showed that mice clustered into relatively distinct
groups based on dietary treatment (Figure 2.3). This suggests that exposure to
different qualities of dietary fats or different energy sources (fat v. carbohydrate) can
significantly alter intestinal microbial populations.
Taxonomy based analysis of the assigned sequences showed that at the phylum
level, the mouse intestinal microbiota is dominated by Firmicutes and Bacteroidetes
(together harbouring on average 92.3% of sequences; Figure 2.4). At the family level,
the most dominant groups were Lachnospiraceae, Erysipelotrichaceae,
Ruminococcaceae, Rikenellaceae and Deferribacteraceae (Table 2.8 and Figure 2.5).
Consistent with the high levels of Firmicutes and Bacteroidetes detected, the dominant
bacteria detected at the genus level were Allobaculum, Ruminococcaceae Incertae
Sedis, Bacteroides and Rikenella (Table 2.8 and Figure 2.6).
The palm oil-fed group had reduced caecal populations of Bacteroidetes at the
phylum level (P < 0.05; Figure 2.4), at 10.5%, compared with the olive oil- and
safflower oil-fed groups (both 20%). All the other phyla remained at relatively similar
proportions across the groups. At the family level, the palm oil- and LF-high sucrose-
fed groups had higher populations of Lachnospiraceae (46.4 and 49.6%, respectively, P
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< 0.05; Figure 2.5), than the LF-high maize starch- and flaxseed/fish oil-fed groups (17.1
and 24.2%, respectively). Among the high-fat diets, as the degree of saturation shifted
from the more SFA source of palm oil to the n-3 PUFA source of flaxseed/fish oil, the
intestinal populations of Lachnospiraceae steadily decreased in a coinciding manner.
Reduced proportions of Lachnospiraceae were also found in the safflower oil-fed
group, relative to the LF-high sucrose-fed group (P < 0.05; Figure 2.5). Within the LF-
high carbohydrate-fed groups, contrasting results were found. The relative proportions
of Ruminococcaceae were higher in the LF-high sucrose-fed group than in the high
maize starch-fed group (P < 0.05; Figure 2.5), while the high maize starch-fed group
had a higher population of Erysipelotrichaceae than the high sucrose-fed group (P <
0.05; Figure 2.5). The olive oil- and flaxseed/fish oil-fed groups had a greater
abundance of Erysipelotrichaceae, compared with the LF-high sucrose-fed group (P <
0.05; Figure 2.5). Again, among the high-fat dietary groups, as the degree of saturation
shifted from the more SFA source of palm oil to the n-3 PUFA source of flaxseed/fish
oil, the intestinal populations of Erysipelotrichaceae steadily increased in a coinciding
manner. Thus, the saturation or quality of fat can shift the intestinal microbiota
population in numerous ways. Interestingly, higher proportions of Bacteroidaceae and
Bacteroides were found in the olive oil-fed group, compared with the palm oil-,
flaxseed/fish oil- and LF-high sucrose-fed groups (P < 0.05; Figures 2.5-2.6).
Additionally, the n-3 PUFA-rich flaxseed/fish oil diet was the only diet to increase
intestinal populations of Bifidobacteriaceae and Bifidobacterium, compared with the
LF-high maize starch diet (P < 0.05; Figures 2.5-2.6).
At the genus level, Allobaculum was found to be higher in the LF-high maize starch-,
HF- flaxseed/fish oil- and HF-olive oil-fed groups than in the LF-high sucrose-fed group
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(38.9, 38.7, 23.8 and 5.4% respectively, P < 0.05; Figure 2.6). High populations of
uncultured Lachnospiraceae, Oscillibacter, Odoribacter and Anaerotruncus were
detected in the LF-high sucrose-fed group, reaching significance compared with a
variety of different groups within each population (P < 0.05; Table 2.8 and Figure 2.6).
2.5 DISCUSSION
The data presented herein reveal that different dietary fatty acids and qualities of
dietary fat from different sources (palm oil, olive oil, safflower oil and flaxseed/fish oil)
and high-carbohydrate diets (maize starch and sucrose) significantly influenced both
metabolic parameters and the composition of the intestinal microbiota in mice. The
present study has further highlighted that consumption of MUFA and PUFA are
generally healthful in comparison with SFA, whereby chronic dietary SFA intake (palm
oil) for 16 weeks resulted in significant increases in the percentage of body weight
gain, the percentage of body fat mass, subcutaneous fat mass and plasma glucose and
leptin concentrations, compared with the other groups. In contrast, consumption of
MUFA (olive oil) for 16 weeks was associated with a significant decrease in the
percentage of body weight gain and the percentage of body fat mass, compared with
mice ingesting a palm oil-rich diet. Current nutritional recommendations suggest that a
reduction in SFA consumption with an increase in plant oils containing MUFA is
desirable; however, the mechanism by which MUFA may be responsible for a
reduction in body weight is largely unknown. Recently, a study has reviewed numerous
health benefits associated with the polyphenol fraction of olive oil, such as anti-
inflammatory and antioxidant activities, which may possibly provide further evidence
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for the positive impact the olive oil diet has on body weight gain observed in the
present study (Martin-Pelaez et al., 2013).
The group that ingested the LF-high sucrose diet had the lowest percentage of
weight gain over the 16 week study period, while the LF-high maize starch-fed group
exhibited a higher percentage of weight gain and plasma blood glucose levels,
compared with the high sucrose-fed group. This difference can partly be explained by
the greater food intake of the high maize starch-fed group, compared with the high
sucrose-fed group. The maize starch diet had a greater impact on food intake, glucose
intolerance and weight gain, compared with dietary sucrose as the primary
carbohydrate source in the diet. While a combination of high dietary fat with high
sucrose has been reported to induce insulin resistance and glucose intolerance (Yang
et al., 2012), it appears that dietary sucrose itself has differential effects depending on
the amount of fat in the diet (Surwit et al., 1995).
Dietary SFA is known to play a substantial clinical role in the onset and progression
of non-alcoholic fatty liver disease (NAFLD) (Tetri et al., 2008; van den Berg et al.,
2010; Wang et al., 2006). Supplementation with palm oil significantly increased both
liver weight and TAG levels in mice after 16 weeks, compared with all the other groups.
Interestingly, it was shown herein that as the degree of saturation shifted from SFA
(palm oil), to MUFA (olive oil), to n-6 PUFA (safflower oil) and finally to n-3 PUFA
(flaxseed/fish oil), the levels of liver TAG steadily decreased in a coinciding manner.
This indicates that it is not only the quantity of fat but also the quality of fat consumed
that has an impact on the tissue distribution of fat in the host. Furthermore, the
increased hepatic expression of Fas and Srebp-1c, which are involved in de novo
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lipogenesis correlated with the increase in hepatic TAG observed for the palm oil-fed
group.
The clinical implications of n-3 PUFA in preventing the progression of NAFLD have
been described (Parker et al., 2012). The reduced levels of liver TAG observed
following dietary intake of flaxseed/fish oil for 16 weeks may be partly explained by
the increase in hepatic expression of Pparγ found for this group, given that Pparγ is
associated with a reduction in inflammatory responses in the liver (Galli et al., 2002;
Marra et al., 2005; Marra et al., 2000). Furthermore, flaxseed/fish oil feeding increased
the levels of α-linolenic acid, EPA, docosapentaenoic acid and DHA in the liver,
epididymal adipose tissue and brain. Dietary EPA and DHA exert anti-inflammatory
properties (Mori and Beilin, 2004) by altering cytokine production (Browning, 2003;
Calder, 2001), often at the expense of arachidonic acid, whereby proinflammatory
eicosanoids derived from arachidonic acid, such as prostaglandin E2 and leukotriene B4,
are replaced by the anti-inflammatory eicosanoids derived from EPA and DHA (Calder,
2009). The present study has demonstrated favourable increases in tissue EPA,
docosapentaenoic acid and DHA and decreases in tissue arachidonic acid for the
flaxseed/fish oil-fed group in this study, whereby DHA has been shown to play
important roles in neurogenesis, neurotransmission, and protection against oxidative
stress (Hashimoto et al., 2002; Innis, 2007; Lim et al., 2005). Importantly, the present
study has demonstrated the ability of flaxseed/fish oil-derived fatty acids EPA,
docosapentaenoic acid and DHA to cross the blood-brain barrier where it is
understood that DHA may influence cognitive processes such as learning and memory
in the brain (Henriksen et al., 2008; Yurko-Mauro et al., 2010). This further highlights
the importance of n-3 PUFA-derived dietary fatty acids to the brain-gut axis.
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Diet composition significantly altered intestinal microbial populations and diversity
after 16 weeks of feeding. A key finding was that all measures of α diversity
demonstrated a high level of overall diversity between the dietary groups, whereby
mice clustered into distinct groups based on dietary treatment. Decreases in the
populations of Bacteroidetes and Bacteroidaceae at the phylum and family levels,
respectively, and increases in the population of Lachnospiraceae at the family level
were observed for the palm oil-fed group. Interestingly, other studies have
demonstrated similar trends in the Bacteroidetes population that positively correlate
with the development of obesity (Ley et al., 2006; Turnbaugh et al., 2009a). Based on
previous studies, it is generally understood that the gut microbiota can indeed increase
the energy-harvesting capacity of the host through the fermentation of non-digestible
complex polysaccharides in the large intestine and thus producing SCFA (Jumpertz et
al., 2011; Turnbaugh et al., 2006). In the present study, the palm oil-fed group
increased total caecal SCFA produced, compared with all the other groups. While the
positive impact these SCFA have on human gastrointestinal health have previously
been described (D'Argenio et al., 1996; Emenaker et al., 2001; Galvez et al., 2005;
Topping and Clifton, 2001), the process by which they drive energy production has also
been portrayed as a potential mechanism involved in the increase in host fat mass
storage (Turnbaugh et al., 2006). Furthermore, it is unclear whether the beneficial
effect of SCFA is somehow compromised in obese subjects, or whether the effect is
simply not strong enough to compensate for an adverse diet.
The group that ingested the olive oil-rich diet had increased populations of
Bacteroidaceae in the caecum at the family level, compared with the palm oil- and
flaxseed/fish oil-fed groups. Interestingly, these bacteria maintain a complex and
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generally beneficial relationship with the host when retained in the gut and their role
as commensals has been extensively reviewed (Xu and Gordon, 2003). In the present
study, between the two LF-high carbohydrate-fed groups, the proportions of
Allobaculum were reduced while Lachnospiraceae were increased in the caecum of the
high sucrose-fed group, compared with the maize starch-fed group. Interestingly, a
recent study by Ravussin et al., (2012) reported an association between low-fat
feeding and increases in the genus Allobaculum, thus suggesting that high dietary
sucrose may be responsible for a reduction in the caecal numbers of Allobaculum
(Ravussin et al., 2012).
The flaxseed/fish oil diet was the only diet to significantly increase the intestinal
populations of Bifidobacteriaceae and Bifidobacterium, at the family and genus levels,
respectively, possibly through the increased ability of flaxseed/fish oil to increase the
adhesion of bifidobacteria to the intestinal wall.
The results from the present study indicate that dietary ingestion of different fatty
acids in a high-fat diet, or a chronic intake of high levels of maize starch or sucrose
significantly influences the distribution of fat in the host and also the intestinal
microbiota. While subtle differences in the intestinal microbiota did exist between the
two LF-high carbohydrate-fed groups, it is apparent that dietary maize starch has a
greater impact on weight gain and glucose intolerance than sucrose. We demonstrated
that dietary SFA (palm oil) had a negative impact on host metabolic parameters often
associated with obesity and the Metabolic Syndrome, while also shifting the intestinal
microbiota population to one similar to that seen in an obese phenotype. In contrast,
dietary MUFA (olive oil) may beneficially alter the bacterial population in the intestine
by increasing the populations of commensal bacteria. Finally, the present study has
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demonstrated that a rich dietary source of n-3 PUFA (flaxseed/fish oil) may have a
bifidogenic effect on the intestinal microbiota composition of the host by increasing
the levels of Bifidobacterium, while also positively influencing the composition of host
tissues with n-3 PUFA-derived health-promoting fatty acids.
Indeed, the mechanism by which dietary fat types alter the intestinal microbiota
remains largely to be elucidated. Promisingly, recent reports by Devkota et al., (2012)
and deWit et al., (2012) suggest that certain saturated fat types can alter conditions for
gut microbial assemblage by promoting changes in host bile composition (Devkota et
al., 2012) and that an overflow of palm oil to the distal small intestine rather than
obesity itself may trigger an elevation of lipid metabolism-related genes in the distal
small intestine, thus altering the intestinal microbiota (de Wit et al., 2012). Further
future studies will confirm a precise mechanism by which diet alters the intestinal
microbiota. In conclusion, the present study has demonstrated some novel findings on
how different qualities of fat and energy subtypes have an impact on the metabolic
health and intestinal microbiota composition of the host.
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TABLE 2.1 Dietary components and fatty acid compositions of experimental oils.
g/Kg
LF-high
maize
starch
LF-high
sucrose
HF-palm
oil
HF-olive
oil
HF-
safflower oil
HF-
flaxseed/fish
oil
Casein 192.0 192.0 230.0 230.0 230.0 230.0
DL-Methionine 3.0 3.0 3.0 3.0 3.0 3.0
Sucrose 120.0 645.0 65.0 65.0 65.0 65.0
Corn Starch 411.0 213.4 213.4 213.4 213.4
Maltodextrin 150.0 150.0 150.0 150.0 150.0
Palm Oil 12.5 12.5 225.0
Olive Oil 12.5 12.5 225.0
Safflower Oil 12.5 12.5 225.0
Flaxseed Oil 6.25 6.25 112.5
Fish Oil 6.25 6.25 112.5
Mineral Mix 35.0 35.0 42.0 42.0 42.0 42.0
Calcium Phosphate 1.4 1.4 1.5 1.5 1.5 1.5
Cellulose 20.08 56.08 50.0 50.0 50.0 50.0
Vitamin Mix 15.0 15.0 17.0 17.0 17.0 17.0
Choline Bitartrate 2.5 2.5 3.0 3.0 3.0 3.0
TBHQ 0.02 0.02 0.1 0.1 0.1 0.1
% of total fat as:
Palmitic acid 19.4 19.4 45.0 13.8 6.7 10.8
Stearic acid 3.6 3.6 4.8 2.6 2.5 3.4
Oleic acid 33.9 33.9 38.5 70.5 13.2 14.8
Linoleic acid 25.6 25.6 9.3 9.9 77.1 8.4
Linolenic acid 7.1 7.1 0.3 0.6 28.2
EPA 1.7 1.7 6.9
DHA 1.3 1.3 5.4
TABLE 2.2 Body mass, fat mass, food intake and cumulative energy intake of mice fed high-fat (HF) diets supplemented with either palm oil,
olive oil, safflower oil or flaxseed/fish oil, compared with those fed low-fat (LF) diets supplemented with either high sucrose or high maize
starch for 16 weeks. (Mean values ± SEM; n 9-10 mice per group).
LF-high maize
starch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil
HF-flaxseed/fish
oil
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Initial weight (g) 21.67 0.66 21.03 0.53 21.8 0.69 20.96 0.52 20.91 0.46 20.5 0.41
Final weight (g) 31.00ac 0.91 26.10bd 0.86 34.49a 0.82 28.93cd 1.56 32.17ac 1.5 31.50ac 0.92
Weight gain (%) 43.35ac 2.96 24.32bd 3.5 58.63a 1.99 37.56cd 5.48 53.33ac 4.85 53.82ac 4.08
Visceral fat mass (g) 2.38a 0.15 1.44b 0.15 3.00a 0.13 2.18a 0.28 2.91a 0.27 2.56a 0.14
Subcutaneous fat mass
(g) 0.75
ac 0.04 0.47c 0.06 1.15b 0.05 0.71ac 0.11 0.94ab 0.1 1.03ab 0.09
Food Intake
(g/day/mouse) 3.67
a 0.11 3.25d 0.11 2.92b 0.06 2.98bd 0.09 2.71bc 0.06 2.52c 0.08
Cumulative energy intake
(kJ/week/mouse) 408.55
a 9.32 362.00bc 9.8 394.23ac 6.39 401.67a 8.73 365.49bc 6.2 340.36b 8.35
a,b,c,d Mean values within a row with unlike superscript letters were significantly different (P < 0.05; ANOVA followed by post hoc Tukey’s
multiple comparison test).
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TABLE 2.3 Plasma variables in mice fed high-fat (HF) diets supplemented with either palm oil, olive oil, safflower oil or flaxseed/fish oil,
compared with low-fat (LF) diets supplemented with either high sucrose or high maize starch for 16 weeks*. (Mean values ± SEM; n 9-10 mice
per group).
LF-high maize
starch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil
HF-flaxseed/fish
oil
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Triglycerides (mg/dL) 45.1 7.8 43.7 9.4 34.9 4.3 33.2 5.3 30.3 5.7 36.8 3.2
Glucose (mg/dL) 160.2ac 9.1 121.1b 5.4 167.3a 5.3 164.2a 6.5 133.4bc 5.1 141.4abc 9.4
Insulin (ng/mL) 0.2 0.04 0.25 0.06 0.36 0.06 0.11 0.03 0.2 0.07 0.37 0.11
Leptin (ng/mL) 25.4ac 3.2 11.1c 1.9 44.6b 3.4 25.0ac 4.8 36.8ab 5.9 29.5ab 4.7
NEFA (mmol/L) 0.57 0.06 0.54 0.08 0.56 0.05 0.49 0.05 0.58 0.05 0.54 0.08
a,b,c Mean values within a row with unlike superscript letters were significantly different (P < 0.05; ANOVA followed by post hoc Tukey’s multiple
comparison test). *Blood was collected after animals were fasted.
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TABLE 2.4 Fatty acid profile (g/100g FAME) in the liver of mice fed high-fat (HF) diets supplemented with either palm oil, olive oil, safflower oil
or flaxseed/fish oil, compared with those fed low-fat (LF) diets supplemented with either high sucrose or high maize starch for 16 weeks. (Mean
values ± SEM; n 9-10 mice per group).
Fatty LF-high maizestarch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil HF-flaxseed/fish oil
Acids g/100g FAME g/100g FAME g/100g FAME g/100g FAME g/100g FAME g/100g FAME
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
14:0 0.51ab 0.02 0.45ad 0.02 0.44ad 0.01 0.37cd 0.01 0.29c 0.02 0.56b 0.04
16:0 24.02ab 0.18 22.51ad 0.50 25.02b 0.29 18.38c 0.28 19.55c 0.67 22.05d 0.33
16:1 cis-9 4.68a 0.18 4.11a 0.20 3.24b 0.10 1.67c 0.10 1.23c 0.13 2.49d 0.10
18:0 6.83a 0.53 7.37ac 0.50 3.62b 0.26 5.12ab 0.68 6.51a 0.83 9.74c 0.43
18:1 cis-9 38.95a 1.77 36.80a 1.79 51.73b 1.11 56.29b 1.85 19.10c 1.86 15.79c 0.58
18:2n-6 7.91a 0.47 8.44a 0.45 4.46b 0.25 4.40b 0.32 34.87c 0.79 8.58a 0.17
18:3n-3 0.71a 0.05 0.72a 0.06 0.03a 0.001 0.18a 0.09 0.18a 0.01 12.14b 0.47
18:3n-6 0.07a 0.01 0.06a 0.004 0.07a 0.01 0.06a 0.01 0.58b 0.02 0.09a 0.01
20:3n-6 0.76ad 0.04 0.86d 0.05 0.36b 0.03 0.54ab 0.07 1.98c 0.09 0.45b 0.02
20:4n-6 2.80a 0.23 3.69a 0.31 2.29a 0.26 3.48a 0.58 7.25b 0.82 3.36a 0.15
20:5n-3 0.88a 0.08 1.10a 0.12 0.01b 0.001 0.03b 0.004 0.02b 0.003 5.10c 0.12
22:5n-3 0.53a 0.05 0.49a 0.04 0.01b 0.001 0.05b 0.01 0.13b 0.01 2.27c 0.06
22:6n-3 4.87a 0.50 5.60a 0.47 0.42b 0.04 1.78b 0.30 1.81b 0.30 12.77c 0.37
Others 5.60a 0.17 6.73c 0.17 6.50cd 0.29 6.22ac 0.17 5.86ad 0.21 3.84b 0.17
FAME, fatty acid methyl ester. a,b,c,d Mean values within a row with unlike superscript letters were significantly different (P < 0.05 ANOVA
followed by post hoc Tukey’s multiple comparison test).
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TABLE 2.5 Fatty acid profile (g/100g FAME) in the epididymal adipose tissue of mice fed high-fat (HF) diets supplemented with either palm oil,
olive oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF) diets supplemented with either high sucrose or high maize starch for 16
weeks. (Mean values ± SEM; n 9-10 mice per group).
Fatty LF-high maizestarch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil HF-flaxseed/fish oil
Acids g/100g FAME g/100g FAME g/100g FAME g/100g FAME g/100g FAME g/100g FAME
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
14:0 1.01a 0.03 1.20f 0.02 0.68b 0.02 0.38c 0.01 0.46cd 0.02 2.47e 0.06
16:0 20.04a 0.44 19.02a 0.16 22.35b 0.30 10.42c 0.20 11.54cd 0.22 20.14a 0.25
16:1 cis-9 7.28a 0.21 8.53d 0.19 7.08ac 0.26 3.01b 0.14 2.60b 0.28 6.13c 0.26
18:0 1.65a 0.06 1.35b 0.03 1.35b 0.02 1.28b 0.05 1.69a 0.09 3.04c 0.06
18:1 cis-9 48.40a 0.67 49.12a 0.50 55.21b 0.48 74.55c 0.39 22.57d 0.25 27.95e 0.31
18:2n-6 13.13a 0.16 12.43a 0.25 8.29b 0.15 5.63c 0.12 56.27d 0.43 12.22a 0.14
18:3n-3 1.45a 0.05 1.61a 0.07 0.10b 0.01 0.22b 0.01 0.35b 0.02 17.51c 0.26
18:3n-6 0.03a 0.001 0.03a 0.001 0.02ac 0.001 0.01bc 0.004 0.10d 0.01 0.07e 0.003
20:3n-6 0.12a 0.003 0.12a 0.003 0.09bd 0.003 0.08b 0.001 0.39c 0.02 0.12ad 0.002
20:4n-6 0.16a 0.01 0.17a 0.006 0.23a 0.01 0.19a 0.01 0.62b 0.04 0.39c 0.01
20:5n-3 0.10a 0.01 0.11a 0.005 ND ND ND 0.98c 0.05
22:5n-3 0.14a 0.01 0.15a 0.004 ND ND ND 0.63c 0.02
22:6n-3 0.35a 0.03 0.38a 0.02 ND 0.06b 0.01 0.06b 0.004 1.94c 0.06
Others 6.16a 0.10 4.95d 0.15 3.43b 0.10 3.49b 0.10 2.44c 0.10 3.79b 0.15
FAME, fatty acid methyl ester. ND, not detected. a,b,c,d,e,f Mean values in a row with unlike superscript letters were significantly different (P <
0.05 ANOVA followed by post hoc Tukey’s multiple comparison test).
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TABLE 2.6 Fatty acid profile (g/100g FAME) in the brain of mice fed high-fat (HF) diets supplemented with either palm oil, olive oil, safflower oil or
flaxseed/fish oil, compared with low-fat (LF) diets supplemented with either high sucrose or high maize starch for 16 weeks. (Mean values ± SEM; n 9-10
mice per group).
Fatty LF-high maizestarch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil HF-flaxseed/fish oil
Acid g/100g FAME g/100g FAME g/100g FAME g/100g FAME g/100g FAME g/100g FAME
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
14:0 0.57a 0.07 0.19b 0.03 0.18b 0.02 0.12b 0.002 0.12b 0.01 0.25b 0.04
16:0 24.31a 0.28 22.18bc 0.11 23.84a 0.15 22.21bc 0.13 21.78b 0.17 22.84c 0.17
16:1 cis-9 1.18a 0.07 0.78de 0.10 0.75bd 0.03 0.49bd 0.01 0.49c 0.02 0.82de 0.07
18:0 20.95a 0.18 21.59ac 0.31 21.20ac 0.17 21.99bc 0.15 21.59ac 0.22 21.67ac 0.25
18:1 cis-9 19.27acd 0.31 20.41d 0.37 19.00c 0.27 20.29ad 0.35 17.53b 0.16 19.99ac 0.26
18:2n-6 0.56a 0.04 0.64a 0.15 0.49a 0.04 0.39a 0.03 1.95b 0.22 0.73a 0.16
18:3n-3 0.09a 0.02 0.20ab 0.15 0.05a 0.004 0.04a 0.001 0.02a 0.002 0.60b 0.23
18:3n-6 ND ND ND ND ND ND
20:3n-6 0.52a 0.01 0.51a 0.01 0.26b 0.002 0.33c 0.01 0.39d 0.01 0.36e 0.004
20:4n-6 6.97a 0.21 7.39a 0.21 8.84b 0.09 8.71b 0.09 8.96b 0.08 6.15c 0.09
20:5n-3 0.10a 0.00 0.10a 0.01 0.01b 0.001 0.01b 0.001 0.01b 0.002 0.42c 0.01
22:5n-3 0.29a 0.01 0.29a 0.01 0.05b 0.001 0.10c 0.003 0.07b 0.001 0.77d 0.01
22:6n-3 13.44a 0.30 13.79a 0.28 11.88b 0.10 13.26a 0.14 12.12b 0.12 15.26c 0.19
Others 9.95a 0.39 10.22a 0.31 11.65b 0.10 10.30ad 0.11 11.28bd 0.22 8.48c 0.17
FAME, fatty acid methyl ester. ND, not detected. a,b,c,d,e Mean values in a row with unlike superscript letters were significantly different (P < 0.05 ANOVA
followed by post hoc Tukey’s multiple comparison test).131
TABLE 2.7 SCFA concentrations (µmol/g) in the caecal contents of mice fed high-fat (HF) diets supplemented with either palm oil, olive oil,
safflower oil or flaxseed/ fish oil, compared with low-fat (LF) diets supplemented with either high sucrose or high maize starch for 16 weeks.
(Mean values ± SEM; n 9-10 mice per group).
SCFA
LF-high maize starch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil HF-flaxseed/fish oil
umol/g umol/g umol/g umol/g umol/g umol/g
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Acetate 31.85ab 1.55 24.53a 1.36 38.61b 4.03 25.73a 1.66 25.91a 1.19 27.08a 1.04
Propionate 14.84a 0.93 11.02a 0.46 19.57b 2.03 11.87a 1.19 11.39a 0.83 11.90a 0.62
Butyrate 14.59a 1.06 11.35a 0.56 21.56b 2.00 11.42a 1.24 11.45a 1.25 12.30a 0.73
Isobutyrate 10.83a 1.03 8.61a 0.62 16.51b 1.45 10.25a 1.26 10.21a 1.36 10.21a 0.80
Total 72.10ab 4.56 55.51a 3.01 96.25b 9.52 59.27a 5.36 58.97a 4.62 61.50a 3.19
a,b Mean values in a row with unlike superscript letters were significantly different (P < 0.05 ANOVA followed by post hoc Tukey’s multiple
comparison test).
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TABLE 2.8 Intestinal microbiota composition (% reads) in the caecal contents of mice fed high-fat (HF) diets supplemented with either palm oil, olive oil,
safflower oil or flaxseed/fish oil ,compared with those fed low-fat (LF) diets supplemented with either high sucrose or high maize starch for 16 weeks. (n 9-
10 mice per group). a,b Mean values within a row with unlike superscript letters were significantly different (P < 0.05; Kruskal-Wallis algorithm).
LF-high maize starch LF-high sucrose HF-palm oil HF-olive oil HF-safflower oil HF-flaxseed/fish oil
Phylum
Spirochaetes 0.01 0.00 0.04 0.00 0.00 0.04
Candidate Division TM7 0.00 0.00 0.04 0.01 0.00 0.00
Family
Desulfovibrionaceae 0.91 0.68 0.96 1.00 0.85 0.52
Rikenellaceae 9.18 6.20 3.37 6.02 6.88 5.88
Lactobacillaceae 2.41 1.95 2.24 1.45 2.25 0.95
Deferribacteraceae 5.98 4.28 5.83 7.93 7.01 6.23
Others 0.94 0.93 2.27 0.55 0.87 0.72
Genus
Alistipes 5.50a 3.62ab 1.83b 3.05ab 3.87ab 4.17ab
Rikenella 3.35 2.22 1.24 2.37 2.48 1.42
Odoribacter 1.06ab 1.99a 0.60ab 0.09b 0.83ab 2.33a
Lachnospiraceae Incertae Sedis 0.59ab 1.28a 1.12ab 0.71ab 0.47b 0.62ab
uncultured (Lachnospiraceae) 0.21ab 0.72a 0.34ab 0.07b 0.16ab 0.38ab
Coprococcus 0.24 0.37 0.61 0.16 0.17 0.24
Anaerotruncus 0.34a 0.99b 0.66ab 0.48ab 0.55ab 0.42a
Peptococcus 0.16 0.22 0.31 0.07 0.25 0.19
Lactobacillus 2.41 1.95 2.24 1.45 2.25 0.95
Mucispirillum 5.98 4.28 5.83 7.93 7.01 6.23
Others 1.58 0.97 2.14 1.28 1.20 0.95
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FIGURE 2.1(A) Body composition as determined by NMR showing the percentage of fat
mass for mice fed high-fat (HF) diets supplemented with either palm oil, olive oil,
safflower oil or flaxseed/fish oil, compared with those fed low-fat (LF) diets
supplemented with either high sucrose or high maize starch for 16 weeks. Values are
means (n 9-10) ± SEM, represented by vertical bars. a,b,c Mean values with unlike letters
were significantly different (P < 0.05; ANOVA followed by post hoc Tukey’s multiple
comparison test). (B) Body composition as determined by NMR showing the
percentage of lean mass for mice fed high-fat (HF) diets supplemented with either
palm oil, olive oil, safflower oil or flaxseed/fish oil, compared with those fed low-fat
(LF) diets supplemented with either high sucrose or high maize starch for 16 weeks.
Values are means (n 9-10) ± SEM, represented by vertical bars. a,b,c,d Mean values with
unlike letters were significantly different (P < 0.05; ANOVA followed by post hoc
Tukey’s multiple comparison test).
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FIGURE 2.2(A) Total liver weight of mice fed high-fat (HF) diets supplemented with
either palm oil, olive oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF)
diets supplemented with either high sucrose or high maize starch for 16 weeks. Values
are means (n 9-10) ± SEM, represented by vertical bars. a,b Mean values with unlike
letters were significantly different (P < 0.05; ANOVA followed by post hoc Tukey’s
multiple comparison test). (B) Total liver triglyceride levels in mice fed high-fat (HF)
diets supplemented with either palm oil, olive oil, safflower oil or flaxseed/fish oil,
compared with low-fat (HF) diets supplemented with either high sucrose or high maize
starch for 16 weeks. Values are means (n 9-10) ± SEM, represented by vertical bars. a,b,c
Mean values with unlike letters were significantly different (P < 0.05; ANOVA followed
by post hoc Tukey’s multiple comparison test).
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FIGURE 2.3 Principal co-ordinate analysis using unweighted UniFrac distances for mice
fed high-fat (HF) diets supplemented with either palm oil, olive oil, safflower oil or
flaxseed/fish oil compared with those fed low-fat (LF) diets supplemented with either
high sucrose or high maize starch for 16 weeks. LF-high maize starch, HF-palm oil,
HF-olive oil, HF-safflower oil, HF-flaxseed/fish oil and LF-high sucrose.
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FIGURE 2.4 Phylum level distributions of the microbial communities in caecal contents,
expressed as a percentage of the total population of assignable tags, in mice fed high-
fat (HF) diets supplemented with either palm oil, olive oil, safflower oil or flaxseed/fish
oil, compared with those fed low-fat (LF) diets supplemented with either high sucrose
or high maize starch for 16 weeks. a,b,c Values with unlike letters were significantly
different (P < 0.05; Kruskal-Wallis algorithm).
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FIGURE 2.5 Family level taxonomic distributions of the microbial communities in caecal
contents, expressed as a percentage of total tags assignable at family level, in mice fed
high-fat (HF) diets supplemented with either palm oil, olive oil, safflower oil or
flaxseed/fish oil, compared with those fed low-fat (LF) diets supplemented with either
high sucrose or high maize starch for 16 weeks. a,b,c Values with unlike letters were
significantly different (P < 0.05; Kruskal-Wallis algorithm).
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FIGURE 2.6 Genus level taxonomic distributions of the microbial communities present
in caecal contents, expressed as a percentage of total tags assignable at the genus
level, in mice fed high-fat (HF) diets supplemented with either palm oil, olive oil,
safflower oil or flaxseed/fish oil, compared with those fed low-fat (LF) diets
supplemented with either high sucrose or high maize starch for 16 weeks. a,b,c Values
with unlike letters were significantly different (P < 0.05; Kruskal-Wallis algorithm).
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SUPPLEMENTARY FIGURE 2.1 Relative mRNA expression of metabolism genes within
the liver of mice fed high-fat (HF) diets supplemented with either palm oil, olive oil,
safflower oil or flaxseed/fish oil, compared with low-fat (LF) diets supplemented with
either high sucrose or high maize starch for 16 weeks. Values are means (n 9-10) ±
SEM, represented by vertical bars. a,b,c Mean values with unlike letters were
significantly different (P < 0.05; ANOVA followed by post hoc Tukey’s multiple
comparison test).
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SUPPLEMENTARY FIGURE 2.2 Chao1 richness estimation of α diversity of intestinal
microbiota compositions of mice fed high-fat (HF) diets supplemented with either
palm oil, olive oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF) diets
supplemented with either high sucrose or high maize starch for 16 weeks. The
nonparametric Kruskal-Wallis test was used to estimate the relationship between
different groups. Values in the same row which do not share a common superscript
letter are significantly different, P < 0.05.
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SUPPLEMENTARY FIGURE 2.3 Simpson index of α diversity of intestinal microbiota
compositions of mice fed high-fat (HF) diets supplemented with either palm oil, olive
oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF) diets supplemented
with either high sucrose or high maize starch for 16 weeks. The nonparametric Kruskal-
Wallis test was used to estimate the relationship between different groups. Values in
the same row which do not share a common superscript letter are significantly
different, P < 0.05.
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SUPPLEMENTARY FIGURE 2.4 Shannon index of α diversity of intestinal microbiota
compositions of mice fed high-fat (HF) diets supplemented with either palm oil, olive
oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF) diets supplemented
with either high sucrose or high maize starch for 16 weeks. The nonparametric Kruskal-
Wallis test was used to estimate the relationship between different groups. Values in
the same row which do not share a common superscript letter are significantly
different, P < 0.05.
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SUPPLEMENTARY FIGURE 2.5 Phylogenetic diversity measurement of α diversity of
intestinal microbiota compositions of mice fed high-fat (HF) diets supplemented with
either palm oil, olive oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF)
diets supplemented with either high sucrose or high maize starch for 16 weeks. The
nonparametric Kruskal-Wallis test was used to estimate the relationship between
different groups. Values in the same row which do not share a common superscript
letter are significantly different, P < 0.05.
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SUPPLEMENTARY FIGURE 2.6 Observed species measurement of α diversity of
intestinal microbiota compositions of mice fed high-fat (HF) diets supplemented with
either palm oil, olive oil, safflower oil or flaxseed/fish oil, compared with low-fat (LF)
diets supplemented with either high sucrose or high maize starch for 16 weeks. The
nonparametric Kruskal-Wallis test was used to estimate the relationship between
different groups. Values in the same row which do not share a common superscript
letter are significantly different, P < 0.05.
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Chapter 3
Bifidobacterium breve and α-linolenic acid impact on
hepatic and intestinal lipid metabolism in the host
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3.1 ABSTRACT
The aim of this study was to address the mechanisms by which an α-linolenic acid
(ALA)-enriched diet supplemented with either Bifidobacterium breve NCIMB 702258 or
B. breve DPC 6330 impacted on fat distribution and composition in the host, as
previously reported (Wall et al., 2010). This was approached by assessing gene
expression of key enzymes involved in n-3 polyunsaturated fatty acid (PUFA)
metabolism in the liver and fatty acid uptake enzymes in the distal small intestine
and/or liver, following dietary supplementation with the strains. Female BALB/c mice
(n 10 mice per group) received a diet enriched with 3% (w/w) ALA either alone or
supplemented with either B. breve NCIMB 702258 or B. breve DPC 6330 (109 CFU/day)
for 6 weeks and compared with unsupplemented controls. Tissue fatty acid
composition was assessed by gas-liquid chromatography (GLC) and gene expression
levels were determined using real-time PCR. Supplementation of the ALA-enriched diet
with B. breve DPC 6330 increased mRNA expression of fatty acid binding protein
(FABP)-1 (P < 0.05) and diacylglycerol acyltransferase (DGAT)-2 (P < 0.05) in the ileum,
compared with unsupplemented controls. In addition, B. breve DPC 6330 increased
ileal mRNA expression of CD-36, compared with all groups (P < 0.05). Liver triglyceride
(TAG) levels were reduced in all ALA-enriched dietary groups, compared with
unsupplemented controls (P < 0.05). Supplementation of B. breve in an ALA-enriched
diet further reduced liver TAG levels (P < 0.05), compared with the ALA-enriched diet
alone and this was associated with a reduced hepatic CD-36 and FABP-1 mRNA
expression (P < 0.05). As expected, (Wall et al., 2012), supplementation of the ALA-
enriched diet with B. breve NCIMB 702258 increased docosapentaenoic acid (precursor
to docosahexaenoic acid (DHA)) (P < 0.05), with a tendency for increased DHA
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concentrations in the liver (P=0.077), compared with mice fed the ALA-enriched diet
alone. This strain-specific effect of B. breve NCIMB 702258 on tissue fatty acid
composition was not associated with an impact on mRNA expression of hepatic n-3
PUFA metabolism enzymes. In conclusion, B. breve NCIMB 702258 and B. breve DPC
6330 both exhibited strain-specific effects on liver TAG levels associated with a
decrease in fatty acid uptake by the liver.
3.2 INTRODUCTION
It has previously been shown that dietary supplementation with B. breve NCIMB
702258 and B. breve DPC 6330 positively influenced fatty acid profiles of the liver,
adipose tissue and brain in different animal species and models, as well as influencing
host intestinal microbiota composition (Barrett et al., 2012; Wall et al., 2012; Wall et
al., 2010; Wall et al., 2009). These studies suggest that dietary supplementation with a
probiotic bacteria can significantly influence health through the production of
bioactive fatty acids such as conjugated derivatives of PUFA (conjugated linoleic acid
(CLA) and conjugated ALA (CALA), for example) and by increasing tissue concentrations
of bioactive long-chain (LC) members of the n-3 PUFA family (eicosapentaenoic acid
(EPA; 20:5n-3), docosapentaenoic acid (22:5n-3) and DHA (22:6n-3), for example). The
interaction between resident gut microbes, dietary derived fatty acids, probiotic
supplementation and implications for health have recently been reviewed (Marques et
al., 2013). However, the mechanisms by which probiotic bacteria such as B. breve can
increase the production of bioactive LC-PUFA in host tissues are unclear.
Optimal dietary intakes of n-6: n-3 PUFA should be in the ratio of ~1-4:1, however
recent shifts in dietary PUFA consumption has increased this ratio to ~15-16:1
149
(Patterson et al., 2012). Coinciding increases in the incidence of diseases linked to
inflammatory processes such as cardiovascular disease (CVD), obesity, inflammatory
bowel disease (IBD) and cancer have all been linked with a low dietary intake of n-3
PUFA (Calder, 2009). In contrast, the benefits of ALA consumption on cardiovascular
health, immune regulation and inflammation have all been described (Pan et al.,
2012). Other functions of ALA require its further metabolism to more highly
unsaturated, members of the n-3 PUFA family. Flaxseed is thus emerging as an
important functional food ingredient since it is one of the richest sources of ALA (Singh
et al., 2011).
ALA is converted to EPA, docosapentaenoic acid and DHA through a series of
desaturation and elongation reactions, primarily in the liver (Patterson et al., 2012).
Dietary supplementation with ALA has previously been shown to increase tissue
concentrations of EPA and DHA (Ander et al., 2010; Ren et al., 2012; Wall et al., 2010).
Furthermore, dietary supplementation with an ALA-enriched diet in combination with
B. breve can increase tissue concentrations of EPA, docosapentaenoic acid and DHA,
compared with an ALA-enriched diet alone (Barrett et al., 2012; Wall et al., 2010). It
was hypothesised that the strains may alter hepatic n-3 PUFA metabolism/uptake or
fatty acid uptake in the distal small intestine (Wall et al., 2012). Thus, the aim of this
study was to determine whether supplementing an ALA-enriched diet with B. breve
NCIMB 702258 or B. breve DPC 6330 could impact on mRNA expression of genes
involved in lipid metabolism in both the ileum and liver, and/or n-3 PUFA metabolism
in the liver.
3.3 MATERIALS AND METHODS
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3.3.1 PREPARATION AND ADMINISTRATION OF B. breve NCIMB 702258 AND B. breve
DPC 6330
It was previously shown that B. breve NCIMB 702258 and B. breve DPC 6330 are
efficient CLA producers, converting up to 65% and 76%, respectively, of linoleic acid to
cis-9, trans-11 CLA when grown in 0.5 mg/mL linoleic acid in vitro (Barrett et al., 2007;
Coakley et al., 2003). Rifampicin resistant variants of B. breve NCIMB 702258 and B.
breve DPC 6330 were isolated by spread-plating ~109 colony forming units (CFU) from
an overnight culture onto MRS agar (de Man, Rogosa & Sharpe; Difco Laboratories,
Detroit, MI, USA), supplemented with 0.05% (w/v) L-cysteine hydrochloride (Sigma,
Wicklow, Ireland) (mMRS), containing 500 µg/mL rifampicin (Sigma). Following
anaerobic incubation (anaerobic jars with Anaerocult A gas packs; Merck, Darmstadt,
Germany) at 37°C for 3 days, colonies were stocked in mMRS broth containing 40%
(v/v) glycerol and stored at -80°C. To confirm that the rifampicin resistant variants
were identical to the parent strain, molecular fingerprinting using pulse-field gel
electrophoresis was employed.
Prior to freeze drying, B. breve NCIMB 702258 and B. breve DPC 6330 were grown in
mMRS by incubating for 48 hr at 37°C under anaerobic conditions. The culture was
washed twice in phosphate buffered saline (PBS) and resuspended at a concentration
of ~21010 cells/mL in 15% (w/v) trehalose (Sigma) in dH2O. One millilitre aliquots were
freeze-dried using a 24 hr programme (freeze temp. -40°C, condenser set point -60,
vacuum set point 600 m Torr). Each mouse that received the bacterial strains
consumed approximately 1109 live microorganisms per day. This was achieved by
resuspending appropriate quantities of freeze-dried powder in water which mice
consumed ad libitum. Mice that did not receive the bacterial strains received placebo
151
freeze-dried powder (15% (w/v) trehalose in dH2O). Water containing either the
bacterial strains or placebo freeze-dried powder was the only water supplied to the
mice throughout the trial. Freeze dried powders with the bacterial strains underwent
continuous quality control checks of cell counts for the duration of the trial, by plating
serial dilutions on mMRS agar supplemented with 100 µg/mL of mupirocin (Oxoid) and
100 µg/mL rifampicin (Sigma) and incubating plates anaerobically for 72 hr at 37°C.
3.3.2 ANIMALS AND TREATMENT
All animal experiments were approved by the University College Cork (UCC) Animal
Ethics Committee and experimental procedures were conducted under the
appropriate license from the Irish Government. Female BALB/c mice were purchased
from Harlan Limited (Briester, Oxon, UK) at 8 weeks of age and housed under barrier-
maintained conditions within the Biological Services Unit, UCC. Mice were allowed to
acclimatise for 1 week prior to commencement of the study and were fed ad libitum
with Teklad Global Rodent Standard Diet (Harlan Laboratories, Madison, WI, USA,
#2018S), with free access to water at all times. Mice were housed in groups of five per
cage and kept in a controlled environment at 25°C under a 12-hr-light/12-hr-dark cycle.
After 1 week of acclimatisation, the mice were randomly divided into four groups (n 10
mice per group): (1) a FXO supplemented dietary group (enriched in ALA) with B. breve
NCIMB 702258 (approximate daily dose of 109 microorganisms); (2) a FXO
supplemented dietary group (enriched in ALA) with B. breve DPC 6330 (approximate
daily dose of 109 microorganisms); (3) a flaxseed-oil (FXO) supplemented dietary group
(enriched in ALA) with placebo freeze-dried powder (15% w/v trehalose in drinking
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water); (4) a control- unsupplemented group fed a standard rodent diet with placebo
freeze-dried powder (15% w/v trehalose in drinking water).
The unsupplemented control diet contained the following nutrient composition:
corn starch (32.45%), casein (20.0%), sucrose (15.0%), maltodextrin (12.0%), cellulose
(5.0%), mineral mix (3.5%), vitamin mix (1.5%), L-cysteine (0.3%), choline bitartrate
(0.25%), TBHQ antioxidant (0.002%) and the following composition of fat: palm oil
(3.0%), safflower oil (3.0%), olive oil (3.0%), FXO (1.0%). The n-6 : n-3 ratio of this diet
was ~5.3 and the diet contained ~0.5% ALA. The FXO supplemented diet contained the
following nutrient composition: corn starch (32.45%), casein (20.0%), sucrose (15.0%),
maltodextrin (12.0%), cellulose (5.0%), mineral mix (3.5%), vitamin mix (1.5%), L-
cysteine (0.3%), choline bitartrate (0.25%), TBHQ antioxidant (0.002%) and the
following composition of fat: FXO (5.5%), palm oil (1.5%), safflower oil (1.5%), olive oil
(1.5%). The n-6 : n-3 ratio of this diet was ~0.75 and the diet contained ~3% ALA.
Body weight and food intake were assessed weekly. Following 6 weeks on
experimental diets, the animals were killed by cervical dislocation. Liver, brain, fat pads
(epididymal, perirenal and mesenteric), gastrointestinal tract from stomach to anus,
and caecal contents were removed, blotted dry on filter paper, weighed and flash-
frozen immediately in liquid nitrogen. All samples were stored at -80°C until processed.
Blood samples were collected in serum collection tubes (BD Diagnostics, Oxford, UK)
from fasted animals, and allowed to clot for at least 30 min at 4°C before
centrifugation for 20 min at 10,000g to separate the serum.
3.3.3 CULTURE DEPENDENT MICROBIAL ANALYSIS
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Fresh faecal samples were taken from BALB/c mice every second week for microbial
analysis. Microbial analysis of the faecal samples involved enumeration of the B. breve
strains by plating serial dilutions on MRS agar supplemented with 100 µg/mL of
mupirocin (Oxoid), 100 µg/mL of rifampicin (Sigma) and 50 units/mL of nystatin
(Sigma). Agar plates were incubated anaerobically for 72 hr at 37°C.
3.3.4 LIPID EXTRACTION AND FATTY ACID ANALYSIS
Lipids were extracted with chloroform-methanol (2:1, vol:vol; Thermo Scientific,
Dublin, Ireland) according to the method of Folch (Folch, 1957) Fatty acid methyl
esters (FAME) were prepared by using first 10mL 0.5 M NaOH (Sigma) in methanol for
10 min at 90°C followed by 10mL 14% BF3 in methanol (Sigma) for 10 min at 90°C (Park
and Goins, 1994). FAME were recovered with hexane (Thermo Scientific). Before GLC
analysis, samples were dried over 0.5g anhydrous sodium sulphate (Sigma) for 1 hr and
stored at -20°C. FAME were separated by GLC (Varian 3800; Varian) fitted with a flame-
ionisation detector by using a Chrompack CP Sil 88 column (Chrompack; 100 m x 0.25
mm internal diameter, 0.20-μm film thickness) and helium as carrier gas. The column
oven was programmed to be held initially at 80°C for 8 min and then increased by
8.5°C/min to a final column temperature of 200°C. The injection volume used was 0.6
μL, with an automatic sample injection on a SPI 1093 splitless on-column temperature-
programmable injector. Peaks were integrated by using the Varian Star
Chromatography Workstation version 6.0 software, and peaks were identified by
comparison of retention times with pure FAME standards (Nu-Chek Prep, MN, USA).
The percentage of individual fatty acids was calculated according to the peak areas
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relative to the total area (total fatty acids were set at 100%). All fatty acid data are
presented as means ± standard errors of the mean (SEM) in g/100g FAME.
3.3.5 MEASUREMENT OF TAG IN THE LIVER AND SERUM
The lipids from 50 mg of frozen liver were extracted and purified according to the
method of Folch (Folch, 1957). Liver lipids were extracted using chloroform-methanol
(2:1, vol:vol; Thermo Scientific) and an aliquot of the organic phase was collected,
dried and resuspended in duplicate in Infinity-TAG lipid-stable reagent (Thermo
Scientific). TAG levels in the samples were determined according to the manufacturer’s
instructions and lipids were quantified using a TAG chemistry calibrator (Pointe
Scientific Inc., MI, USA). Serum TAG levels were analysed in duplicate using the
commercial L-Type TAG M kit (Wako Diagnostics, Neuss, Germany).
3.3.6 RNA EXTRACTIONS AND COMPLEMENTARY DNA SYNTHESIS
Total RNA was isolated from the liver and ileum using the commercial RNeasy Mini-
Kit (Qiagen, West Sussex, UK), according to the manufacturer’s instructions. Total
isolated RNA was quantified using the Nanodrop (Thermo Scientific). Single stranded
complementary DNA (cDNA) was synthesised from 1μg of total RNA using 2.5ng/μL
random primers (Promega, WI, USA), 10mM PCR nucleotide mix (Promega), 40units/μL
RNasin Plus RNase inhibitor (Promega) and the Im-Prom II reverse transcriptase
(Promega).
3.3.7 REAL-TIME PCR ANALYSIS
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Amplification of generated cDNA was performed in the Lightcycler 480 system
(Roche Diagnostics Ltd., West Sussex, UK) using 0.25μM primers (MWG Eurofins,
Ebersberg, Germany), 1μL cDNA and the Lightcycler 480 SYBR Green I Master kit
(Roche Diagnostics Ltd). Real-time PCR conditions were set at: 95°C for 10 min
followed by 50 cycles at 95°C for 10 sec, 60°C for 5 sec and 72°C for 15 sec. Specific
forward and reverse primers used to amplify cDNA were newly designed and are listed
in Table 3.1. All samples were analysed in duplicate and normalised to β-actin, as a
constitutively expressed control gene. Melting curve analysis allowed the validation of
the authenticity of the real-time PCR products. Basic relative quantification of
expression was determined using the comparative 2-ΔΔCt method.
3.3.8 STATISTICAL ANALYSIS
All results are presented as means ± SEM (per group). To assess whether differences
between the treatment groups were significant, data were analysed using one-way
ANOVA followed by post hoc Tukey’s multiple comparison test using GraphPad Prism
version 4.0 for Windows (GraphPad Software). Statistical significance was accepted at
P < 0.05.
3.4 RESULTS
3.4.1 SURVIVAL AND TRANSIT OF B. breve DPC 6330 AND B. breve NCIMB 702258 IN
BALB/c MICE
Quantification of the numbers of administered B. breve strains in the faeces of mice
confirmed gastrointestinal transit and survival. Stool recovery of B. breve NCIMB
702258 and B. breve DPC 6330 were approximately 1x107 CFU/g faeces and 5x106
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CFU/g faeces, respectively after 1 week of feeding and remained at similar numbers at
weeks 2 and 4. At week 6, there was a decline in the numbers of excreted B. breve
strains, with stool recovery of B. breve NCIMB 702258 and B. breve DPC 6330 being
9x105 CFU/g faeces and 8x105 CFU/g faeces, respectively.
3.4.2 DIETARY SUPPLEMENTATION WITH B. breve NCIMB 702258 AND B. breve DPC
6330 REDUCED LIVER TAG LEVELS
No differences in food intake, body weight gain, visceral fat mass or serum TAG
levels were observed between the groups (Table 3.2). Analysis of total liver TAG levels
showed that ALA-supplementation, either alone or in combination with either B. breve
strain significantly reduced liver TAG levels, compared with unsupplemented controls
(P < 0.05; Table 3.2). Supplementation of B. breve NCIMB 702258 and B. breve DPC
6330 in an ALA-enriched diet further reduced liver TAG, compared with feeding the
ALA-enriched diet alone (P < 0.05; Table 3.2).
3.4.3 EFFECT OF DIETARY ENRICHMENT WITH ALA ALONE OR SUPPLEMENTED WITH
B. breve NCIMB 702258 AND B. breve DPC 6330 ON TISSUE FATTY ACID
COMPOSITION
To investigate the effects of the ALA-enriched diet on tissue fatty acid composition,
fatty acid profiling was performed on liver, epididymal adipose tissue and brain. As
expected, following the 6 week feeding period, enrichment of the diet with ALA
significantly increased tissue ALA concentrations, by 5- and 6-fold in the epididymal
adipose tissue (P < 0.05; Table 3.4) and liver (P < 0.05; Table 3.3) respectively,
compared with unsupplemented controls. Furthermore, the ALA-enriched dietary
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groups exhibited significantly higher concentrations of EPA in the liver (by ~8-fold; P <
0.05; Table 3.3), in the epididymal adipose tissue (by ~6-fold; P < 0.05; Table 3.4) and in
the brain (by ~2-fold; P < 0.05; Table 3.5), compared with unsupplemented controls.
Additionally, docosapentaenoic acid concentrations were significantly higher in the
ALA-enriched groups in the liver (by ~2-fold; P < 0.05; Table 3.3), in the epididymal
adipose tissue (by ~4-fold; P < 0.05; Table 3.4) and in the brain (by 2-fold; P < 0.05;
Table 3.5), compared with unsupplemented controls. Supplementation of the ALA-
enriched diet with B. breve NCIMB 702258 significantly increased concentrations of
EPA in the brain, compared with B. breve DPC 6330 supplementation (P < 0.05; Table
3.5). Moreover, docosapentaenoic acid concentrations in the liver were significantly
higher following supplementation of the ALA-enriched diet with B. breve NCIMB
702258, compared with the ALA-enriched diet (P < 0.05; Table 3.3). In addition,
supplementation of the ALA-enriched diet with B. breve NCIMB 702258 led to
significantly increased DHA in the liver, compared with unsupplemented controls (P <
0.05; Table 3.3) and resulted in a tendency for increased DHA in the liver, compared
with mice fed the ALA-enriched diet (P=0.077; Table 3.3). Dietary ALA enrichment
regardless of microbial supplementation, significantly increased epididymal adipose
tissue concentrations of DHA, compared with unsupplemented controls (P < 0.05;
Table 3.4) while in the brain, the ALA-enriched diet increased DHA concentrations,
compared with unsupplemented controls (P < 0.05; Table 3.5).
All groups fed the ALA-enriched diet exhibited lower oleic acid (18:1 cis-9) in the
liver and epididymal adipose tissue (P < 0.05; Tables 3.3 and 3.4) and higher dihomo-γ-
linolenic acid (20:3n-6) in the brain (P < 0.05; Table 3.5), compared with
unsupplemented controls. In addition, concentrations of arachidonic acid (20:4n-6)
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were significantly lower in the liver (P < 0.05; Table 3.3) and epididymal adipose tissue
(P < 0.05; Table 3.4) in all ALA-enriched dietary groups, compared with
unsupplemented controls. Both groups that received B. breve supplementation with
the ALA-enriched diet exhibited higher palmitoleic acid (16:1 cis-9) and oleic acid in the
brain (P < 0.05; Table 3.5) and higher stearic acid (18:0) in the liver (P < 0.05; Table
3.3), compared with the ALA-enriched dietary group. Supplementation with B. breve
DPC 6330 also resulted in higher palmitic acid (16:0) and lower linoleic acid and γ-
linolenic acid in the liver (P < 0.05; Table 3.3), compared with the ALA-enriched dietary
group.
3.4.4 IMPACT ON mRNA GENE EXPRESSION LEVELS OF ENZYMES INVOLVED IN n-3
PUFA METABOLISM WITHIN THE LIVER AND THE UPTAKE OF FATTY ACIDS TO THE
LIVER FOLLOWING DIETARY ENRICHMENT WITH ALA EITHER ALONE OR
SUPPLEMENTED WITH B. breve NCIMB 702258 OR B. breve DPC 6330
Following the 6 week feeding period, mRNA expression of enzymes involved in n-3
PUFA metabolism within the liver (Figure 3.1(A)) and genes involved in the transport
and uptake of fatty acids to the liver (Figure 3.1(B)) were determined using real-time
PCR.
An increase in the mRNA expression of Δ-6-desaturase was found in all ALA-
enriched dietary groups, compared with unsupplemented controls (P < 0.05; Figure
3.1(A)). Hepatic mRNA expression of elongation of very long chain fatty acids (ELOVL)-5
was significantly reduced in mice fed the ALA-enriched diet, compared with
unsupplemented controls and the ALA-enriched dietary group supplemented with B.
breve DPC 6330 (P < 0.05; Figure 3.1(A)). In addition, supplementation of the ALA-
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enriched diet with B. breve DPC 6330 significantly increased mRNA expression of
ELOVL-6, compared with the ALA-enriched diet (P < 0.05; Figure 3.1(A)). Both ALA-
enriched dietary groups supplemented with B. breve and the unsupplemented control
group exhibited significantly reduced hepatic mRNA expression of Δ-5-desaturase,
compared with the ALA-enriched dietary group (P < 0.05; Figure 3.1(A)). No significant
differences were observed in hepatic mRNA expression of stearyl-CoA desaturase
(SCD)-1 or ELOVL-2 (Figure 3.1(A)).
Both groups fed the ALA-enriched diet supplemented with B. breve NCIMB 702258
and B. breve DPC 6330 exhibited significantly decreased hepatic mRNA expression of
CD-36, compared with mice that received the ALA-enriched diet and unsupplemented
controls (P < 0.05; Figure 3.1(B)). In addition, supplementation of the ALA-enriched
diet with both B. breve strains was associated with significantly decreased hepatic
mRNA expression of FABP-1, compared with the ALA-enriched dietary group (P < 0.05;
Figure 3.1(B)). The unsupplemented controls exhibited ~5-fold increase in hepatic
mRNA expression of fatty acid synthase (FAS), compared with all ALA-enriched groups
(P < 0.05; Figure 3.1(B)). Hepatic mRNA expression of sterol regulatory element binding
protein (SREBP)-1c was significantly increased following supplementation with ALA
either alone or in combination with B. breve DPC 6330, compared with
unsupplemented controls (P < 0.05; Figure 3.1(B)). No differences in hepatic mRNA
expression of fatty acid transport protein (FATP)-5 were observed between the groups
(Figure 3.1(B)).
3.4.5 IMPACT ON mRNA GENE EXPRESSION LEVELS OF ENZYMES INVOLVED IN THE
TRANSPORT AND UPTAKE OF FATTY ACIDS TO THE ILEUM FOLLOWING DIETARY
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ENRICHMENT WITH ALA EITHER ALONE OR SUPPLEMENTED WITH B. breve NCIMB
702258 OR B. breve DPC 6330
Supplementation of the ALA-enriched diet with B. breve DPC 6330 significantly
increased ileal mRNA gene expression of FABP-1 and DGAT-2, compared with
unsupplemented controls (P < 0.05; Figure 3.2). No differences in the expression of
FABP-1, DGAT-2, FABP-2 or FATP-4 were observed between the ALA-enriched dietary
groups (Figure 3.2). Mice supplemented with B. breve DPC 6330 with the ALA-enriched
diet exhibited a significant increase in CD-36 mRNA expression, compared with all
other groups (P < 0.05; Figure 3.2). No differences were observed in mRNA expression
of FABP-2 or FATP-4 between the groups (Figure 3.2).
3.5 DISCUSSION
The mechanisms by which both dietary substrates and ingested probiotics influence
tissue fatty acid composition with implications for health are unclear. The present
study investigated the mechanisms involved in modulation of tissue fatty acid
composition by B. breve NCIMB 702258 and B. breve DPC 6330 following dietary
supplementation. In particular, we focused on the impact of B. breve in an ALA-
enriched diet on lipid metabolism in the distal small intestine and liver.
Supplementation of the ALA-enriched diet with B. breve DPC 6330 significantly
increased hepatic mRNA expression levels of ELOVL-5 and ELOVL-6, involved in the
elongation of fatty acids to more unsaturated members of the n-3 PUFA family. This
indicates a strain-specific effect of B. breve DPC 6330 on hepatic n-3 PUFA metabolism.
Despite an increase in hepatic ELOVL-5 and ELOVL-6 expression following
supplementation of the ALA-enriched diet with B. breve DPC 6330, no additional
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increases in tissue EPA, docosapentaenoic acid or DHA concentrations were observed
in this group. All ALA-enriched dietary groups exhibited increased hepatic mRNA
expression of Δ-6-desaturase. This enzyme is involved in the biosynthetic pathway of
LC-PUFA (Stoffel et al., 2008) and thus, may partly explain the increased EPA and
docosapentaenoic acid concentrations in the liver, epididymal adipose tissue and brain
exhibited for all ALA-enriched dietary groups. Beyond docosapentaenoic acid
formation, Δ-6-desaturase also metabolises tetracosapentaenoic acid (precursor to
DHA), however since Δ-6-desaturase is used by two substrates in the same pathway of
n-3 PUFA metabolism, there is intrinsic potential for competitive substrate inhibition to
occur (Gregory et al., 2011). Previous studies have revealed that high dietary ALA up
regulates hepatic Δ-6-desaturase mRNA expression levels in different models (Li et al.,
2008; Ren et al., 2012). One recent study demonstrating the impact of ALA
supplementation on Δ-6-desaturase and ELOVL-5 expression in the common carp
showed that after 42 days of feeding, while Δ-6-desaturase activity decreased, there
was an increase in ELOVL-5 expression (Ren et al., 2012). This suggests that while the
activity of one rate-limiting enzyme involved in the metabolism of n-3 PUFA increases,
there may not be a corresponding increase in the activity of the other at the same
time, thus the sequence of enzyme activity is time dependent. This may explain why
we did not observe an increase in ELOVL-5 expression in all ALA-enriched dietary
groups since Δ-6-desaturase activity was increased at this time.
Supplementation of an ALA-enriched diet with B. breve DPC 6330 had a significant
effect on increasing the mRNA expression of genes involved in the transport and
uptake of fatty acids to the ileum. Significant increases in mRNA expression of FABP-1,
DGAT-2 and CD-36 in the ileum were found following supplementation of the ALA-
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enriched diet with B. breve DPC 6330. The increase in mRNA expression of CD-36
following supplementation of the ALA-enriched diet with B. breve DPC 6330 was
significant compared with the group fed the ALA-enriched diet alone, thus indicating a
strain-specific effect of B. breve DPC 6330 on lipid metabolism in the ileum. FABP-1 and
CD-36 glycoprotein, which play a role in cellular adhesion and in the regulation of fatty
acid transport and uptake, have previously been shown to be increased in the intestine
following in vivo exposure of human intestinal mucosa to the probiotic species
Lactobacillus plantarum WCFSI (Troost et al., 2008). Furthermore, the role of the
microbiota in stimulating dietary fatty acid absorption in the intestinal epithelium have
previously been demonstrated (Semova et al., 2012).
Hepatic TAG levels were significantly reduced following 6 weeks of dietary
intervention with an ALA-enriched diet, thus indicating an n-3 PUFA impact on hepatic
TAG reduction. It has been reported that EPA may be a promising novel therapy to
decrease hepatic TAG (Masterton et al., 2010; Shapiro et al., 2011) and may therefore
be of importance in the treatment of non-alcoholic fatty liver disease (NAFLD).
Coincidently, all ALA-enriched diets in this study increased liver EPA concentrations. In
addition, all groups fed the ALA-enriched diets exhibited reduced hepatic FAS mRNA
expression. Supplementation of the ALA-enriched diet with either B. breve NCIMB
702258 or B. breve DPC 6330 further decreased hepatic TAG levels, compared with the
ALA-enriched dietary group. These data demonstrate a potential for B. breve to reduce
liver TAG levels in the host. The decrease in liver TAG following supplementation of the
ALA-enriched diet with B. breve correlated with a significant decrease in hepatic mRNA
expression levels of CD-36 and FABP-1, compared with the ALA-enriched dietary group,
whereby CD-36 and FABP-1 are involved in transport and uptake of fatty acids to the
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liver (Garcia-Monzon et al., 2011; Newberry et al., 2003). This indicates a strain-specific
effect of B. breve NCIMB 702258 and B. breve DPC 6330 toward reducing hepatic TAG
levels which correlates with a reduction in the uptake of fatty acids to the liver. Recent
studies have described a potential therapeutic role for certain probiotic strains in the
treatment of NAFLD (Iacono et al., 2011). For example, using a cholesterol enriched
diet, administration of Lactobacillus plantarum MA2 to rats reduced liver TAG and
increased the numbers of faecal lactobacilli and bifidobacteria (Wang et al., 2009).
Furthermore, the potential of VSL#3, a multistrain preparation composed of
Streptococcus thermophilus and several strains of Lactobacillus and Bifidobacterium at
reducing inflammation and oxidative damage to the liver while also ameliorating liver
lipid profiles has been demonstrated (Esposito et al., 2009).
Dietary ALA-supplementation increased liver EPA and docosapentaenoic acid
concentrations, epididymal adipose tissue EPA, docosapentaenoic acid and DHA
concentrations and brain EPA and docosapentaenoic acid concentrations. In addition,
the increases in liver and epididymal adipose tissue EPA and docosapentaenoic acid
concentrations following dietary ALA-supplementation were at the expense of
arachidonic acid. EPA replaces arachidonic acid as a eicosanoid substrate in cell
membranes (Simopoulos, 2003), resulting in decreased production of arachidonic-acid
derived proinflammatory eicosanoids such as prostaglandin E2 and leukotriene B4
(Calder, 2006) thus, increases in tissue EPA concentrations would be beneficial in a
variety of chronic inflammatory settings such as NAFLD and IBD. Moreover, dietary
ALA-supplementation increased docosapentaenoic acid concentrations in the brain.
Since docosapentaenoic acid is the precursor to DHA, which has been shown as a vital
fatty acid for brain development, influencing cognitive processes such as memory and
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learning (Innis, 2007; Yurko-Mauro et al., 2010), the observed increases in brain
docosapentaenoic acid concentrations following dietary ALA supplementation is
beneficial. Supplementation of the ALA-enriched diet with B. breve NCIMB 702258
increased liver docosapentaenoic acid with a tendency towards increased liver DHA,
compared with mice fed the ALA-enriched diet. This is consistent with previous
observations, i.e. that the response of fatty acid metabolism to administration of
bifidobacteria is strain-dependent (Wall et al., 2012).
The data presented in this study have demonstrated strain-specific effects of B.
breve DPC 6330 supplementation in an ALA-enriched diet on lipid metabolism in the
ileum and strain-specific effects of both B. breve NCIMB 702258 and B. breve DPC 6330
on lipid metabolism in the liver. Supplementation with either B. breve strains in an
ALA-enriched diet reduced liver TAG levels and this was associated with reduced
hepatic CD-36 and FABP-1 expression, involved in the uptake of fatty acids to the liver.
The effect of B. breve NCIMB 702258 and B. breve DPC 6330 on reducing hepatic TAG
levels may be of therapeutic importance for the future treatment of NAFLD. Dietary
ALA-supplementation positively impacted on tissue fatty acid compositions, increased
hepatic n-3 PUFA metabolism enzymes and reduced hepatic TAG levels, hepatic fatty
acid synthesis enzymes and hepatic uptake of fatty acids. In conclusion, this study
provided some promising data on the potential mechanisms through which the
probiotic strains B. breve NCIMB 702258 and B. breve DPC 6330 may influence fat
distribution in the host by altering lipid metabolism at the molecular level.
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TABLE 3.1 Primer sequences used for real-time PCR
Liver
Gene Symbol Forward Primer Reverse Primer
β-actin 5'-AGAGGGAAATCGTGCGTGAC-3' 5'-CAATAGTGATGACCTGGCGT-3'
Δ-6-desaturase 5'-CCTGGACCGTGGCAAAAG-3' 5'-GTGGGACAGGAGGAGAAAGAAG-3'
Δ-5-desaturase 5'-CACTGTGGCCTTCTCTTCTCA-3' 5'-ACGCGGTTTTCTTATCTGTCA-3'
ELOVL-2 5'-AGCTGCCATGCCCTTTCTGA-3' 5'-CCCTGGGGCTCTGTTGATTATG-3'
ELOVL-5 5'-GTCCTCCATCCCGTCCAT-3' 5'-TGATTGTCAGCACAAACTGGA-3'
ELOVL-6 5'-TGGCTGGCTTGAAAATGGAGTCTT-3' 5'-GAACAGGGAGGGAGGCGAACAC-3'
SCD-1 5'-ACTGCTGGGGCGAGACTTTTGTA-3' 5'-CCGGGATTGAATGTTCTTGTCGTA-3'
CD-36 5'-TGATACTATGCCCGCCTCTCC-3' 5'-TTTCCCACACTCCTTTCTCCTCTA-3'
FAS 5'-TCCACCTTTAAGTTGCCCTG-3' 5'-TCTGCTCTCGTCATGTCACC-3'
SREBP-1c 5'-CTCCAGCTCATCAACAACCAAGAC-3' 5'-AGAGGAGGCCAGAGAAGCAGAAGA-3'
FATP-5 5'-CCGGCAGCATGGCGTAACAG-3' 5'-ACACATTTGCCCGAAGTCCATTG-3'
FABP-1 5'-GAAGCCTCGTTGCCACCAT-3' 5'-CGATTTCTGACACCCCCTTGAT-3'
Ileum
Gene Symbol Forward Primer Reverse Primer
FABP-2 5'-TGAGGCCAAGCGATTCT-3' 5'-TGAGCCTGGCATTAGCAT-3'
FATP-4 5'-TGCCCGCCCCATCTTCCT-3' 5'-AACAGCGGGTCTTTCACAACAG-3'
DGAT-2 5'-CACAGGTGCCGTCTTGGGTTATC-3' 5'-CAGACTTGGGGTGTGGCTCAGGA-3'
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TABLE 3.2 Body mass, fat mass, liver mass, liver and serum triglyceride (TAG) levels in
mice fed an ALA-enriched diet either alone or in combination with Bifidobacterium
breve NCIMB 702258 or B. breve DPC 6330 or an unsupplemented diet for 6 weeks.
(Mean values ± SEM; n 10 mice per group).
a,b,c Mean values within a row with unlike superscript letters were significantly
different (P < 0.05 ANOVA followed by post hoc Tukey’s multiple comparison test). 2
Includes epididymal, perirenal and mesenteric fat pads.
Unsupplemented ALA-enriched
ALA-enriched diet
and
ALA-enriched diet
and
diet diet
B. breve NCIMB
702258 B. breve DPC 6330
Mean SEM Mean SEM Mean SEM Mean SEM
Initial weight (g) 19.06a,b 0.12 19.82a 0.15 19.05b 0.29 19.52a,b 0.20
Final weight (g) 20.37 0.23 21.13 0.21 20.21 0.35 21.19 0.30
Weight gain (%) 6.87 1.12 6.65 1.03 6.12 1.06 8.54 1.05
Visceral fat mass (g)² 0.61 0.05 0.75 0.06 0.70 0.05 0.78 0.07
Liver TAG (mg/g) 16.26b 0.79 12.89a 0.54 10.03c 0.64 9.79c 0.35
Serum TAG (mg/dL) 80.21 10.02 58.31 5.18 73.62 4.57 70.98 5.25
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TABLE 3.3 Fatty acid profile (g/100g FAME) in the liver of mice fed an ALA-enriched
diet either alone or in combination with Bifidobacterium breve NCIMB 702258 or B.
breve DPC 6330 or an unsupplemented diet for 6 weeks. (Mean values ± SEM; n 10
mice per group).
FAME, fatty acid methyl ester. a,b,c Mean values within a row with unlike superscript
letters were significantly different (P < 0.05 ANOVA followed by post hoc Tukey’s
multiple comparison test).
Unsupplemented ALA-enriched
ALA-enriched diet
and
ALA-enriched diet
and
Fatty
acid diet diet
B. breve NCIMB
702258 B. breve DPC 6330
g/100g FAME g/100g FAME g/100g FAME g/100g FAME
Mean SEM Mean SEM Mean SEM Mean SEM
16:0 26.51a,b 0.36 25.68a 0.47 26.42a,b 0.47 27.78b 0.66
16:1 cis-9 2.36 0.16 2.73 0.20 2.55 0.13 2.72 0.19
18:0 6.85a 0.35 7.41a 0.29 8.67b 0.20 8.60b 0.39
18:1 cis-9 35.45b 0.60 31.68a 0.82 29.85a 0.70 29.50a 0.82
18:2n-6 15.34a 0.39 15.35a 0.35 13.39a,b 0.31 13.84b 0.43
18:3n-3 0.76b 0.04 5.09a 0.15 4.89a 0.13 4.72a 0.16
18:3n-6 0.25b 0.02 0.17a 0.01 0.13a,c 0.01 0.10c 0.01
20:3n-6 0.44 0.02 0.43 0.03 0.50 0.03 0.49 0.02
20:4n-6 4.10b 0.21 2.82a 0.23 2.85a 0.16 2.79a 0.17
20:5n-3 0.12b 0.01 0.91a 0.09 1.11a 0.05 1.09a 0.07
22:5n-3 0.09b 0.01 0.23a 0.02 0.32c 0.02 0.29a,c 0.02
22:6n-3 2.04a 0.12 2.21a,b 0.22 2.81b 0.17 2.64a,b 0.19
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TABLE 3.4 Fatty acid profile (g/100g FAME) in the epididymal adipose tissue of mice
fed an ALA-enriched diet either alone or in combination with Bifidobacterium breve
NCIMB 702258 or B. breve DPC 6330 or an unsupplemented diet for 6 weeks. (Mean
values ± SEM; n 10 mice per group).
FAME, fatty acid methyl ester. a,b Mean values within a row with unlike superscript
letters were significantly different (P < 0.05 ANOVA followed by post hoc Tukey’s
multiple comparison test).
Unsupplemented ALA-enriched
ALA-enriched diet
and
ALA-enriched diet
and
Fatty acid diet diet
B. breve NCIMB
702258
B. breve DPC
6330
g/100g FAME g/100g FAME g/100g FAME g/100g FAME
Mean SEM Mean SEM Mean SEM Mean SEM
16:0 19.83b 0.42 18.35a 0.23 18.67a,b 0.32 18.87a,b 0.28
16:1 cis-9 3.57 0.19 4.03 0.25 3.95 0.22 3.98 0.20
18:0 3.17a 0.21 2.68a,b 0.12 2.54b 0.09 2.79a,b 0.15
18:1 cis-9 47.84b 0.34 43.34a 0.64 42.63a 0.54 42.65a 0.53
18:2n-6 17.49 0.49 18.53 0.62 19.09 0.74 18.42 0.68
18:3n-3 1.13b 0.03 6.07a 0.12 6.42a 0.29 6.44a 0.14
18:3n-6 0.06b 0.00 0.05a,b 0.00 0.04a 0.00 0.05a,b 0.00
20:3n-6 0.12b 0.00 0.11a 0.00 0.10a 0.00 0.11a,b 0.00
20:4n-6 0.25b 0.01 0.21a 0.01 0.21a 0.01 0.20a 0.01
20:5n-3 0.01b 0.00 0.06a 0.00 0.07a 0.01 0.07a 0.00
22:5n-3 0.04b 0.00 0.15a 0.01 0.17a 0.01 0.17a 0.01
22:6n-3 0.14b 0.01 0.25a 0.01 0.28a 0.02 0.30a 0.02
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TABLE 3.5 Fatty acid profile (g/100g FAME) in the brain of mice fed an ALA-enriched
diet either alone or in combination with Bifidobacterium breve NCIMB 702258 or B.
breve DPC 6330 or an unsupplemented diet for 6 weeks. (Mean values ± SEM; n 10
mice per group).
FAME, fatty acid methyl ester. a,b,c Mean values within a row with unlike superscript
letters were significantly different (P < 0.05 ANOVA followed by post hoc Tukey’s
multiple comparison test).
Unsupplemented ALA-enriched
ALA-enriched diet
and
ALA-enriched diet
and
Fatty acid diet diet
B. breve NCIMB
702258 B. breve DPC 6330
g/100g FAME g/100g FAME g/100g FAME g/100g FAME
Mean SEM Mean SEM Mean SEM Mean SEM
16:0 31.61 0.53 30.44 0.69 30.34 0.42 30.24 0.54
16:1 cis-9 0.75a,b 0.02 0.71a 0.02 0.78b 0.02 0.78b 0.02
18:0 23.31 0.19 23.18 0.20 28.87 0.20 23.35 0.34
18:1 cis-9 20.26a,b 0.22 20.01a 0.13 20.75b 0.11 20.85b 0.25
18:2n-6 0.88 0.03 0.88 0.02 1.00 0.05 0.99 0.02
18:3n-3 ND ND ND ND ND ND ND ND
18:3n-6 0.27 0.01 0.30 0.02 0.27 0.01 0.29 0.01
20:3n-6 0.34b 0.01 0.42a 0.01 0.44a 0.10 0.45a 0.01
20:4n-6 6.03 0.13 5.90 0.15 6.20 0.08 6.32 0.18
20:5n-3 0.03b 0.00 0.08a,c 0.00 0.08a 0.00 0.05c 0.02
22:5n-3 0.05b 0.01 0.15a 0.01 0.13a 0.01 0.13a 0.02
22:6n-3 5.75b 0.34 7.20a 0.44 6.54a,b 0.24 6.51a,b 0.48
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FIGURE 3.1(A) Expression of fatty acid metabolism enzymes in the livers of mice fed
ALA-enriched diets either alone or in combination with Bifidobacterium breve NCIMB
702258 or B. breve DPC 6330, or an unsupplemented diet, relative to β-actin.
Expression in the unsupplemented and ALA-enriched diets supplemented with either
B. breve NCIMB 702258 or B. breve DPC 6330 is relative to the ALA-enriched diet,
which was set to 1. Values are means (n 10) ± SEM, represented by vertical bars. a,b
Mean values within a row with unlike superscript letters were significantly different (P
< 0.05 ANOVA followed by post hoc Tukey’s multiple comparison test).
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FIGURE 3.1(B) Expression of fatty acid uptake enzymes in the livers of mice fed ALA-
enriched diets either alone or in combination with Bifidobacterium breve NCIMB
702258 or B. breve DPC 6330, or an unsupplemented diet, relative to β-actin.
Expression in the unsupplemented diet and ALA-enriched diets supplemented with
either B. breve NCIMB 702258 or B. breve DPC 6330 is relative to the ALA-enriched
diet, which was set to 1. Values are means (n 10) ± SEM, represented by vertical bars.
a,b Mean values within a row with unlike superscript letters were significantly different
(P < 0.05 ANOVA followed by post hoc Tukey’s multiple comparison test).
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FIGURE 3.2 Expression of fatty acid uptake and transport enzymes in the ileum of mice
fed ALA-enriched diets either alone or in combination with Bifidobacterium breve
NCIMB 702258 or B. breve DPC 6330, or an unsupplemented diet, relative to β-actin.
Expression in the unsupplemented diet and ALA-enriched diets supplemented with
either B. breve NCIMB 702258 or B. breve DPC 6330 is relative to the ALA-enriched
diet, which was set to 1. Values are means (n 10) ± SEM, represented by vertical bars.
a,b Mean values within a row with unlike superscript letters were significantly different
(P < 0.05 ANOVA followed by post hoc Tukey’s multiple comparison test).
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Chapter 5
Streptozotocin induced type-1-diabetes disease onset in
Sprague-Dawley rats is associated with an altered
intestinal microbiota composition, coupled with
decreased diversity
217
5.1 ABSTRACT
The aim of this study was to assess the impact of streptozotocin (STZ) induced type-
1-diabetes (T1D) on intestinal microbiota composition and diversity in Sprague-Dawley
rats, compared with healthy controls over time. T1D was induced by injection of a
single dose (60 mg/Kg) of STZ, administered via the intraperitoneal cavity. Total DNA
was isolated from faecal pellets at week 0 (pre- STZ injection), week 1, week 2, week 4
and from caecal content at week 5 from both healthy and T1D groups. High
throughput 16S rRNA sequencing was employed to investigate intestinal microbiota
composition. The data revealed that while intestinal microbiota composition between
the groups was similar at week 0, a dramatic impact of T1D development and
progression on microbiota composition was apparent post- STZ injection and up to 5
weeks. Most notably, T1D onset was associated with a shift in the Bacteroidetes:
Firmicutes ratio (P < 0.05), while at the genus level, increased proportions of lactic acid
producing bacteria such as Lactobacillus and Bifidobacterium were associated with the
later stages of T1D progression (P < 0.05). Coincidently, T1D increased caecal lactate
levels (P < 0.05). Microbial diversity was also reduced following T1D (P < 0.05).
Principle co-ordinate analyses demonstrated temporal clustering in T1D and control
groups over time with separation of the T1D clusters at each time point from healthy
controls. The results provide a comprehensive account of how T1D is associated with
an altered intestinal microbiota composition and reduced microbial diversity over
time.
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5.2 INTRODUCTION
T1D is an organ-specific autoimmune disease involving the selective destruction of
insulin-producing pancreatic β-cells. While the pathophysiology of T1D is not yet
entirely clear, it is the genetic predisposition of an individual combined with
environmental factors which initiate the process of autoimmune destruction of
pancreatic β-cells (Boerner and Sarvetnick, 2011). The human leukocyte antigen (HLA)
complex allows the immune system to distinguish between the body’s own proteins
and foreign proteins; however, certain combinations of various genes belonging to the
HLA complex are associated with a higher genetic risk of developing T1D (Ziegler and
Nepom, 2010). This process, involving both the innate and adaptive immune systems,
remains subclinical, until approximately 80% of the β-cell mass is destroyed (Notkins
and Lernmark, 2001). Over time, β-cell destruction results in insulin deficiency,
worsening hyperglycemia and an eventual call for insulin therapy. As the incidence of
T1D is increasing at a rate far beyond the rate of population growth, additional
emphasis has been placed on the contribution of environmental factors towards
disease onset (Ehehalt et al., 2010; Patterson et al., 2001; Vaarala et al., 2008). Indeed,
the intestinal microbiota is an environmental factor which cannot be overlooked as
contributing towards T1D development.
Many studies have linked alterations in the intestinal microbiota composition with
conditions such as obesity (Ley et al., 2005; Ley et al., 2006; Murphy et al., 2010;
Turnbaugh et al., 2006), inflammatory bowel disease (Greenblum et al., 2012), colitis
(Bellavia et al., 2013; Klimesova et al., 2013) and T1D (Giongo et al., 2011; Murri et al.,
2013; Roesch et al., 2009). For example, risk of T1D onset in childhood is higher in
children delivered by Caesarean section (Cardwell et al., 2008). Previous studies which
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have examined the role of the intestinal microbiota in the development of T1D are
often limited due to the models used (i.e. genetically pre-disposed animals and
humans who develop T1D). While it has been reported that stool from bio-breeding
diabetes-resistant (BBDR) rats contained higher abundances of Lactobacillus and
Bifidobacterium, compared with bio-breeding diabetes-prone (BBDP) rats (Roesch et
al., 2009), others have reported that lactic acid producing species such as Lactobacillus,
Lactococcus and Bifidobacterium were increased in the stool of children who tested
positive for β-cell autoimmunity (Brown et al., 2011; Giongo et al., 2011). In contrast,
de Goffau et al., (2013) observed a low relative abundance of two of the most common
Bifidobacterium species, B. adolescentis and B. pseudocatenulatum associated with β-
cell autoimmunity in children who had tested positive for at least two diabetes-
associated auto-antibodies (de Goffau et al., 2013). Giongo et al., (2011) identified a
reduction in the stability and diversity of the intestinal microbiota present in
autoimmune infants, which worsens with age (Giongo et al., 2011). In addition, a high
ratio of Firmicutes: Bacteriodetes was observed as early as six months post birth in
autoimmune case children, compared with healthy age-matched controls (Giongo et
al., 2011). Murri et al., (2013) highlighted a negative correlation between the numbers
of Bifidobacterium and Lactobacillus with the plasma glucose levels of diabetic
children, while Clostridium correlated positively with glycaemic levels in case children,
compared with healthy controls (Murri et al., 2013). Recently, Brown et al., (2012)
linked T1D with microbial fermentation products and mucin synthesis, important for
maintaining intestinal integrity, often implicated in T1D (Brown et al., 2011).
Administration of the probiotic strain Lactobacillus johnsonii N6.2, previously
isolated from the stool of BBDR rats, to BBDP rats, inhibited the onset of T1D
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(Valladares et al., 2010), while early oral administration of the probiotic compound
VSL#3 to non-obese diabetic (NOD) mice prevented T1D development (Calcinaro et al.,
2005). Antibiotics have also been shown to prevent autoimmune diabetes in BBDP rats
(Brugman et al., 2006), while the intestinal microflora have demonstrated a capacity to
influence the development of T1D (King and Sarvetnick, 2011). Finally, specific
pathogen-free NOD mice lacking MyD88, an adaptor for multiple innate immune
receptors that recognise microbial stimuli, do not develop T1D (Wen et al., 2008) and
this effect is dependent on commensal microbes. The role of the intestinal microbiota
in the development of T1D or indeed modulating the resident intestinal ecosystem as a
therapeutic strategy in T1D has only very recently been investigated and extensively
reviewed (Atkinson and Chervonsky, 2012).
STZ is a glucosamine–nitrosourea compound, originally derived from cultures of
Streptomyces achromogenes and is used clinically as a chemotherapeutic agent in the
treatment of pancreatic β-cell carcinoma. STZ produces rapid pancreatic β-cell
destruction, resulting in hypoinsulinemia and hyperglycemia. The selectivity for β-cells
is associated with preferential accumulation of the chemical in these cells after entry
through glucose transporter 2 (GLUT2), whereby chemical structural similarity with
glucose allows STZ to bind to this receptor. Diabetes was induced in male Sprague-
Dawley rats in this study through a single intraperitoneal injection of STZ. The impact
of T1D disease onset and progression on intestinal microbiota composition and
microbial fermentation products was investigated. DNA was isolated from faecal
pellets at week 0, (pre- STZ injection in one of the groups), then at week 1, week 2 and
week 4 and from caecal content at week 5 from T1D and healthy control rats and
prepared for 16S rRNA pyrosequencing.
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5.3 MATERIALS AND METHODS
5.3.1 ASSESSMENT OF ANTIMICROBIAL ACTIVITY OF STZ
Bioactivity of STZ (Sigma, Wicklow, Ireland) was assessed by well-diffusion assays.
For this purpose, molten agar was cooled to 48°C and seeded with fresh overnight
cultures of various Gram-positive (Bifidobacterium, Lactobacillus and Listeria) and
Gram-negative (Escherichia coli and Cronobacter) strains. The inoculated medium was
dispensed into sterile Petri dishes in 20 mL volumes, allowed to solidify and dried.
Wells (4.6 mm in diameter) were then bored in the seeded agar plates and 50 μL
volumes of various concentrations (7.5, 4, 2 and 1 mg/mL) of freshly prepared STZ in
filter sterilised sodium citrate buffer (50mM; pH 4.5) to be assayed were dispensed
into the wells. Petri dishes were incubated accordingly for each of the strains used.
5.3.2 ANIMALS AND TREATMENT
All animal experiments were approved by the University College Cork (UCC) Animal
Ethics Committee and experimental procedures were conducted under the
appropriate license from the Irish Government. Male Sprague-Dawley rats were
purchased from Harlan Limited (Briester, Oxon, UK) at 5 weeks of age and housed
under barrier-maintained conditions within the Biological Services Unit, UCC. Rats
were allowed to acclimatise for 1 week before the start of the study and were fed ad
libitum with Teklad Global Standard Rodent Diet (Harlan Laboratories, Madison, WI,
USA, #2018S), with free access to water at all times. Rats were housed in groups of 5
per cage and kept in a controlled environment at 25°C under a 12-hr-light/12-hr-dark
cycle. The rats were divided into 2 groups (n 15 rats per group): a non-diabetic healthy
control group and an STZ induced T1D group. After 1 week of acclimatisation, T1D was
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induced in the latter group by injection of a single dose (60mg/Kg) of freshly prepared
STZ (Sigma) administered via the intraperitoneal cavity, according to the method
described by (Wu and Huan, 2008). Glucose levels were measured in triplicate using a
Contour Next glucometer (Bayer, UK) in blood samples collected from a tail vein each
week. Rats with blood glucose higher than 200 mg/dL were considered diabetic and
STZ induced rats with lower glucose levels were excluded from the rest of the study.
Body weight was assessed and fresh faecal pellets were collected weekly. At the end of
the 5 weeks, the rats were killed by decapitation. Caecal content was removed from
individual rats and flash-frozen immediately on dry ice. All samples were stored at -
80°C until processed.
5.3.3 DNA ISOLATION FROM FAECAL PELLETS AND CAECAL CONTENT AND HIGH-
THROUGHPUT AMPLICON SEQUENCING
Total DNA was isolated from fresh individual rat faecal pellets collected at week 0,
pre- STZ induced diabetes in the T1D group, then 1 week, 2 weeks and 4 weeks post-
STZ injection and from the individual caecal content of all rats, 5 weeks following STZ
injection, using the QIAmp DNA Stool Mini Kit (Qiagen, West Sussex, UK). The
extraction was coupled with an initial bead-beating step (30 sec x 3). Isolated DNA was
then stored at -20°C (n 10 per group), until further processing. The microbiota
composition of the samples was established by amplicon sequencing; universal 16S
rRNA primers estimated to bind to 94.6% of all 16S genes (i.e. the forward primer F1
(5’-AYTGGGYDTAAAGNG-3’) and a combination of four reverse primers, R1 (5’-
TACCRGGGTHTCTAATCC-3’), R2 (5’-TACCAGAGTATCTAATTC-3’), R3 (5’-
CTACDSRGGTMTCTAATC-3’) and R4 (5’-TACNVGGGTATCTAATC) (RDP’S Pyrosequencing
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Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp) were employed for PCR
amplification. Molecular identifier tags were attached between the 454 adaptor
sequence and the target-specific primer sequence, allowing for identification of
individual sequences from the pooled amplicons. Ampure purification system
(Beckman Coulter, Takeley, UK) was used to clean the amplicons prior to being
sequenced on a 454 Genome Sequencer FLX platform (Roche Diagnostics Ltd., West
Sussex, UK), in line with 454 protocols at the Teagasc high throughput sequencing
centre.
5.3.4 BIOINFORMATICS SEQUENCE ANALYSIS
Quality trimming of sequence reads was performed using the Qiime suite of tools
(version 1.7) (Caporaso et al., 2010); reads shorter than 200 bp, failing to reach a
quality score of 25 and not exact matches to barcoded tags and primer sequence were
discarded. A locally installed version of SILVA 16S rRNA database (version 106)
(Pruesse et al., 2007) was used to BLAST (Altschul et al., 1997) the trimmed sequence
using default parameters. Resulting BLAST output files were parsed through MEGAN
(Huson et al., 2007); similar to previous studies a bit-score cut-off of 86 was selected
(Rea et al., 2011; Urich et al., 2008). Clustering of sequence reads into operational
taxonomical units (OTUs) at 97% identity and subsequent alignments were achieved
using QIIME suite software tools (Caporaso et al., 2010). ChimeraSlayer was used to
remove chimeric OTUs from aligned OTUs and the FastTreeMP tool generated a
phylogenetic tree (Haas et al., 2011; Price et al., 2010). α and β diversities were
calculated on the sequence reads. Principal co-ordinate analyses were performed on
the samples and viewed within KiNG viewer (Chen et al., 2009).
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5.3.5 SHORT CHAIN FATTY ACID, LACTIC AND FORMIC ACID ANALYSIS OF CAECAL
CONTENT
Short chain fatty acid (SCFA) analysis was performed as previously described (Wall
et al., 2012). Briefly, caecal content was vortex-mixed with Milli-Q water, incubated at
room temperature for 10 min and centrifuged to pellet bacteria and other solids. The
supernatant was filtered, transferred to a clear GC vial and 2-ethylbutyric acid (Sigma)
was added as internal standard. The concentrations of SCFA was measured using a
Varian 3800 GC flame-ionization system, fitted with a ZB-FFAP column (30 m x 0.32
mm x 0.25 um; Phenomenex, Macclesfield, Cheshire, UK). The initial oven temperature
was set at 100oC for 0.5 min, raised to 180oC at 8oC/min and held for 1 min, then
increased to 200oC at 20oC/min, and finally held at 200oC for 5 min. The temperature
of the injector and the detector were set at 240oC and 250oC, respectively. Helium was
used as the carrier gas at a flow rate of 1.3 mL/min. A standard curve was built with
different concentrations of a standard mix containing acetic acid, propionic acid and N-
butyric acid (Sigma). Peaks were integrated by using the Varian Star Chromatography
Workstation version 6.0 software. Formic acid and lactic acid were measured using
formic acid and D/L lactate commercial kits (Megazyme, Wicklow, Ireland).
5.3.6 STATISTICAL ANALYSIS
All results are presented as means ± standard errors of the mean (SEM) (per group).
To assess whether differences between treatment groups were significant, the
unpaired student t-test was used with the use of GraphPad Prism version 5.0 for
Windows (GraphPad Software). Statistical significance was accepted at P < 0.05.
Compositional data were statistically analysed using the nonparametric Mann-Whitney
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and Kruskal-Wallis tests (Kruskal and Wallis, 1952) to estimate the relationships
between different groups using GraphPad Prism version 5.0. Statistical significance was
accepted at P < 0.05.
5.4 RESULTS
5.4.1 ANTIMICROBIAL ACTIVITY OF STZ
Initially, the antimicrobial activity of different concentrations of STZ was tested
against Gram-positive (Bifidobacterium, Lactobacillus and Listeria) and Gram-negative
(Escherichia coli and Cronobacter) strains. At a concentration of 7.5 mg/mL, STZ
produced a clear zone of inhibition of strains Lb. bulgaricus, Lb. plantarum, Lb. gasseri
and B. infantis which decreased at concentrations of 4 mg/mL, 2 mg/mL and 1 mg/mL
(data not shown). At a concentration of 7.5 mg/mL, STZ had a bacteriostatic effect on
B. breve, Lb. acidophilus, E. coli and C. sakazakii which decreased at concentrations of
4 mg/mL, 2 mg/mL and 1 mg/mL (data not shown). No zone of inhibition was observed
for any concentration of STZ on B. bifidus and L. monocytogenes (data not shown).
5.4.2 INDUCTION OF T1D BY STZ INJECTION IN RATS
One week after STZ injection, rats were severely diabetic as indicated by elevated
blood glucose levels (572.6 ± 10.3 mg/dL), compared with the normoglycemic range
observed in healthy controls (104.2 ± 2.1 mg/dL) (P < 0.05; Figure 5.1(B)). The chronic
increase in blood glucose levels were maintained throughout the study period (Figure
5.1(B)). Diabetic rats exhibited polyuria, polydipsia, hyperphagia and excessive faecal
output (data not shown). Diabetic rats displayed significant decreases in percentage
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body weight gain from week 3 onwards (following STZ injection), compared with
healthy controls (P < 0.05; Figure 5.1(A)).
5.4.3 STZ INDUCED T1D DECREASES α DIVERSITY OF THE RAT INTESTINAL
MICROBIOTA OVER TIME
A total of 777,796 reads were sequenced, corresponding to a total of 388,898 reads
per group and an average of 7,857 reads per rat. At the 97% similarity level, a total of
five metrics were used to estimate α diversity; Shannon, Simpson, Chao1
(Supplementary Figures 5.1-5.3), phylogenetic diversity and observed species (Figures
5.2-5.4). At week 0, pre- STZ injection and T1D induction in one of the groups, no
differences were observed across any of the five metrics calculated between the
groups (Supplementary Figures 5.1-5.3 and Figures 5.2-5.3). This indicated that pre-
STZ injection in the T1D group, all rats had similar levels of diversity. However, 1, 2, 4
and 5 weeks post- STZ injection in the T1D group, Chao1, phylogenetic diversity and
observed species were all significantly reduced in the T1D group, compared with
healthy controls (P < 0.05; Figures 5.2-5.4 and Supplementary Figure 5.1). While
Shannon diversity data revealed no change to the biodiversity of the microbiota within
the healthy controls and the T1D group at week 2, significant reductions to the
diversity profile were found between the T1D group and the healthy controls at all
other time points taken (P < 0.05; Supplementary Figures 5.2(A) and 5.2(B)). Similarly,
the Simpson diversity index-based analysis, which also takes into account the number
of species present and the relative abundance of each species, highlighted a significant
reduction in diversity in animals induced with T1D at 1, 4 and 5 weeks following STZ
injection, compared with healthy controls (P < 0.05; Supplementary Figures 5.3(A) and
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5.3(B). Rarefaction curves were seen to be parallel (Supplementary Figure 5.4)
indicating that additional sampling would yield a limited increase in species richness.
5.4.4 TAXONOMICAL ANALYSIS HIGHLIGHTS THE EFFECT OF STZ INDUCED T1D ON
INTESTINAL MICROBIAL COMPOSITION OVER TIME
Taxonomy based analysis of the assigned sequences highlighted few differences in
the intestinal microbiota populations between the groups at week 0, pre- STZ
injection. While no significant differences were observed at the phylum level at week 0
(Figure 5.5(A)), significantly lower proportions of Clostridiaceae (P < 0.05; Figure
5.6(A)) and Clostridium (P < 0.05; Figure 5.7(A)) were found at the family and genus
levels, respectively while the proportions of Parabacteroides were significantly
increased in the group yet to be induced with T1D, compared with the control group (P
< 0.05; Figure 5.7(A)).
Analysis of the microbial profile of the intestine at week 1 (post- STZ injection in one
of the groups) revealed a greater number of statistically significant differences
between the groups at the phylum, family and genus levels. While the relative
abundance of the Tenericute population was significantly increased in the T1D group
(P < 0.05; Figure 5.5(A)), the proportions of Actinobacteria and Deferribacteres were
significantly reduced (P < 0.05; Figure 5.5(A)), compared with healthy controls. Most
notably, just 1 week after STZ injection, the proportions of Bacteroidetes were
significantly increased (P < 0.05; Figure 5.5(A)) in the T1D group, while the Firmicutes
population was significantly reduced (P < 0.05; Figure 5.5(A)), compared with healthy
controls. At the family level, the proportions of S24-7, Prevotellaceae,
Erysipelotrichaceae, Porphyromonadaceae and Anaeroplasmataceae were significantly
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increased in the T1D group (P < 0.05; Figure 5.6(A)), while Bifidobacteriaceae and
Peptococcaceae were significantly reduced, compared with healthy controls (P < 0.05;
Figure 5.6(A)). At the genus level, both the proportions of Parabacteroides and
Mucispirillium were significantly increased (P < 0.05; Figure 5.7(A)) while the
proportions of Ruminococcus were significantly reduced (P < 0.05; Figure 5.7(A)) in the
T1D group, compared with healthy controls.
While the significant changes in the proportions of certain intestinal microbiota
populations at week 2 remained the same as they were at week 1, many more
significant changes to the intestinal microbiota, at the family and genus levels were
observed 2 weeks post- STZ induced T1D, compared with healthy controls. At the
phylum level, the proportions of Firmicutes remained significantly reduced (P < 0.05;
Figure 5.5(A)), while the proportions of Deferribacteres became significantly increased,
(P < 0.05; Figure 5.5(A)) in the T1D group, compared with healthy controls. Similar to
week 1, the proportions of Prevotellaceae and Erysipelotrichaceae remained
significantly higher while Peptococcaceae remained significantly lower in the T1D
group, compared with healthy controls at week 2 (P < 0.05; Figure 5.6(A)), while the
proportions of Porphyromonadaceae shifted from being significantly higher at week 1
to significantly lower in the T1D group at week 2 (P < 0.05; Figure 5.6(A)). Progression
of T1D increased the proportions of Lactobacillaceae, Peptostreptococcaceae and
Clostridiaceae (P < 0.05; Figure 5.6(A)), while reducing the proportions of RF-9 group (P
< 0.05; Figure 5.6(A)), after 2 weeks in the T1D group, compared with healthy controls.
At the genus level, the proportions of Ruminococcus and Mucispirillium remained
significantly lower (P < 0.05; Figure 5.7(A)) and higher (P < 0.05; Figure 5.7(A)),
respectively, in the T1D group, as they had at week 1, compared with healthy controls.
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Significant increases in the proportions of Bacteroides, Lactobacillus, Turicibacter and
Clostridium were also observed 2 weeks after STZ induced diabetes in the T1D group (P
< 0.05; Figure 5.7(A)), compared with healthy controls. The proportions of
Parabacteroides, previously observed as significantly higher in the T1D group, 1 week
following STZ injection, were significantly lower 2 weeks after STZ induced T1D,
compared with healthy controls (P < 0.05; Figure 5.7(A)). The proportions of
Ruminococcaceae Incertae Sedis, one of the most dominant populations at the genus
level, was significantly reduced at week 2 in the T1D group, compared with healthy
controls (P < 0.05; Figure 5.7(A)).
Four weeks after STZ injection in the T1D group, the proportions of Tenericutes
were significantly higher in the T1D group (P < 0.05; Figure 5.5(A)), as they had been at
week 1, compared with healthy controls. The proportions of Actinobacteria and
Proteobacteria (P < 0.05; Figure 5.5(A)) were significantly higher, compared with
healthy controls. Similar to week 1 and 2, the proportions of Firmicutes remained
significantly lower in the T1D group, compared with healthy controls (P < 0.05; Figure
5.5(A)). At the family level, the proportions of Prevotellaceae recovered in the healthy
controls, while Lactobacillaceae and Clostridiaceae remained significantly higher (P <
0.05; Figure 5.6(A)), and Peptococcaceae and RF9 group remained significantly lower in
the T1D group, compared with healthy controls (P < 0.05; Figure 5.6(A)), as they had
been at week 2. At week 4, the abundance of Porphyromonadaceae was significantly
higher in the T1D group, compared with healthy controls (P < 0.05; Figure 5.6(A)).
Bacteroidaceae, Bifidobacteriaceae and Alcaligenaceae proportions were significantly
higher (P < 0.05; Figure 5.6(A)), while Ruminococcaceae and Lachnospiraceae
proportions were significantly lower (P < 0.05; Figure 5.6(A)), 4 weeks after T1D
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induction, compared with healthy controls. Correlating with the changes seen at the
family level, the abundances of Parasuterella, Bifidobacterium, Lactobacillus and
Clostridium were all significantly higher (P < 0.05; Figure 5.7(A)), while the proportions
of Alistipes, Ruminococcus and Ruminococcaceae Incertae Sedis were all significantly
lower (P < 0.05; Figure 5.7(A)) in the T1D group, at week 4, compared with healthy
controls.
Data highlighting the intestinal microbiota changes at week 5 following T1D
induction, compared with healthy controls correspond to microbiota populations from
the caecal content of the rats after they had been killed. Thus, week 5 data is graphed
separately from the other time points as variations between the microbiota of faecal
and caecal content may skew results. The proportions of Actinobacteria and
Proteobacteria remained significantly higher, compared with healthy controls (P <
0.05; Figure 5.5(B)). The Bacteroidetes: Firmicutes ratio appeared to equilibrate as no
significant differences were seen between the groups in either of these phyla from
caecal content (Figure 5.5(B)), similarly, the proportion of Tenericutes were no longer
significant between the groups (Figure 5.5(B)). The abundance of Deferribacteres were
significantly decreased (P < 0.05; Figure 5.5(B)), as they had been at week 1, in the T1D
group, compared with healthy controls. Again, similar to week 4, the proportions of
Bacteroidaceae, Bifidobacteriaceae and Alcaligenaceae were significantly increased (P
< 0.05; Figure 5.6(B)), while Ruminococcaceae and Peptococcaceae were significantly
decreased (P < 0.05; Figure 5.6(B)) in the T1D group, compared with healthy controls.
The proportions of Rikenellaceae and Peptostreptococcaceae were also significantly
reduced (P < 0.05; Figure 5.6(B)) in the T1D group, compared with healthy controls,
while Erysipelotrichaceae was significantly increased (P < 0.05; Figure 5.6(B)), as in
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week 2, in the T1D group, compared with healthy controls. At the genus level,
Parasuterella and Bifidobacterium were found at significantly higher proportions (P <
0.05; Figure 5.7(B)), while the proportions of Alistipes, Ruminococcus and
Ruminococcaceae Incertae Sedis were all significantly reduced (P < 0.05; Figure 5.7(B))
in the T1D group, compared with healthy controls. The proportions of Bacteroides
were significantly higher while the abundance of Phascolarctobacterium, not
previously highlighted at any other week to be significantly different was also higher
and Peptostreptococcaceae Incertae Sedis and Mucispirillium abundances were both
significantly lower in the T1D group, compared with healthy controls (P < 0.05; Figure
5.7(B)). The abundance of Mucispirillium was previously shown as significantly higher
both 1 (P < 0.05; Figure 5.7(A)) and 2 weeks (P < 0.05; Figure 5.7(A)) following STZ
induced diabetes in the T1D group, compared with healthy controls.
Throughout the study, from week 0 to week 5, the relative populations of the
intestinal microbiota at phylum, family and genus levels fluctuated only slightly within
the healthy control group (Supplementary Figures 5.5-5.7). In contrast, the proportions
of the intestinal microbiota at all levels in the group induced with T1D fluctuated
significantly at all weeks following T1D induction (Supplementary Figures 5.8-5.10).
5.4.5 β DIVERSITY HIGHLIGHTS AN STZ INDUCED T1D EFFECT ON MICROBIAL
POPULATION VARIATION OVER TIME AS DISEASE PROGRESSES
Principal co-ordinate analyses, based on unweighted Unifrac distances of the 16S
rRNA sequences, illustrated changes to the microbial populations following STZ
induced T1D, compared with healthy controls. Figure 5.8(A) shows data points
corresponding to healthy controls (red for weeks 0, 1, 2 and 4 and orange for week 5)
232
cluster closely together, irrelevant of time point, between week 0, 1, 2, 4 and 5
(different shades of red for weeks 0, 1, 2 and 4 and orange for week 5; Figure 5.8(B)).
Similarly, Figure 5.8(A) also shows data points corresponding to T1D rats (blue for
weeks 0, 1, 2 and 4 and green for week 5) initially cluster close together with healthy
controls (red) at week 0, since T1D had not been induced at this time point. However,
subsequent data points corresponding to the T1D rats (different shades of blue for
weeks 0, 1, 2 and 4 and green for week 5), as the trial progressed from week 1 to week
5 following T1D induction became increasingly distant from the healthy control data
points (red). Individual data points within particular time points for the T1D group
(blue and green) become much more dispersed and fail to form distinct clusters with
each other (Figure 5.8(B)). These results are in line with the α diversity and
taxonomical data presented since data points corresponding to T1D rats cluster away
from those corresponding to healthy controls in all time points from week 1 onwards
(post- STZ injection).
5.4.6 STZ INDUCED T1D ALTERED THE PRODUCTION OF SCFA AND LACTIC ACID
T1D was associated with a significant decrease in caecal propionate (P < 0.05) and
butyrate (P < 0.05) and a significant increase in caecal acetate (P < 0.05) and lactate
levels (P < 0.05), compared with healthy controls (Figure 5.9). No differences in
formate were exhibited between the groups (Figure 5.9).
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5.5 DISCUSSION
This study provides a comprehensive account of the impact of STZ induced T1D on
the intestinal microbiota compositon, diversity and microbial fermentation metabolite
production over time. The antimicrobial effect of STZ has previously been described
(Vavra et al., 1959), however, very little is understood of the antimicrobial impact a
single intraperitoneal injection of STZ could have on intestinal microbiota composition.
A circulating half-life of only 15 minutes has been reported in man, following
intravenous infusion (Schein et al., 1973) or 30-40 minutes following intravenous bolus
injection (Adolphe et al., 1975). In addition, approximately 70% of 14C-labelled STZ
administered intravenously to rats in single doses of 70 mg/Kg was recovered in the
urine over the first 6 hours, thus indicating rapid excretion (Karunanayake et al., 1976).
It is therefore unlikely that the changes to microbiota composition found in this study
were caused by the antimicrobial activity of STZ and were most likely a result of T1D
onset and progression.
The data revealed that STZ induced T1D altered the Bacteroidetes: Firmicutes ratio,
increasing the abundance of Bacteroidetes and depleting the Firmicutes population
following disease onset, as previously demonstrated in various T1D models (de Goffau
et al., 2013; Giongo et al., 2011; Murri et al., 2013). Initially, pre- T1D induction, no
difference in the Bacteroidetes: Firmicutes ratio was observed between the groups. In
contrast, the intestinal relative proportions of Actinobacteria and Proteobacteria were
significantly increased at week 4 and 5 following T1D induction, compared with healthy
controls. Overall bacterial diversity was also significantly reduced in the T1D group,
compared with healthy controls, creating an opportunity for the members of the phyla
Actinobacteria and Proteobacteria to thrive. The data correlate with previous
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observations (Giongo et al., 2011), that T1D was associated with decreased
abundances of Ruminococcaceae and Lachnospiraceae and increased abundances of
Bacteroidaceae, compared with healthy controls at the later stages of diabetes
development. However, in contrast to this study which found Porphyromonadaceae
significantly more abundant in healthy control children, the data generated in this
study reveal that the proportions of Porphyromonadaceae were higher in T1D rats, 1
and 4 weeks after T1D induction and lower at week 2, compared with healthy controls.
This data highlights the impact of STZ induced T1D onset on intestinal microbiota
composition and furthermore, the time-dependent changes to intestinal microbiota
composition in response to T1D progression in an altered intestinal environment. The
proportions of Bifidobacteriaceae, Lactobacillaceae and Clostridiaceae were all
increased in T1D rats at the later stages of T1D progression, compared with healthy
controls.
The intestinal surface barrier is one of the most important components of the
innate immune system (Vaarala et al., 2008) and several studies report that T1D
compromises intestinal integrity (Carratu et al., 1999; Kuitunen et al., 2002; Sapone et
al., 2006). Abnormalities of the intestinal barrier; the so called “leaky gut”, exposes the
intestinal immune system to antigens in the setting of T1D (Vaarala et al., 2008).
Brown et al., (2011) in a follow up study to Giongo et al., (2011) revealed knock-on
effects of an impaired intestinal microbiota composition in children pre-diagnosed
with autoimmune diabetes on microbial fermentation metabolite production (Brown
et al., 2011). Butyrate producers such as Eubacterium, Fusobacterium, Anaerostipes
and Roseburia were higher in the faeces of control, healthy children and lactic acid
producers such as Lactobacillus, Lactococcus, Bifidobacterium and Streptococcus were
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higher in the faeces of children pre-diagnosed with autoimmune diabetes (Brown et
al., 2011). The fate of lactate is crucial in determining intestinal health as conversion to
butyrate results in mucin synthesis and tighter junctions, while conversion to other
SCFA, such as propionate, acetate and succinate reduces mucin synthesis and tight
junction assembly (Brown et al., 2011). Mucin is a glycoprotein made by the host that
is believed to maintain the integrity of intestine epithelium (Brown et al., 2011).
Interestingly, the data in this study revealed increases in the abundances of lactic acid
producing bacteria such as Bifidobacterium and Lactobacillus in T1D rats, as were the
concentrations of lactate and acetate, while butyrate was decreased in the caecum of
T1D rats, compared with healthy controls. Butyrate contributes to colonic health due
to its anti-inflammatory properties (Hamer et al., 2008; Louis and Flint, 2009; Pryde et
al., 2002). In addition, butyrate induces mucin synthesis (Barcelo et al., 2000; Burger-
van Paassen et al., 2009; Finnie et al., 1995; Shimotoyodome et al., 2000), decreases
bacterial transport across metabolically stressed epithelia (Lewis et al., 2010) and
improves the intestinal barrier by increasing tight junction assembly (Peng et al., 2007;
Peng et al., 2009). The mucin synthesis induced by butyrate is believed to maintain the
integrity of the intestinal epithelia (Brown et al., 2011), thus preventing the
development of the so-called “leaky gut” associated with T1D. Acetate, on the other
hand does not induce mucin synthesis, and so renders the intestinal epithelia of the
T1D animals more susceptible to developing “leaky gut” based on the production of
SCFA by the intestinal microbiota of T1D rats. Furthermore, the proportions of
Bacteroides were higher 2 and 5 weeks after T1D onset, compared with healthy
controls. Bacteroides have recently been implicated in both diabetic animal and human
studies (Brown et al., 2011; Brugman et al., 2006; de Goffau et al., 2013; Giongo et al.,
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2011; Roesch et al., 2009). Such studies have highlighted an association between
Bacteroides and enhanced intestinal bacterial translocation, resulting in β-cell
autoimmunity, associated with T1D (de Goffau et al., 2013). Bifidobacteria have
previously been associated with an inhibition of bacterial translocation (Duffy, 2000;
Romond et al., 2008; Wang et al., 2004) and it has recently been hypothesised (de
Goffau et al., 2013) that bifidobacteria may inhibit the translocation and growth of
Bacteroides as they compete for space and/or adherence (Stecher and Hardt, 2008)
and nutrients (Gibson et al., 1996). Furthermore, bifidobacteria enhance the intestinal
epithelial barrier function (Lievin et al., 2000) by increasing the thickness of the
mucous layer (Kleessen and Blaut, 2005; Kleessen et al., 2003). The data generated in
this study demonstrate increased proportions of Bifidobacterium in the T1D group at
the later stages of diabetes progression which may have a protective role for the host
by enhancing intestinal epithelial barrier function to prevent “leaky-gut”.
Recent advances in sequencing technology have highlighted that a diverse intestinal
microbiota is positively associated with human health and that a decrease in the
number and abundance distribution of distinct intestinal microbes has been linked to
intestinal diseases (Manichanh et al., 2006; Sartor, 2008; Turnbaugh et al., 2009) and
in particular, T1D (Brown et al., 2011; de Goffau et al., 2013; Giongo et al., 2011; Knip
et al., 2011). Recently, the importance of a diverse microbiota to the health status of
the host has been demonstrated in an elderly population whereby community dwelling
elderly populations, with a more diverse diet had a greater microbial diversity,
compared with elderly in long-stay care (Claesson et al., 2012). The data herein found
that intestinal microbiota composition diversity was significantly decreased just 1 week
post-STZ induced T1D and did not recover for the duration of the trial following
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disease onset. In addition, the principal co-ordinate analyses plots further
demonstrated a temporal decrease in diversity. As disease progressed over the 5
weeks, the individual microbiota populations of T1D rats became less diverse,
compared with healthy controls and failed to cluster together distinctly, suggesting
vast alterations in the intestinal microbiota composition between T1D rats.
This study highlighted temporal variations in the intestinal microbiota of T1D rats
over time coinciding with disease progression. The data describes a comprehensive
account of the impact T1D onset and progression had on intestinal microbiota diversity
and composition. The proportions of lactic acid producing bacteria such as
Lactobacillus and Bifidobacterium, particularly within the later stages of T1D
progression correlated with increased caecal lactate concentrations. The intestinal
microbiota composition further impacted on microbial fermentation metabolites
produced and T1D was associated with increased acetate and total SCFA
concentrations in the caecum. Butyrate, associated with mucin synthesis, involved in
maintaining intestinal integrity was reduced in T1D rats, compared with healthy
controls. Furthermore, the intestinal proportions of bifidobacteria were increased in
T1D rats which could have a protective role in the diabetic host. Importantly, this study
highlights the importance of a diverse microbiota for health as T1D temporally reduced
diversity over the five time points taken. The changes observed in the intestinal
microbiota of T1D rats resulted from disease development only and did not have any
causative role in the onset of diabetes. Although this study did not provide any data on
functional changes related to the observed bacterial diversity, the results provide a
comprehensive account of the effect of T1D onset and progression on the intestinal
microbiota composition, diversity and microbial metabolite production in the host.
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FIGURE 5.1(A) Percentage body weight gain over the 8 week trial. At week 3, T1D was
induced in one of the groups by injection of a single dose of STZ, administered via the
intra-abdominal cavity (B) Blood glucose levels (mg/dL) of healthy control and T1D
rats.
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FIGURE 5.2 Phylogenetic diversity metric of α diversity between healthy control and
T1D rats at weeks 0, 1, 2 and 4. T1D was induced in the T1D group at week 1. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. ** P < 0.01, ***P < 0.001.
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FIGURE 5.3 Observed species measurement of α diversity between healthy control and
T1D rats at weeks 0, 1, 2 and 4. T1D was induced in the T1D group at week 1. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. ** P < 0.01, ***P < 0.001.
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FIGURE 5.4 Phylogenetic diversity and observed species measurements of α diversity
between healthy control and T1D rats from caecal content at week 5. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. ** P < 0.01.
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FIGURE 5.5(A) Phylum level distributions of the microbial communities which were
either significantly increased or decreased in DNA extracted from the faecal content of
T1D rats, compared with healthy controls between weeks 1, 2 and 4. No significant
differences were observed at the phylum level at week 0 between the groups. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05.
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FIGURE 5.5(B) Phylum level distributions of the microbial communities which were
either significantly increased or decreased in DNA extracted from the caecal content of
T1D rats, compared with healthy controls at week 5. The nonparametric Mann-
Whitney test was used to estimate the relationship between the groups. Statistical
significance was accepted at P < 0.05.
252
FIGURE 5.6(A) Family level distributions of the microbial communities which were
either significantly increased or decreased in DNA extracted from the faecal content of
T1D rats, compared with healthy controls between weeks 0, 1, 2 and 4. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05.
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FIGURE 5.6(B) Family level distributions of the microbial communities which were
either significantly increased or decreased in DNA extracted from the caecal content of
T1D rats, compared with healthy controls at week 5. The nonparametric Mann-
Whitney test was used to estimate the relationship between the groups. Statistical
significance was accepted at P < 0.05.
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FIGURE 5.7(A) Genus level distributions of the microbial communities which were
either significantly increased or decreased in DNA extracted from the faecal content of
T1D rats, compared with healthy controls between weeks 0, 1, 2 and 4. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05.
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FIGURE 5.7(B) Genus level distributions of the microbial communities which were
either significantly increased or decreased in DNA extracted from the caecal content of
T1D rats, compared with healthy controls at week 5. The nonparametric Mann-
Whitney test was used to estimate the relations between the groups. Statistical
significance was accepted at P < 0.05.
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FIGURE 5.8(A) Principal co-ordinate analysis based on unweighted UniFrac distances in
T1D and healthy control rats over the 5 time points measured (week 0 to week 5).
DNA extracted from the faecal pellets of healthy control rats at weeks 0, 1, 2 and 4.
DNA extracted from the caecal content of healthy control rats at week 5. DNA
extracted from the faecal pellets of T1D rats at weeks 0, 1, 2 and 4. DNA extracted
from the caecal content of T1D rats at week 5.
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FIGURE 5.8(B) Principal co-ordinate analysis based on unweighted UniFrac distances in
T1D and healthy control rats over the 5 time points measured (week 0 to week 5). Data
point’s coloured different shades of red correspond to DNA extracted from the faecal
pellets of healthy control rats at weeks 0, 1, 2 and 4. Orange data points correspond to
DNA extracted from the caecal content of healthy control rats at week 5. Data point’s
coloured different shades of blue correspond to DNA extracted from the faecal pellets
of T1D rats at weeks 0, 1, 2 and 4. Green data points refer to DNA extracted from the
caecal content of T1D rats at week 5. The blue data points which cluster together with
the data points coloured different shades of red for the healthy control group,
corresponds to DNA extracted from the T1D group before STZ injection.
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FIGURE 5.9 Caecal content SCFA, lactate and formate concentrations (umol/g) in T1D
and healthy control rats. The unpaired student t-test was used to compare the levels
of caecal acetate, propionate, butyrate, lactate and formate between the groups.
Values are means ± SEM, represented by vertical bars. Statistical significance was
accepted at P < 0.05. *P < 0.05, ** P < 0.01, ***P < 0.001.
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SUPPLEMENTARY FIGURE 5.1(A) Chao1 richness estimation of α diversity between
healthy control and T1D rats at weeks 0, 1, 2 and 4. T1D was induced in the T1D group
at week 1. The nonparametric Mann-Whitney test was used to estimate the
relationship between the groups. Statistical significance was accepted at P < 0.05. ** P
< 0.01, ***P < 0.001.
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SUPPLEMENTARY FIGURE 5.1(B) Chao1 richness estimation of α diversity between
healthy control and T1D rats at week 5. T1D was induced in the T1D group at week 1.
The nonparametric Mann-Whitney test was used to estimate the relationship between
the groups. Statistical significance was accepted at P < 0.05. ** P < 0.01.
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SUPPLEMENTARY FIGURE 5.2(A) Shannon index of α diversity between healthy control
and T1D rats at weeks 0, 1, 2 and 4. T1D was induced in the T1D group at week 1. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. ***P < 0.001.
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SUPPLEMENTARY FIGURE 5.2(B) Shannon index of α diversity between healthy control
and T1D rats at week 5. T1D was induced in the T1D group at week 1. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. *** P < 0.001.
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SUPPLEMENTARY FIGURE 5.3(A) Simpson index of α diversity between healthy control
and T1D rats at weeks 0, 1, 2 and 4. T1D was induced in the T1D group at week 1. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. ***P < 0.001.
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SUPPLEMENTARY FIGURE 5.3(B) Simpson index of α diversity between healthy control
and T1D rats at week 5. T1D was induced in the T1D group at week 1. The
nonparametric Mann-Whitney test was used to estimate the relationship between the
groups. Statistical significance was accepted at P < 0.05. *** P < 0.001.
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SUPPLEMENTARY FIGURE 5.4 Rarefraction curves seen to be parallel, signifying that
additional sequencing would yield a limited increase in species richness.
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SUPPLEMENTARY FIGURE 5.5 Phylum level distributions of the microbial communities
between weeks 0 and week 5 for the healthy control group. The nonparametric
Kruskal-Wallis test was used to estimate the relations between the healthy control
group over the 5 time points taken. Statistical significance was accepted at P < 0.05. *
P < 0.05, ***P < 0.001.
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SUPPLEMENTARY FIGURE 5.6 Family level distributions of the microbial communities
between weeks 0 and week 5 for the healthy control group. The nonparametric
Kruskal-Wallis test was used to estimate the relations between the healthy control
group over the 5 time points taken. Statistical significance was accepted at P < 0.05. *
P < 0.05, ***P < 0.001
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SUPPLEMENTARY FIGURE 5.7 Genus level distributions of the microbial communities
between weeks 0 and week 5 for the healthy control group. The nonparametric
Kruskal-Wallis test was used to estimate the relations between the healthy control
group over the 5 time points taken. Statistical significance was accepted at P < 0.05. *
P < 0.05, **P < 0.05, ***P < 0.001.
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SUPPLEMENTARY FIGURE 5.8 Phylum level distributions of the microbial communities
between weeks 0 and week 5 for the T1D group. The nonparametric Kruskal-Wallis test
was used to estimate the relations between the healthy control group over the 5 time
points taken. Statistical significance was accepted at P < 0.05. * P < 0.05, **P < 0.05,
***P < 0.001
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SUPPLEMENTARY FIGURE 5.9 Family level distributions of the microbial communities
between weeks 0 and week 5 for the T1D group. The nonparametric Kruskal-Wallis test
was used to estimate the relations between the healthy control group over the 5 time
points taken. Statistical significance was accepted at P < 0.05. * P < 0.05, **P < 0.05,
***P < 0.001
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SUPPLEMENTARY FIGURE 5.10 Genus level distributions of the microbial communities
between weeks 0 and week 5 for the T1D group. The nonparametric Kruskal-Wallis test
was used to estimate the relations between the healthy control group over the 5 time
points taken. Statistical significance was accepted at P < 0.05. * P < 0.05, **P < 0.05,
***P < 0.001
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Chapter 7
General Discussion
310
High-throughput sequencing technologies have demonstrated that approximately
100 trillion microorganisms reside within the adult intestine (Qin et al., 2010). Over
90% of the bacterial species residing in the intestine belong to the phyla Firmicutes
and Bacteroidetes (Sommer and Backhed, 2013). A plethora of evidence indicates links
between perturbations of the intestinal microbiota with inflammatory and metabolic
disorders, such as obesity (Ley et al., 2006; Zhang et al., 2009), malnutrition (Kau et al.,
2011) and diabetes (de Goffau et al., 2013; Qin et al., 2012).
Diet impacts on the composition (De Filippo et al., 2010; de Wit et al., 2012;
Devkota et al., 2012; Huang et al., 2013; Mujico et al., 2013) and balance of metabolic
products produced by the intestinal microbiota (Scott et al., 2008). Alterations in the
Firmicutes: Bacteroidetes ratio has been implicated in obesity whereby an “obese”
microbiota exhibits an increased capacity to extract energy from the diet (Murphy et
al., 2010), which impacts on weight gain. Previously, different dietary fat types have
been associated with altering the intestinal microbiota and metabolic activity of the
host (Devkota et al., 2012; Mujico et al., 2013). In Chapter 2, the impact of dietary fat
quantity and quality on metabolic health status and intestinal microbiota composition
was assessed in mice. The data presented highlight the effects of dietary fat quality on
metabolic health and intestinal microbiota composition. For example, dietary palm oil
(saturated fat (SFA)) had a negative impact on metabolic health by increasing hepatic
triglyceride content, body weight gain and percentage body fat mass and was
associated with a decreased relative abundance of Bacteroidetes (P < 0.05) and an
increased Firmicutes: Bacteroidetes ratio, previously associated with obesity (Murphy
et al., 2010). Dietary flaxseed/fish oil (n-3 polyunsaturated fatty acids (PUFA)) led to
increased tissue concentrations of the beneficial long-chain n-3 PUFA,
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eicosapentaenoic acid (EPA) (P < 0.05), docosapentaenoic acid (P < 0.05) and
docosahexaenoic acid (DHA) (P < 0.05) and was associated with an increased intestinal
abundance of Bifidobacterium (P < 0.05). Overall, the data indicated that as the degree
of saturation of dietary fat decreased from SFA to n-3 PUFA, liver triglycerides (P <
0.05) and intestinal abundances of Lachnospiraceae decreased (51% following SFA
feeding to 26% following n-3 PUFA feeding), while proportions of Erysipelotrichaceae
increased (17% following SFA feeding to 42% following n-3 PUFA feeding). Potential
mechanisms involved in such effects of dietary fat quality on intestinal microbiota
composition may include dietary fat promoted changes in hepatic bile acid
composition, altering conditions for intestinal microbial assemblage (Devkota et al.,
2012) or through SFA triggered extension of fat absorption, impacting on lipid-
metabolism gene expression in the distal parts of the small intestine (de Wit et al.,
2012).
Intestinal microbiota derived PUFA metabolites such as conjugated linoleic acid
(CLA), have been shown to exert health benefits based on in vitro and in vivo studies. It
has previously been shown that dietary supplementation with linoleic acid in
combination with CLA-producing Bifidobacterium breve NCIMB 702258 led to
enhanced liver CLA status, in addition to higher concentrations of EPA and DHA in
adipose tissue of mice and pigs (Wall et al., 2009). Furthermore, dietary
supplementation with B. breve NCIMB 702258 resulted in higher EPA concentrations in
the liver (Wall et al., 2010) and higher DHA concentrations in the brain of mice (Wall et
al., 2012; Wall et al., 2010). The mechanism by which B. breve NCIMB 702258 altered
tissue fatty acid profiles is unclear and may either involve its ability to modulate fat-
absorption in the small intestine and/or affect host lipid metabolism including hepatic
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desaturase and elongase enzyme activity involved in n-3 PUFA metabolism. In Chapter
3, the impact of dietary supplementation with B. breve NCIMB 702258 and B. breve
DPC 6330 on mRNA gene expression levels of fatty acid transport and uptake enzymes
in the distal small intestine and liver and hepatic desaturase/elongase enzymes were
investigated. The data indicated that B. breve NCIMB 702258 and B. breve DPC 6330
reduced hepatic triglyceride levels (P < 0.05) and this was associated with reduced
hepatic CD-36 and fatty acid binding protein (FABP)-1 mRNA gene expression, involved
in the uptake of fatty acids to the liver (Garcia-Monzon et al., 2011), compared with
unsupplemented controls. In addition, B. breve DPC 6330 exerted a strain-specific
effect on the mRNA gene expression levels of enzymes involved in fatty acid uptake to
the ileum (P < 0.05). The role of the upper and lower intestine in the absorption of gut
microbiota derived PUFA metabolites has recently been demonstrated (Druart et al.,
2014). Dietary supplementation with ALA increased liver, adipose tissue and brain
concentrations of n-3 PUFA, ALA, EPA and docosapentaenoic acid (P < 0.05), compared
with unsupplemented controls and this was associated with an increase in mRNA gene
expression of Δ-6 desaturase (P < 0.05), regardless of microbial supplementation, for
both B. breve strains used in this study. The data therefore indicate that the
mechanisms by which B. breve impacts on tissue fat content and fatty acid
composition include effects on fatty acid uptake enzymes in the intestine and liver.
Future studies using a microarray may yield more detailed information on how B.
breve supplementation may function in the proximal and distal gut.
Certain commensal bacteria possess the ability to produce exopolysaccharides (EPS)
such as beta-glucan with known immuno-stimulatory, antitumoral and
anticarcinogenic activity. It has been shown that dietary beta-glucan may modulate
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satiety in the host and thus control appetite (Huang et al., 2011). The effect of
microbial beta-glucan production on health status was assessed in Chapter 4 using
recombinant Lactobacillus paracasei NFBC 338, genetically engineered to
heterologously express the glycotransferase (gtf) gene responsible for microbial beta
glucan production and compared with an isogenic control Lb. paracasei NFBC 338
strain (Stack et al., 2010). Specially equipped TSE Phenomaster cages measured the
impact of feeding a beta-glucan producing probiotic on feeding patterns and energy
metabolism in mice. The data indicated that an altered feeding pattern was obtained
due to microbial beta-glucan production (P < 0.05), with mice consuming smaller meal
sizes (P < 0.05) more frequently (P < 0.05) during the experiment, but overall dietary
intake remained unchanged. Moreover, the group supplemented with beta-glucan
producing Lb. paracasei NFBC 338 maintained a stable oxygen consumption (VO2) and
heat production during a 24hr food deprivation period, compared with
unsupplemented controls (P < 0.05). The altered feeding pattern associated with
ingesting the probiotic beta-glucan producer may be associated with increased
viscosity and thus, increased colonic bulking capacity in this group, compared with
isogenic controls, although this remains to be clarified. Overall, the study
demonstrated that feeding a beta-glucan producing probiotic alters feeding patterns
leading to ingestion of smaller meal portions and thus, may have future applications as
dietary adjuncts, particularly for weight loss/management. The genetically engineered
beta-glucan producing Lb. paracasei NFBC 338 used in this study is considered a
genetically modified organism (GMO) and not Generally Recognised As Safe (GRAS).
Future studies to screen for natural beta-glucan producing strains for use as probiotics
may lead to new nutritional supplements for weight management.
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Perturbations of the intestinal microbiota have been linked with diabetes (de
Goffau et al., 2013; Qin et al., 2012). The relationship between type-2-diabetes and the
intestinal microbiota have been extensively studied in recent literature (Karlsson et al.,
2013; Qin et al., 2012; Zhang et al., 2013). Type-1-diabetes (T1D) is more complex,
despite alterations in the microbiota observed in both animal (Roesch et al., 2009) and
human models (Brown et al., 2011; de Goffau et al., 2013; Giongo et al., 2011; Murri et
al., 2013). Whether the changes observed in the intestinal microbiota represent a
cause or an effect of T1D development remain to be elucidated and this was the
subject addressed in Chapter 5. Sprague-Dawley rats were induced with T1D through a
single intraperitoneal injection of the pancreatic β-cell toxin, streptozotocin (STZ). With
preferential toxicity towards insulin-producing pancreatic β-cells, T1D rapidly and
irreversibly develops and injected animals display hyperglycemia (>200mg/dL blood
glucose) as soon as one week following injection. In Chapter 5, intestinal microbial
composition of rats that developed T1D was compared with healthy controls over 5
weeks. The data indicated that T1D development and progression had a dramatic
impact on intestinal microbial composition and diversity. In agreement with previous
studies, the data revealed that STZ induced T1D was associated with an altered
Bacteroidetes: Firmicutes ratio, favouring the abundance of Bacteroidetes, with
depletion of Firmicutes following disease onset (de Goffau et al., 2013; Giongo et al.,
2011; Murri et al., 2013). Moreover, the abundances of lactic acid producing bacteria
such as Bifidobacterium and Lactobacillus and caecal lactate levels were higher in T1D
rats, compared with healthy controls (P < 0.05). Brown et al., (2011) reported that
bacterial fermentation products, such as SCFA and lactic acid play a distinct role in the
maintenance of intestinal integrity, often compromised in T1D (Brown et al., 2011).
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Butyrate is an anti-inflammatory SCFA which induces mucin synthesis and is involved in
maintaining intestinal integrity, often compromised in T1D (Brown et al., 2011) and
was found to be significantly decreased in T1D rats in this study, compared with
healthy controls. The data presented in Chapter 5 also indicate that T1D onset and
progression immediately and irreversibly reduces intestinal microbial diversity. Future
studies involving metagenomics would provide information on the functionality of the
microbiota following T1D onset and its impact on different metabolic pathways. STZ
treatment did not result in T1D development in all injected rats and therefore it would
be interesting to compare the intestinal microbiota of such rats to investigate what
impact the toxin had on the intestinal microbiota, without T1D development.
Furthermore, as none of the STZ injected T1D rats received insulin therapy, future
studies addressing the impact of how insulin treatment and maintenance of T1D
progression would impact on intestinal microbial composition and diversity would be
of interest.
Due to the increasing demand for health-promoting probiotics, continuous
screening processes to discover bacteria with such properties as CLA, EPS, vitamin K,
gamma-aminobutyric acid (GABA) and serotonin production, for example, are
desirable. These screening processes are fundamental for discovering the bioactive
potential of future potential probiotics. In Chapter 6, we assessed the impact of
feeding a recently discovered conjugated fatty acid producing strain, isolated from a
faecal swab taken from a 3 day old breast-fed infant and identified as
Propionibacterium avidum DPC 6544 (Hennessy et al., unpublished data). In light of
recent investigations which demonstrate the impact of probiotic bacteria on the
microbiota-gut-brain axis, with implications on psychiatric and neurodevelopmental
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health of the host (Bravo et al., 2011; Desbonnet et al., 2008), the effects of this strain
on behaviour patterns was assessed in a feeding study in mice. Feeding the strain to
mice did not alter fatty acid composition after 10 weeks, possibly due to the limited
availability of substrate for conjugation in vivo. The data did however demonstrate a
potential use of P. avidum DPC 6544 as a “psychobiotic”. Recently defined, a
psychobiotic is a live organism that, when ingested in adequate amounts, produces a
health benefit in patients suffering from psychiatric illness (Dinan et al., 2013).
Following P. avidum DPC 6544 ingestion, mice exhibited reduced anxiety-like
behaviour (P < 0.05), compared with unsupplemented controls. The phenomenon of
using probiotic bacteria to decrease anxiety in the host has previously been
demonstrated (Bravo et al., 2011; Hsiao et al., 2013). Furthermore, the essentiality of
the gut microbiota for social interaction and development in the host have been
described (Desbonnet et al., 2013). Hsiao et al., (2013) recently demonstrated that
feeding the probiotic Bacteroides fragilis to animals symptomatic of autism spectrum
disorder (ASD), provided some alleviation of the social abnormalities associated with
the disease (Hsiao et al., 2013). In this study, supplementation with P. avidum DPC
6544 exhibited dietary dependent increases in social interaction (P < 0.05), compared
with unsupplemented controls. Clinically, replacement of anxiolytic and antipsychotic
drugs with a probiotic which induces a similar affect in the host provides an attractive
novel approach for the treatment of psychiatric illness. Furthermore, prospective
studies to determine whether the psychobiotic potential of P. avidum DPC 6544, as
observed from this study, could alleviate symptoms of ASD, depression, or anxiety
would be desirable. Metagenomic studies could uncover pathways unique to P.
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avidum DPC 6544 responsible for its unusual fatty acid conjugating abilities and
psychobiotic potential.
The data presented in this thesis reveals the impact of nutrition and disease (T1D)
on intestinal microbiota composition while also highlighting how modulation of the
intestinal microbiota through probiotic supplementation, capable of producing
bioactive metabolites can positively shape health status. An unperturbed, stable
intestinal microbial ecosystem is important for health and the recent advent of high-
throughput sequencing technology has allowed an in-depth analysis of a once
unexplored world of gastrointestinal microbiology. We are still at the very early stages
of understanding how nutrition modulates intestinal bacteria and indeed how
probiotic bacteria mechanistically alter metabolic processes as well as the intestinal
microbial ecosystem to impact on health. Further in vivo studies are required to
understand the role of the intestinal microbiota on health as well as effects on
psychiatric and neurodevelopmental health and development.
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